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Abstract 
 
This dissertation will explore the factors that influence development of Diabetes 
complications for Medicare and dual eligible beneficiaries, for three Diabetes 
complications: retinopathy, nephropathy and neuropathy.  Both predictive and 
explanatory models are explored.  Predictive models focus on finding factors most 
predictive of Diabetes complications among Medicare and dual eligible beneficiaries.  
Explanatory models seek to answer the three hypothesis of this study.  The first 
hypothesis states that higher treatment investment is associated with lower rates of 
Diabetes complications in Medicare and dual eligible beneficiaries.  The second 
hypothesis states that physicians who are specialists (vs. primary care) and urban (vs. 
rural) are associated with lower rates of Diabetes complications among Medicare and 
dual eligible beneficiaries.  Finally, the third hypothesis associates higher patient total 
cost sharing with improvement in Diabetes complications outcomes among Medicare and 
dual eligible beneficiaries.  For dual eligible beneficiaries, patient cost sharing is defined 
as state Medicaid investment per beneficiary for the state where each beneficiary resides 
in.   
 
The results for the predictive models are strongest for nephropathy complication, and 
weakest for retinopathy complication.  The results for the explanatory models show that 
for the first hypothesis, nephropathy has lower rate of Diabetes complication for higher 
total treatment investment.  For the second hypothesis, rural providers have lower rate of 
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Diabetes complications for nephropathy (non-dual beneficiaries) and neuropathy (for 
dual beneficiaries).    Also, primary care providers have lower rates of Diabetes 
complication for retinopathy and neuropathy (non-dual beneficiaries) and retinopathy 
(dual beneficiaries).  For neuropathy, specialists have lower rates of Diabetes 
complications (for non-dual beneficiaries).  Finally, for the third hypothesis, no 
complications are associated with lower Diabetes complication rates with higher patient 
total cost sharing for non-dual beneficiaries.  For dual beneficiaries, retinopathy and 
nephropathy (to a lesser extent) show evidence of lower Diabetes complication rates with 
higher State Medicaid investment per beneficiary.  Model performance results based on 
the C-statistic are moderate overall, with nephropathy showing the best performance and 
retinopathy the lowest performing among all of the Diabetes complications. 
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Chapter 1 Introduction 
 
This dissertation will focus on the roles that the provider, treatment and patient play in 
development of complications in Diabetes patients.  In particular, the dissertation will 
explore the answers to the following questions: 
Do different providers use different treatments on a cohort of Diabetes patients, and are 
their outcomes different?  Also, do different patients play a role in different outcomes, for 
a given provider and treatment regimen? 
This dissertation will explore these types of questions with the hope of offering some 
background into what factors may be playing a role in the development of complications 
in Diabetes patients, and ultimately to finding approaches to prevention of these 
complications. 
 
1.1 Study Description 
 
This dissertation will be exploring the factors that impact the development of Diabetes 
complications (retinopathy, nephropathy and neuropathy) in Medicare and dual eligible 
beneficiaries.  The study design will be based on two years of data, from 2010 (base year) 
to 2011 (follow-up year).  In 2010, patients are chosen who have Diabetes but who have 
no complications.  In other words, the patients chosen are non-complicated Diabetes 
patients.  Then in 2011, the complications rates for those patients are measured to see 
which of these patients develop any of the three complications of interest in this study-
retinopathy, nephropathy or neuropathy. 
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One of the unique aspects of this study is the selection of a set of patients without any 
Diabetes complications.  Thus in the base year, a clean sample of Diabetes patients is 
selected in the sense of having patients with no previous record of any complications.  
These patients are then observed for development of complications in the follow-up year.   
The selection of a pure sample of Diabetes patients having no complications in their 
background allows for a study design that attributes as much as possible the effect of 
those factors on the development of Diabetes complications in patients.  In other words, 
the effect of the development of complications in Diabetes patients is isolated as much as 
possible in this study design by selecting a clean sample approach.  Although this is an 
observational study design, it creates a framework to attribute as much of the impact as 
possible to the various factors on development of Diabetes complications.   
 
In addition to selecting a clean sample of Diabetes patients without having had any 
complications, another unique aspect of this study is in its extensive focus on risk 
adjustment.  Once the factors have been isolated with regards to their impact on 
complications development in patients, it is then necessary to apply risk adjustment to 
make a comparison between similar risk groups.  It is not sufficient to simply compare 
impact of factors on complications development, but it is also important that those 
impacts are adjusted based on risk levels.  Risk adjustment allows for comparison of 
similar risk category of patients. 
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To study the exploration of the factors that impact development of Diabetes 
complications in patients, the overall study will be divided into two parts.   
 
In the first part, predictive models are obtained to study the impact of risk factors on 
development of Diabetes complications in patients.  In this part, only demographic 
comorbidity and health utilization risk factors are considered in their impact on Diabetes 
complications development.  These factors represent patients’ health risk status.  These 
factors are considered non-controllable risk factors due to the fact that a patient does not 
have control to change those factors’ status.  For instance, health comorbidities for a 
patient are typically not within the patient’s control to alter.  These factors are present in 
patients and there are usually no options to alter those factors in a patient.  These factors 
are medical risk factors that generally cannot be altered in patients and impact their 
development of Diabetes complications.   
 
In this stage, predictive models will be used to study the impact that those non-
controllable risk factors in patients have on the development of Diabetes complications in 
those patients in the follow-up year.  The results of the predictive models allow the 
identification of beneficiaries at risk of developing Diabetes complications.  It is the 
purpose of the second stage (and the main purpose of this dissertation) to identify ways to 
control the rate of development of Diabetes complications for those beneficiaries at risk. 
 
In the second stage, controllable risk factors of patients are studied for their impact on 
development of Diabetes complications.  In contrast to the non-controllable risk factors in 
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the first stage, these factors are controllable in that they can in general be altered for a 
given patient.  For example, the type of treatment a patient received, or the amount of 
treatment spending given for a patient.  In a sense, those are social risk factors, in contrast 
to the medical risk factors considered in the first stage. 
 
The controllable risk factors that are explored in this study will include: 1) total cost of 
treatment 2) physician attributes (primary vs. specialty and urban vs. rural) and 3) patient 
cost sharing (or Medicaid cost per beneficiary in the case of dual eligible patients).  
Explanatory models will be developed to evaluate the impact of each of those factors on 
their impacts on the development of Diabetes complications in Medicare and dual eligible 
patients. 
 
There will be three hypothesis that will be explored for each of those factors and their 
impact on Diabetes complications in the second stage.  The following gives an overview 
of the hypotheses that are explored in this study: 
 
1. Higher treatment investment is associated with lower rates of complications in 
Diabetes patients 
2. Provider type plays a role in development of complications in Diabetes patients 
a. Specialist providers have lower rates of complications than generalist 
providers in Diabetes patients 
b. Urban providers have lower rates of complications than rural providers in 
Diabetes patients 
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3. Patients with higher cost-sharing (or higher Medicaid cost per beneficiary for dual 
eligible beneficiaries) have lower rates of Diabetes complications 
 
1.2 Specific Aims, Including Statement of Hypothesis  
 
The aim of this dissertation is to study factors that influence progression of complications 
in Diabetes patients.  There will be three factors that will be explored for their influence 
in development of complications in Diabetes patients: the provider, the patient and the 
treatment investment.   These three factors will form the core of the three hypotheses of 
this dissertation, and each will be explored in more depth in the dissertation.  The 
following are the three hypothesis, along with the types of questions each will attempt to 
answer: 
1. Do different treatment investment levels influence the development of 
complications in Diabetes patients, for given provider type?   
a. Is higher treatment investment associated with lower rates of 
complications in Diabetes patients? 
b. Treatment investment consist of costs associated with inpatient, outpatient, 
professional and other related expenses, for both Diabetes and 
comorbidities. 
2. Do provider types play a role in development of complications in Diabetes 
patients, for given treatment cost level?  Three different provider types will be 
explored. 
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a. Generalist vs. Specialist-Do specialist provider deliver superior care and 
have lower rates of complications in their Diabetes patients? 
b. Urban vs. Rural-Do urban providers have lower rates of complications in 
their Diabetes patients? 
3. Does patient insurance cost sharing level play a role in development of 
complication in Diabetes patients, for given provider type and treatment cost 
level?  This hypothesis will examine two areas: 
a. Do patients with higher deductible (or coinsurance) take more active role 
in their Diabetes self-management and show lower rates of complications 
development? 
b. For patients who are dual eligible, does state per beneficiary investment in 
Medicaid influence the rate of complications development in Diabetes 
patients of that state? 
 
It is hoped that by answering the above questions relating to each hypothesis, that more 
insight is gained into the factors that influence progression of complications in Diabetes 
patients.  These types of factors play a role in the overall care provided for Diabetes 
patients.  The insight gained from learning about these factors will enable a Diabetes 
delivery of care model that most effectively considers the role of provider, patient and 
treatment leading to outcomes with lower rates of complications for Diabetes patients. 
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Chapter 2 Literature Review 
 
2.1 Diabetes 
 
Diabetes is a leading chronic condition, affecting over 25 million people in the US (or 
8.3% of the US population) [1].  Approximately 19 million of those are diagnosed, with 
another 7 million undiagnosed.  The trends show that the prevalence of Diabetes has been 
increasing and expected to continue rising in the future, especially in light of our growing 
obesity trends  [2].  Diabetes is the 7th leading cause of death in the US [1].  It is clear 
that Diabetes is a growing concern and becoming an epidemic for our country with trends 
growing at an alarming rate.  By 2030, 36 million people are expected to be diagnosed 
with Diabetes and 48 million by 2050 [3].  
 
Diabetes is also a very costly chronic condition.  According to the American Diabetes 
association, the total costs of Diabetes in the US is estimated to be $245 billion in 2012.  
This is a 41% increase from the 2007 estimate, where it was at $174 billion.  Of that 
amount, $176 billion is attributed to direct medical costs (the remaining to indirect costs, 
or cost due to lost productivity).  People with Diabetes typically cost on average 2.3 times 
more than those without  
Diabetes [4].  Further, people with Diabetes have 2 times higher risk of death than people 
without Diabetes (and with similar age) [1].  The trends for future costs are increasing at 
a fast rate and expected to at least double in the next 25 years (from 2009) [5].   
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An estimated 26.9% of Medicare beneficiaries have diabetes, or 10.9 million of the US 
population [1].  According to the CMS, 32% of total Medicare spending accounts for 
Diabetes spending (or 1 in 3 dollars).  Medicare dual eligibles are beneficiaries who 
qualify for both Medicare and Medicaid, generally due to their financial hardship.  There 
are nearly 9 million total dual eligibles (about 2/3 are low income and >65) [6].  Dual 
eligibles per beneficiary costs are more than 4 times the per beneficiary costs of Medicare 
beneficiaries [6].  This dissertation will focus only on Medicare and dual eligible 
beneficiaries in the study of factors that influence development of Diabetes 
complications. 
 
2.2 Diabetes Complications 
 
Complications resulting from Diabetes make up a significant portion of the total cost 
spent on Diabetes [7].  Overall, cost associated with complications make up about 50% of 
Diabetes total (direct) cost.  In 2007, Diabetes cost was estimated at $174 billion, and 
$116 billion was attributed to direct medical costs.  Of that amount, $27 billion (23.3%) 
was spent to treat diabetes, $58 billion (50%) to treat Diabetes complications and the 
remaining (26.7%) was excess general medical cost [4].  Lifetime costs attributed to 
Diabetes complications are estimated at $47,240 per patient over a 30 years period [8].  
In a similar study, age-gender weighted average of the lifetime medical costs for Diabetes 
patients was estimated at $85,200, of which 53% was spent on treating Diabetes 
complications [9].   
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Diabetes complications are usually classified as either microvascular or macrovascular.  
Microvascular complications usually include retinopathy (eye disease), nephropathy 
(kidney disease) and neuropathy (nerve disease, attributed to foot amputations in 
Diabetes patients) [7].  Macrovascular complications usually include complications such 
as stroke and heart disease [7].  Macrovascular complications comprise the biggest 
portion of total Diabetes costs-up to 85% in the first 5 years [9].  Another study found 
macrovascular complications to account for 57% of lifetime Diabetes costs [8].  
Additionally, in that study, complications types as a percentage of costs over a 30 year 
time period had the following percentage breakdown: macrovascular (52%), nephropathy 
(21%), neuropathy (17%) and retinopathy (10%).   
 
Microvascular complications are a significant burden on the health of Diabetes patients.  
According to the CDC, retinopathy is the leading cause of blindness in the US among 
adults 20-74 years.  Also, 44% of all new cases of kidney failure in 2008 are attributed to 
diabetes.  Finally, 60% of nontraumatic lower-limb amputations are attributed to patients 
with Diabetes [1].  It is evident that microvascular complications have a significant 
impact on the health of Diabetes patients.  This dissertation will be focusing 
predominantly on microvascular complications in Diabetes patients. 
 
2.3 Diabetes Comorbidities 
 
Although Diabetes complications are a costly component of total amount spent on 
diabetes, costs are more significant in Diabetes patients who have been diagnosed with a 
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comorbidity.  Only 14% of Diabetes are reported to having no comorbidities [10].  In 
general, Diabetes costs are underestimated when comorbidities are not considered, as was 
found in a Swedish study where Diabetes costs were 2.5 times higher than earlier 
estimated when comorbidities were considered [11].  Health utilization in Diabetes 
patients is increased as a result of having comorbidities.  Having both Diabetes and non-
Diabetes related comorbidities were both found to have an impact on health utilization, 
with certain comorbidities having greater impacts [12].  Also, vascular and non-vascular 
(i.e., non-Diabetes related) comorbidities were found to be equally important in their 
effects on health utilization in Diabetes [12].   
 
In general, having more than one comorbidity leads to an increase of health utilization 
and costs in Diabetes patients.  A higher number of comorbidities is related with 
increasing health utilization in patients [12].  A comparison of pairwise combinations of 
three comorbidities in Diabetes patients showed an increase in costs compared to patients 
having only one of the comorbidities, and patients having all three comorbidities showed 
the highest costs [13]. 
 
Hypertension is a common comorbidity in Diabetes patients [10].  Patients with both 
Diabetes and hypertension comorbidities would benefit from better adherence to drug 
regimen [14].  Depression is also a frequent comorbidity in Diabetes patients [7].  Having 
depression in Diabetes patients (both minor and major) is associated with increased 
mortality [15].  Further, it has been found that Diabetes can be a predictor of depression 
in some patients-it can double the odds of comorbid depression [16].  Obesity, is also a 
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common comorbidity among Diabetes patients [10], and is associated with an increase in 
total Diabetes costs [17].  Cardiovascular disease is one of the most significant 
comorbidities for patients with Diabetes [7].  Diabetes patients with comorbid 
cardiovascular diseases experience increased hospital expenditures [18].  Nephropathy, as 
a comorbidity in Diabetes patients, is associated with increases in higher medical care 
costs in Diabetes patients who are also hypertensive [19]. 
 
2.4 Prevention of Complications  
 
As a result of the detrimental effects of diabetes, both in terms of cost and health, it is 
desirable to practice prevention.  Prevention should first and foremost be focused on 
avoidance of getting Diabetes in the first place.  There are a number of ways persons at 
risk should consider in order to avoid developing diabetes, which generally include eating 
healthy and remaining active [20].   
 
If a person has already been diagnosed with diabetes, then prevention should turn its 
focus on avoidance of complications associated with the disease as much as possible.  
This dissertation will be focused on this case, with Diabetes patients who have no 
complications (as defined in our study) but who are at risk of developing Diabetes 
complications.  It is believed that there is a difference between those patients with 
Diabetes who have developed complications and those who have not.  Patients with 
Diabetes who have not yet developed a complication should focus on maintaining that 
state as long as possible.   
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Even if a Diabetes patient has developed a complication, it may be worthwhile to avoid 
developing further complications.  Hence prevention must continue to be observed even 
after development of a complication has occurred in a Diabetes patient [21].   
 
Prevention of Diabetes complications is typically accomplished by controlling clinical 
factors in Diabetes patients1.  These clinical factors include glycemic (glucose) and non-
glycemic factors including blood pressure, cholesterol levels and body weight [22].  
Generally, glycemic control and blood pressure are effective in prevention against 
microvascular complications.  Non-glycemic control factors including blood pressure and 
lipids are generally effective in prevention against macrovascular complications [7].  
There are numerous studies that show the benefit of both glycemic and non-glycemic 
control in the prevention of Diabetes complications, both interventional and 
observational.    
 
Two well-known interventional studies took place that established the benefit of 
glycemic and other clinical factors in the prevention of Diabetes complications.  The 
DCCT study, which occurred in the US from 1983-1993, showed that glycemic control 
does have an impact on the prevention of complications in Diabetes I patients (also 
applicable to Diabetes 2 patients [23]) [24].  The UKPDS was a seminal study that took 
place in the UK from 1977-1997.  The UKPDS showed the benefit of controlling 
                                                 
1
 This could be achieved in a number of ways, typically with the use of medications or other regimen 
proposed by the physician 
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glycemic clinical factors and the impact on prevention of complications (both 
microvascular and macrovascular) in Diabetes patients [25].  
 
Raised blood pressure was found to raise the risk of Diabetes complications using 
UKPDS patients, both for microvascular and macrovascular complications [26].  Also in 
UKPDS patients, an association between glycaemia and both microvascular and 
macrovascular complications in Diabetes was determined [27]. 
 
Numerous observational studies also highlighted the impact of controlling various 
clinical factors in the prevention of complications in Diabetes patients.  Controlling for 
glucose and blood pressure were shown to have an impact on microvascular 
complications (nephropathy and retinopathy), and blood pressure an impact on 
macrovascular complications (cardiovascular and stroke) in Diabetes patients [28].  
Glycemic control demonstrated a reduced risk of additional complications in Diabetes 
patients who already had one complication [21].  In a study involving both commercial 
and Medicare patients, it was found that control of A1c, blood pressure and lipids lead to 
improved probabilities of complications (using probabilities based on UKPDS risk 
model) as well as improvements in cost [29].  Finally, Diabetes patients with metabolic 
syndrome (as defined by AHA/NHLBI and IDF criteria) are at greater risk in the 
development of all Diabetes complications [30].   
 
The benefits of glycemic control are more effective if administered to patients with early 
onset of diabetes.  In a study that used Markov models to quantify the benefits of 
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glycemic control (in the prevention of both blindness and end-stage renal disease in 
Diabetes patient), substantial benefit was achieved from almost-normal glycemic control 
in prevention of complications [31].  For Diabetes patients with later onset, the study 
found moderate glycemic control was effective in the prevention of most end-stage 
microvascular Diabetes complications.  The benefits of beginning early treatment for 
Diabetes patients is significant.  Glycemic control is more effective when given early to 
Diabetes patients and in some cases may help prevent long-term macrovascular 
complications when given at early stages of the disease in some patients [32]. 
 
For Diabetes patients who have comorbidities glycemic control can be a challenge and is 
not always easy to measure.  In patients with severe nephropathy, assessing glycemic 
control is a challenge and accuracy of glucose assays (used for glycemic control) for 
those patients is affected [33].   
 
This dissertation considers a broader approach to the prevention of complications in 
Diabetes patients than the current focus on glycemic and other clinical factors.  The 
approach in this dissertation is a multi-fold approach that considers the role of the 
provider, the patient and treatment type and their impact in the development of 
complications in Diabetes patients.  This approach is more comprehensive in the 
treatment of complications in Diabetes patients than simply focusing on controlling 
glycemic and nonglycemic factors.  Fitch et al. discuss the benefits of treatment of 
Diabetes that goes beyond clinical factors [29].  Their discussion focuses on both 
provider and patient programs that have the potential to provide more effective care 
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programs for Diabetes patients.  With innovative provider and patient programs, more 
patients would receive Diabetes preventive care at more appropriate times, leading to 
better outcomes.  Krein et al. offer suggestions to Diabetes care management that will 
lead to improved economic outcomes [34].  The topics discussed include improved 
patient cost sharing programs, more effective insurance designs and provider programs 
that are aimed at quality improvement.  This dissertation’s goals are to explore the impact 
of these types of innovative approaches and the role they have in prevention of 
complications in Diabetes patients.  The three areas explored will include treatment 
investment, provider type and patient cost sharing in the management and prevention of 
Diabetes complications. 
 
2.4.1 Treatment Investment 
 
First, the amount of treatment investment2 will be explored.  In this dissertation, the 
amount invested in treatment of Diabetes will be used as a proxy for treatment type, as 
this captures both the treatment intensity and the quality of the treatment provided.  In 
general, treatment investment increases after Diabetes complications take place in 
Diabetes patients.  Patients who had better control of glycemic, blood pressure and lipid 
factors demonstrated cost savings, in both commercially insured and Medicare patients 
[29].  Patients with maintained good glycemic control (at or below A1c levels of 7%) had 
lower diabetes-related cost than Diabetes patients who did not [35].  However, it is of 
                                                 
2
 Treatment investment refers to all expenses resulting from inpatient, outpatient, physician office, skilled 
nursing facility or home health   
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interest to study the role treatment investment plays in Diabetes patients who have not yet 
developed complications, and this will be explored in this dissertation. 
 
In addition, certain patients may require specialized treatment for their condition, 
sometimes requiring administration of treatment at early stages of Diabetes (before 
symptoms may arise)  [32].  These types of patients would require higher levels of 
treatment investments.   It is the goal of this dissertation to evaluate the role of treatment 
investment as a way to capture the impact that various treatments have on the 
developments of complications in Diabetes patients. 
 
2.4.2 Provider Type 
 
This dissertation will also evaluate the impact that providers play in the development of 
complications in Diabetes patients.  Two different components of provider type will be 
explored.  First the difference between generalist vs. specialist providers will be 
considered.  In general it is believed that specialist providers provide better care for 
Diabetes patients, especially in terms of complications development [36-38].  However, it 
has also been found that treatment of Diabetes patients with both a generalist and an 
endocrinologist provides for best outcomes [39].  In the second area, rural vs. urban 
providers will be considered.  Many studies have examined the impact of rural vs. urban 
provider in the treatment of diabetes, and generally it is believed that urban providers 
deliver better care [40-43].   
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2.4.3 Patient Cost Sharing 
 
The last focus of this dissertation will be on the role the patient in the management of 
Diabetes and in the prevention of complications.  In recent years, there has been an 
increased interest in involving the patient in the treatment of Diabetes (and other chronic 
diseases in general).  This dissertation will study the impact that insurance plays in 
providing the patient incentives to be active in the management of their Diabetes disease.  
Diabetes in particular is a disease that requires active involvement of the patient in 
management of their treatment [44].  This study will explore the impact that patients’ cost 
sharing has on developments of complications in Diabetes patients.  There is conflicting 
evidence about patient cost sharing’s relation to health outcomes.  Increase in patient cost 
share has been shown to have an adverse effect on health utilization, and particularly in 
diabetes preventive services [45].  On the other hand, there improved health utilization 
has been observed in consumer driven health plans (CDHP) that offer patients high 
deductible cost sharing [46-48]  
 
One extension to patient insurance will be to evaluate the dual eligible patients 
separately.  Dual eligible patients do not have any cost sharing, as they are covered by 
Medicaid in addition to their Medicare coverage.  In this extension the study will explore 
the impact that states’ per beneficiary investment in Medicaid has on the outcome of 
Diabetes dual eligible patients and their development of complications.   
 
2.5 Study Design 
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The study design in this dissertation will consider patients without any Diabetes 
complications and examine the impact that various factors have on whether they develop 
Diabetes complications in the following year.  Also, risk adjustment will play a pivotal 
role, in order to ensure that there is a level comparison between various patient risk 
groups.  To some extent, there have been some similar such study designs for various 
different disease conditions.  For instance, Menzin et al. consider a multivariate logistic 
regression model to study the impact that mean A1c levels of patients had on Diabetes 
related hospital inpatient admission [49].  In that study, mean A1c is divided into five 
distinct levels (from <7% to 10% and more).  The impact of mean A1c on patient 
hospitalization was risk adjusted for a number of risk related covariates, including age, 
sex, number of A1c test, diagnosis of cancer and follow-up time.   
 
In Wagner et al used linear regression with risk adjustment to evaluate the impact that 
HbA1c control had on both cost and utilization intensity of patient [50].  Utilization 
intensity included % admission to hospital, mean total visits to primary care and mean 
total visits to specialist visits.  Patients were divided into two groups, those whose HbA1c 
levels improved and those that did not improve.  Thus there are two levels for 
comparisons in this case.  Risk adjustment factors included age, sex, baseline HbA1c 
level and baseline presence of any of six Diabetes complications.   
 
Bertoni et al. considered patients who did not have prevalence of heart failure in the base 
year (1994) and evaluated incident heart failure in the follow-up period (1995-99) for 
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those patients [51].  Proportional hazard regression was used to evaluate the risk of 
incident heart failure among the cohort, with risk adjustment of covariates including age, 
sex, race and Diabetes related comorbidities.  The study population was Medicare 
beneficiaries who are older (>= 65 years) and not in managed care, similar to the 
population in this dissertation.   
 
2.5.1 Prediction 
 
In addition to studying the impact of analytical factors on disease outcomes, risk 
adjusting for risk factors, another approach is prediction of disease prevalence based on 
risk factors.  This dissertation will explore prediction of Diabetes complications among 
Medicare and dual eligible beneficiaries based on a variety of socio-demographic and 
health related risk comorbidities.   
 
There are a number of studies related to predictive modeling of patient disease risk based 
on a variety of risk factors, including patient disease history.  Many of these recent 
studies are employing more cutting edge analytics in their modeling using claims based 
data sets.  Davis et al. explored prediction of individual disease risk based on a patient’s 
medical history (using ICD-9 diagnosis codes) [52].  Although the data requirement is 
fairly straightforward in Davis et al. (using only claims based data), the approach is fairly 
sophisticated.  Collaborative filtering combined with clustering is used to discover 
disease risk for patient based on disease diagnosis in prior visits.  This approach shows 
improvements in prediction based on more number of visits by the patient. 
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Khalilia et al. is also an innovative approach to prediction of disease based on patient 
diagnosis history, using the National Inpatient Sample Data [53].  Random forests are 
used for prediction of eight diseases.  To deal with the highly imbalanced nature of the 
data, ensemble learning approach based on repeated random sub-sampling is used.  The 
results based on random forest ensemble learning prediction are shown to outperform 
other prediction approaches (including support vector machine (SVM), bagging and 
boosting).  Moturu et al. also tackle the imbalanced data issue in their Medicaid cost 
prediction study, using claims based data (the Arizona Health Care Cost Containment 
System) [54].  Although this study is concerned with cost prediction, the classes of cost 
can be viewed as a proxy for patient risk (i.e., disease risk).  Moturu et al. apply non-
random sampling (under-sampling and over-sampling) to deal with the data imbalance 
problem and apply several predictive modeling methods including SVM, logistic 
regression and logistic model trees. 
 
Yu et al. apply SVM for prediction of common diseases, for both Diabetes and pre-
Diabetes [55].  The data set was based on the National Health and Nutrition Examination 
Survey, and only included common clinical measurement (without more sophisticated 
laboratory tests).  The results of the prediction based on SVM were shown to be 
equivalent to the more mainstream multivariate logistic regression that is more 
commonly used in these studies.  The advantages of using SVM is it does not require any 
distributional assumptions and this becomes valuable as more variables are introduced in 
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the model.  Robinson explores using boosted regression trees with simple claims data and 
shows the advantages in consideration of all variable interactions with this approach [56].   
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Chapter 3 Methods 
 
3.1 Data Source 
 
The population that will be studied in this dissertation will be Medicare beneficiaries 
(including dual eligible beneficiaries).  The data source will be based on Medicare 
Limited Data Set (LDS) from 2010-2011.  This data set contains both institutional and 
non-institutional claim files for a 5% sample of Medicare Beneficiaries.  Both Medicare 
Parts A and B are included in the data set.  A very thorough introduction on the use of the 
Medicare Limited Data Set is provided in Parente et al [57].   
 
Within the Medicare LDS data set, five distinct files are investigated for beneficiary 
claim utilization.  These claim utilization files consist of: 1) Carrier 2) Outpatient (OP) 3) 
Inpatient (IP) 4) Skilled Nursing Facility (SNF) and 5) Home Health (HHA) files.  The 
following table shows summary results for each of those five claim files for the year 2010 
(the base year), including results for total unique claims, total costs (claim payment 
made) and total unique beneficiaries. 
 
  
Total          
Claims 
Total                    
Costs 
Total               
Beneficiaries 
Carrier 43,075,835 $4,278,138,670.80 1,711,151 
Outpatient 7,432,322 $2,696,479,024.90 1,210,151 
Inpatient 622,201 $6,284,780,092.40 356,405 
SNF 281,601 $1,366,641,320.10 96,850 
HHA 350,082 $1,133,951,371.10 173,154 
Table 1: Claim files utilization summaries by each component, in the year 2010 
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In addition to the claim utilization data files, a master beneficiary file (or denominator 
file) is also included as a data source.  The master beneficiary file is also part of the LDS 
Medicare data set and contains detailed information about beneficiaries enrolled in 
Medicare.  For instance, some of the information included consists of demographics 
(age/sex/race), original (and current) reason for enrollment of a beneficiary in Medicare, 
enrollment in Part A or B (or both), and more.  The following table shows the total 
unique beneficiaries included in the 2010 and 2011 master beneficiary files that are used 
in this study.  Note that in 2011, the total includes all of the Medicare population (instead 
of a 5% sample, as is the case in the Medicare LDS data set in general).  However, this 
study will only consider a 5% sample which will be restricted based on the 2010 
beneficiary data. 
  
  
Year 1                             
(2010) 
Year 2                     
(2011) 
Total Beneficiaries 2,499,647 51,548,729 
Table 2: Total unique beneficiaries in master beneficiary files, in 2010 and 2011 
 
For Medicare beneficiaries who are dual eligible, additional data for State Medicaid per 
beneficiary investment will be needed.  The data source for State Medicaid per 
beneficiary investment will be obtained from the CMS Medicaid Statistical Information 
System (MSIS) State Summary Datamart.  This database contains Medicaid spending 
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data by state for years prior to 2012, which is the case for this study (where data for the 
year 2010 will be obtained)3.   
 
3.2 Data Collection  
 
Using the data sources as presented above, the study will be focused on investigating the 
impact of factors that influence the development of Diabetes complications in Medicare 
and dual eligible patients.  The data collection process will proceed in the following two 
phases.  In the first phase, data for a beneficiary is collected during the base year (2010).  
In the second data collection phase, data for a beneficiary is obtained during the follow-
up year (2011).  The following provides an overview of the data collection process in the 
dissertation: 
 
A. Phase I: 
Patients are chosen in year 1 (2010) who meet the following criteria: 
1. Have at least 1 Diabetes diagnosis in that year 
2. Have no observed diabetes complications  
For each beneficiary, the following information is collected in the base year: 
1. Socio-demographic (age, sex, race)  
2. Health utilization factors 
3. Patient co-morbidities  
                                                 
3
 The CMS MSIS data is located at http://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-
Data-and-Systems/MedicaidDataSourcesGenInfo/MSIS-Mart-Home.html 
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4. Analytical factors-Total cost of treatment, MD factors and patient cost 
sharing/Medicaid state per beneficiary investment (for dual eligible 
beneficiaries) 
B. Phase 2: 
In year 2 (2011), patients will be observed for the complications that they 
develop.  
1. They must have at least 1 Diabetes diagnosis in that year  
2. Deceased patients are not included in study 
 
 
3.3 Sample Selection 
 
The sample selection process in this dissertation is shown in Figure 1.  The following 
describes the steps in the sample selection process in Figure 1 in more detail. First, 
patients are chosen in 2010 based on having a Diabetes diagnosis.  In this study, Diabetes 
diagnosis is defined as having an ICD-94 diagnosis code of 250.xx [49].  Each of the five 
claim utilization source files are used to determine a Diabetes diagnosis for a beneficiary: 
carrier, IP, OP, SNF and HHA.  For carrier and OP source files, at least two occurrences 
of ICD-9 code 250.xx are used to define a patient as having Diabetes.  All other source 
files (IP, SNF and HHA) only require at least one such occurrence of ICD-9 code 250.xx.  
The reason for this distinction is that both the carrier and OP claim files are much larger 
sources of claim utilization than IP, SNF or HHA.  This stricter guideline for carrier and 
OP claim files minimizes the potential for error in identification of Diabetes patients from 
those two sources [58, 59].  For all the claim utilization source files, a patient’s primary 
                                                 
4
 International Classification of Diseases, Ninth Revision (ICD-9) 
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diagnosis and an additional five diagnosis codes are used in order to identify a patient as 
having Diabetes diagnosis5.   
 
The total number of beneficiaries that are obtained after considering all five claim 
utilization sources for occurrence of Diabetes diagnosis in 2010 results in a total of 
423,957 beneficiaries (see Figure 1)6.   
 
In addition to the restrictions above based on the claim utilization source files, additional 
restrictions are also made that are based on the master beneficiary tables in both 2010 and 
2011.  These restrictions are meant to reduce the set of beneficiaries to only those 
presumed eligible for this study.  These restrictions are all based on recommendations 
obtained from the Research and Data Assistance Center (RESDAC) at the University of 
Minnesota7.  The justification provided for these adjustments is that they are necessary in 
order to obtain a complete data set for beneficiaries who are enrolled in Medicare FFS.  If 
a beneficiary does not meet the restrictions presented, it would mean that there is missing 
data for that beneficiary during a portion of the year.   
 
                                                 
5
 Some claims utilization sources have anywhere from 10-25 additional diagnosis codes.  Only the first five 
were considered in this study. 
6
 Note that in Figure 1 the numbers represent the final amounts after filtering is done, whereas the 
discussion highlights the actual amounts filtered in each case (offering a different perspective). 
7
 http://www.resdac.org/ 
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Figure 1: Sample selection process to obtain data sets for non-dual and dual beneficiaries 
 
 
 28 
 
Before using either of the master beneficiary tables in 2010 and 2011 in the study, they 
are first both scanned for any possible duplicates.  In both years, duplicates were found 
but accounted for less than .01% duplicates in both tables.  Those duplicates were 
removed from both tables.  The total beneficiaries in the master beneficiary tables after 
removing duplicates for both 2010 and 2011 were shown previously in Table 2 above. 
 
The first adjustment made based on the master beneficiary tables is to select only 
beneficiaries who were not enrolled in HMO Medicare coverage in any of the 12 months 
during 2010 or 2011.  Any beneficiary with a record of at least 1 month enrollment in an 
HMO type coverage in either 2010 or 2011 would be excluded from the study8.  A total 
of 768,605 beneficiaries were found to have at least 1 month of enrollment in an HMO 
plan and those beneficiaries were excluded from the study. 
 
A second modification is to only select beneficiaries who were enrolled in both Medicare 
parts A and B during either 2010 or 20119.  This refers to a beneficiary being enrolled in 
both parts A and B in a year, in contrast to being enrolled in only one of those two parts 
(either in part A or part B but not both).  There were a total of 226,769 beneficiaries who 
did not meet this criteria of having enrollment in both parts A and B together during 
either 2010 or 2011 and those beneficiaries were removed from the study. 
 
                                                 
8
 Patients may elect to be enrolled in Medicare Part C or Medicare Advantage and that would qualify them 
as being HMO beneficiary for that month 
9
 Medicare consists of four parts: A, B, C and D.  Part A is the hospital component, part B is the physician 
component.  Part C is for Medicare managed care and Part D is for the drug component. 
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A third modification was to only choose beneficiaries who had a full 12 months 
enrollment in each year.  This limited the total beneficiaries by a total of 135,382 
beneficiaries. 
 
The final modification was to select only aged beneficiaries.  In Medicare, a beneficiary 
generally meets enrollment eligibility as a result of being aged (reaching the age of 65).  
However, being disabled or having ESRD may also make a beneficiary qualified to enroll 
in Medicare.  In this study, only aged beneficiaries are selected10.  This restriction limited 
the set of beneficiaries by a total of 238,207 beneficiaries.   
 
The final list of beneficiaries, after considering all the restrictions imposed as outlined 
above, comes to a total of 1,130,622 beneficiaries.  This is down from an original size of 
2,499,585 beneficiaries in 2010 (or about 45% of the original size), after removing a total 
of 1,368,963 beneficiaries that are not considered eligible for this analysis. 
 
After obtaining the reduced set of beneficiaries eligible for this study, the next step is to 
limit the sample of beneficiaries having Diabetes in 2010 as identified above to only 
those meeting eligibility criteria as has been identified.  The final set of beneficiaries after 
combining those two results comes to a total of 273,715 beneficiaries.  Thus our previous 
total of 423,957 beneficiaries having Diabetes in 2010 is now reduced to 273,715 
beneficiaries (or about 65% of the original size) after considering all the additional 
beneficiary eligibility modifications that were discussed above.  The new updated set of 
                                                 
10
 Beneficiaries who were aged and having ESRD were chosen.  However, beneficiaries with only ESRD 
were not chosen. 
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Diabetes beneficiaries will now have complete data for the study period, making them 
suitable for the study. 
 
After obtaining the eligible beneficiaries who have been diagnosed with Diabetes in 
2010, additional restrictions are made to this list of beneficiaries.  The following two 
restrictions are both based on events occurring 2011.  First, beneficiaries that were 
deceased in 2011 are removed from the sample.  A total of 1,674 beneficiaries in our 
sample of 273,715 beneficiaries diagnosed with Diabetes in 2010 were deceased in 2011.  
These beneficiaries were removed from the sample and the new sample now consists of 
272,041 beneficiaries.  This list of beneficiaries have complete data in 2011 which will be 
suitable for this study11.   
 
A second restriction is made to select only those beneficiaries who have also been 
diagnosed with Diabetes in 2011.  A similar process is followed in 2011 as was done in 
2010 above to identify a beneficiary who is diagnosed with Diabetes in 2011.  
Beneficiaries are selected based on having at least one occurrence of Diabetes diagnosis 
during that year (or at least 2 occurrences in the case of carrier and OP claim files as was 
done previously).  In addition, only the primary diagnosis and five additional diagnosis 
codes are evaluated for presence of ICD-9 code 250.xx.  After evaluating the list of 
272,041 beneficiaries diagnosed with Diabetes in 2010, 31,331 of these beneficiaries (or 
11.5%) do not have a Diabetes diagnosis in 2011, and those are removed from the 
sample-resulting in a sample of 240,710 beneficiaries.   
                                                 
11
 There is a concern of a bias due to removing sicker beneficiaries who more likely may die in 2011.  One 
approach is to perform the analysis with and without removing the deceased.  Ideally, the impact should not 
be significant; otherwise, deceased beneficiaries should not be removed and censoring could be considered. 
 31 
 
 
At this point, the sample consists of beneficiaries having been diagnosed with Diabetes in 
both 2010 and 2011.  However, the study also requires that the sample consist of 
beneficiaries that do not have any of the three Diabetes complications in 2010-
retinopathy, nephropathy and neuropathy.  The criteria for these three complications is 
included in Appendix A where each complication is defined by a list of ICD-9 codes.  
The list of ICD-9 codes is obtained from surveying the literature related to Diabetes 
complications [14, 49, 60, 61].  In addition to the three complications in this study, 
beneficiaries are chosen who do not show evidence of any long-term Diabetes 
complications.  Long-term Diabetes complications are defined with ICD-9 code range 
250.4x-250.9x.  The first three codes in that range are included in the three main 
complications of this study.  Thus the remaining three codes (250.7x-250.9x) are added to 
the list of codes defined in Appendix A in defining a beneficiary with Diabetes 
complications in this study.   
 
The process of identifying beneficiaries with Diabetes complications is similar to the 
identification of beneficiaries who are diagnosed with Diabetes that was done previously.  
Similar to the Diabetes diagnosis process, each of the five claim utilization sources are 
utilized in identifying Diabetes complications diagnosis.  In the case of OP and carrier 
claim utilization source files, at least two occurrences of the Diabetes complications 
codes must be met for a beneficiary to be considered to have a Diabetes complication 
diagnosis-only one such occurrence is required in the case of the other claim utilization 
source files (IP, SNF and HHA).  Also, in each case only the principal and five additional 
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diagnosis codes are used to determine Diabetes complications diagnosis, as was done 
previously.   
 
Once a beneficiary is identified as having any of the Diabetes complications defined 
above, they are subsequently removed from the study sample.  This will result in a 
sample of beneficiaries for this study who 1) have Diabetes diagnosis in both 2010 and 
2011 (as was obtained above) and 2) have no occurrence of long-term Diabetes 
complications.  A total of 88,109 beneficiaries are found to have at least one of the 
defined long-term Diabetes complications.  After removing those beneficiaries from the 
sample, the total sample size is reduced to a total 152,601 beneficiaries. 
 
One additional data modification to the final data set related to negative costs.  This will 
be outlined in more detail in the next section when discussing the analytic factor of total 
costs.  Essentially, beneficiaries with any cost components that are negative are removed 
from the final data set.  A total of 113 are found with such negative costs (<0.1%) and the 
final data set is reduced to 152,488 beneficiaries12.   
 
Finally, the data set is divided into a non-dual and dual Medicare beneficiaries.  Dual 
beneficiaries are defined as those having at least 1 month of state subsidy in the 
beneficiary file.  After making the split, the final non-dual data set has 126,942 
beneficiaries and the dual data set has 25,546 beneficiaries.  Those are the final data sets 
that will are used for modeling in the study. 
 
                                                 
12
 This will be discussed in more detail in the section below related to cost analytical factors. 
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3.4 Model Design and Variables 
 
As has been discussed, the objective of this study is to consider the role that various 
factors have on the development of complications in Diabetes patients.  Some of those 
factors have already been presented, including a differentiation that was made between 
controllable and non-controllable risk factors.  This section will highlight in detail all the 
variables that are used in the model, including the approaches used to derive some of 
those variables. 
 
The first part will highlight the independent variables in the model.  These will include 
the: 1) socio-demographic variables 2) comorbidity risk factors 3) health utilization 
variables (hospital inpatient length of stay, inpatient and outpatient total admissions, total 
office visits and SNF stay) and 4) analytical variables (total cost of treatment, physician 
factors and patient cost sharing/Medicaid State per Beneficiary investment in the case of 
dual eligible beneficiaries).  The second part will cover the outcome variables in the 
study, including: 1) retinopathy 2) nephropathy and 3) neuropathy.   
 
3.4.1 Independent Variables 
 
3.4.1.1 Socio-Demographic Variables 
 
3.4.1.1.1 Age 
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The first socio-demographic variable used in the study is age.  Age is initially in the data 
as a continuous variable representing a person’s age in years.  The first modification 
applied to age is to transform it into a discrete variable called Age_group.  The following 
table shows the results of this transformation as well as the frequencies obtained, for dual 
and non-dual beneficiaries in the year 2010: 
 
    Non-Duals   Duals 
Age Age_group Count Percent   Count Percent 
64<=age<70 64 to 69 39,415 31.05%   7,566 29.62% 
70<=age<75 70 to 74 33,558 26.44% 6,298 24.65% 
75<=age<80 75 to 79 25,126 19.79% 5,032 19.70% 
80<=age<85 80 to 84 17,412 13.72% 3,777 14.79% 
85<=age 85 and over 11,431 9.00%   2,873 11.25% 
Table 3: Frequency distribution of Age_group variable, for non-dual and dual 
beneficiaries  
 
After considering the frequencies of Age_group in Table 3, the last two categories (’80 to 
84’ and ’85 and over’) appear less frequent than the rest.  It was decided to merge those 
two groups into one (to be called ‘80 and over’).  This allows a more smooth distribution 
of the age groups in the new variable.  This new variable is called the Age_grp variable 
and other than the merging of the last two groups, it is identical to Age_group variable.  
The following table shows the frequencies for Age_grp variable, for dual and non-dual 
beneficiaries in the year 2010: 
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  Non-Duals   Duals 
Age_grp Count Percent Count Percent 
64 to 69 39,415 31.05%   7,566 29.62% 
70 to 74 33,558 26.44% 6,298 24.65% 
75 to 79 25,126 19.79% 5,032 19.70% 
80 and over 28,843 22.72%   6,650 26.03% 
Table 4: Frequency distribution of Age_grp variable, for non-dual and dual beneficiaries 
 
3.4.1.1.2 Sex 
 
The second socio-demographic variable used in this study is sex.  The only adjustment 
made to sex was to change the labeling from ‘1’ and ‘2’ to ‘M’ and ‘F’, respectively.  The 
following shows the frequency of sex in the study, for dual and non-dual beneficiaries in 
the year 2010: 
 
  Non-Duals   Duals 
Sex Count Percent Count Percent 
F 65,662 51.73%   18,305 71.66% 
M 61,280 48.27%   7,241 28.34% 
Table 5: Frequency distribution of Sex variable, for non-dual and dual beneficiaries  
 
3.4.1.1.3 Race 
 
The last socio-demographic variable used in the study is race.  Race was adjusted in a 
similar way to age above, by grouping categories to create a more smooth distribution.  
The adjustment essentially grouped all the low frequency categories into one (this 
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included Asian, Hispanic, North American, Other and Unknown)13.  The new updated 
variable is called Race_1, with a new category of ‘Other’ for the grouped categories.  The 
following tables show the distribution of the Race variable (table 6) and Race_1 variable 
(table 7), for dual and non-dual beneficiaries in the year 2010:  
 
  Non-Duals   Duals 
Race Count Percent Count Percent 
Asian 1,312 1.03%   2,426 9.50% 
Black 10,311 8.12% 4,685 18.34% 
Hispanic 957 0.75% 2,266 8.87% 
North American 603 0.48% 305 1.19% 
Other 2,163 1.70% 758 2.97% 
Unknown 118 0.09% 72 0.28% 
White 111,478 87.82%   15,034 58.85% 
Table 6: Frequency distribution of Race variable, for non-dual and dual beneficiaries  
 
  Non-Duals   Duals 
Race_1 Count Percent Count Percent 
Black 10,311 8.12%   4,685 18.34% 
Other 5,153 4.06% 5,827 22.81% 
White 111,478 87.82%   15,034 58.85% 
Table 7: Frequency distribution of Race_1 variable, for non-dual and dual beneficiaries 
  
3.4.1.2 Comorbidity Risk Factors 
 
Comorbidities are used in this study to risk adjust beneficiaries to obtain a relatively 
uniform population for the analysis14.  For this study, the primary approach used for risk 
adjusting comorbidities is with the Elixhauser comorbidity measure.  Elixhauser 
                                                 
13
 All of these categories have frequencies less than 2.5% 
14
 Comorbidities are also used as predictive factors in the predictive models initially as well. 
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comorbidity consists of 31 distinct disease categories defined based on ICD-9 codes [62].  
In this study, the Elixhauser comorbidity measures are applied to the five sources of 
claim utilization (Carrier, IP, OP, SNF and HHA), as was done with Diabetes diagnosis 
above.  Also, as was done with Diabetes diagnosis, main claim diagnosis and five 
additional diagnosis codes are used with the Elixhauser comorbidity measures to identify 
occurrences of an Elixhauser disease category.  However, for Elixhauser comorbidity 
measures, unlike with Diabetes diagnosis above, all five claim utilization sources are 
based on only one occurrence of an ICD-9 code to establish presence a disease condition 
(i.e., Carrier and OP do not require at least 2 occurrences of an ICD-9 code to attribute a 
condition to a beneficiary). 
 
A total of 31 disease comorbidities are included in Elixhauser measures.  However, in 
this study, the two comorbidity measures that directly relate to Diabetes (for Diabetes 
non-complicated and Diabetes complicated) are removed from the analysis.  This is done 
due to the fact that these two conditions have already been captured in the analysis, in 
both the Diabetes and complicated Diabetes diagnosis conditions.  The frequency 
distribution of Elixhauser comorbidities for the remaining 29 variables is shown in 
Appendix B.  These results are shown for both non-dual and dual beneficiaries, in the 
year 2010.   
 
A summary of total comorbidities by beneficiary is shown in table 8 below, for both non-
dual and dual beneficiaries in 2010.  This table highlights the fact that most beneficiaries 
have total comorbidities in the vicinity of three to five (the median total comorbidity for 
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both non-dual and dual beneficiaries is four).  However, beneficiaries with higher 
comorbidities, even though constitute lower percentage would typically have a higher 
percentage of the cost.  A grouping of beneficiaries by total comorbidity will be 
considered in the model as way to categorize the risk level of a beneficiary. 
 
  Non-Duals   Duals 
Total 
Comorbidity Count Percent   Count Percent 
0 25 0.02%   6 0.02% 
1 3,787 2.98% 471 1.84% 
2 26,674 21.01% 3,868 15.14% 
3 30,405 23.95% 5,052 19.78% 
4 23,688 18.66% 4,560 17.85% 
5 16,390 12.91% 3,625 14.19% 
6 10,550 8.31% 2,718 10.64% 
7 6,488 5.11% 1,907 7.46% 
8 3,987 3.14% 1,322 5.17% 
9 2,308 1.82% 811 3.17% 
10+ 2,640 2.08%   1,206 4.72% 
Table 8: Frequency distribution of total comorbidity, for non-dual and dual beneficiaries  
 
3.4.1.3 Health Utilization Variables 
 
3.4.1.3.1 Inpatient Length of Stay 
 
Length of stay was calculated for each beneficiary based on inpatient stays.  This 
measure was considered as providing valuable information regarding a patient’s health 
status.  This would be valuable to use as a risk adjuster, in addition to the Elixhauser 
comorbidity risk factors above.   
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The following describes the steps used in this study to calculate each patient’s total length 
of stay, including any assumptions that were made.  It should be noted that this 
calculation only uses inpatient claim utilization as a source (for the year 2010).   
 
Length of stay for a patient was calculated based on the following formula: 
 
Total length of stay (LOS) = sum [(date of discharge – date of admission) + 1] 
 
The following assumptions were used in the calculation above of length of stay.  First, for 
each person, a date of admission was updated with ‘Jan 1 2010’ if it was found that the 
date of admission for a patient was prior to 2010.  This ensures that length of stay will 
only go back only as far as Jan 1 2010.  This ultimately allows total length of stay for a 
patient to remain less than or equal to a year. 
 
In addition, the date of discharge for each person where the last occurring stay has a 
blank is updated with ‘Dec 31 2010’.  This is done to ensure that no null length of stays 
are obtained.  For each person with at least one record of an inpatient stay, total length of 
stay should at least be equal or exceed 1 day. 
 
Also, for each occurrence of an inpatient stay, a one is added to the calculation as is 
shown in the formula above.  This is done to ensure that the last day is counted as 
inclusive in the calculation and considered in the total for that inpatient stay. 
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Finally, there were some instances of patients having duplicate admission and discharge 
dates (i.e., having both of these the same).  For these patients, only one such occurrence 
is counted in the total length of stay calculation and the duplicates are not considered. 
 
In the tables below, the summary measures are shown for the final results for length of 
stay (n, min, max, mean and median).  In the first table (table 9), the results are shown 
only for patients who have an inpatient stay (Los variable).  In the second table, length of 
stay for patients without an inpatient stay is defined to be 0.  The results are defined in a 
new variable called Los_1 and those results are shown in table 1015. 
 
  Non-Duals Duals 
N 21,892 5,797 
Mean 8.28 10.27 
Median 5 6 
Min 1 1 
Max 266 366 
Table 9: Summary measures of Los variable, for non-dual and dual beneficiaries  
 
  Non-Duals Duals 
N 126,942 25,546 
Mean 1.43 2.33 
Median 0 0 
Min 0 0 
Max 266 366 
Table 10: Summary measures of Los_1 variable, for non-dual and dual beneficiaries 
 
3.4.1.3.2 Inpatient and Outpatient Admissions and Total Office Visits 
                                                 
15
 Note that Los_1 also captures if a patient has a hospitalization, since length of stay would be >=1 for that 
patient. 
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Other health utilization variables considered in the study include inpatient and outpatient 
total admissions and total office visits.  These totals are for each beneficiary during the 
year 2010.  Table 11 below shows summaries for all three of those measures (n, mean, 
median, min and max) for non-dual and dual beneficiaries in the year 201016.   
 
  Non-Duals   Duals 
  Inpatient Outpatient 
Office 
Visit   Inpatient Outpatient 
Office 
Visit 
N 126,942 126,942 126,942   25,546 25,546 25,546 
Mean 0.25 4.21 8.88 0.36 5.46 8.18 
Median 0 2 7 0 3 6 
Min 0 0 0 0 0 0 
Max 13 249 170   14 124 112 
Table 11: Summary measures for inpatient and outpatient admissions and office visits, 
for non-dual and dual beneficiaries  
 
3.4.1.3.3 Skilled Nursing Facility Admission 
 
In addition to inpatient and outpatient admissions and office visits, SNF stay was another 
health utilization variable considered in this study.  SNF stay is a binary measure that 
shows if a beneficiary has had at least one SNF inpatient admission during the year in 
2010.  For beneficiaries with no SNF stay during the year, a value of zero is assigned.  
Table 12 below shows the frequency distribution for the SNF stay variable, for both non-
dual and dual beneficiaries in 2010.  It should be noted that dual eligible beneficiaries are 
expected to have a significantly higher SNF stay rate than Medicare beneficiaries [6].  
                                                 
16
 As was done with LOS in table 10 above, all measures in table 11 are assigned a value of zero when a 
beneficiary does not have any utilization for that measure during the year. 
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This is reflected in Table 12, where the SNF rate of admission is almost twice that for 
dual eligible than for Medicare beneficiaries.   
 
  Non-Duals   Duals 
SNF_stay Count Percent Count Percent 
0 122,451 96.46%   23,522 92.08% 
1 4,491 3.54%   2,024 7.92% 
Table 12: Frequency distribution of SNF_stay variable, for non-dual and dual 
beneficiaries  
 
3.4.1.4 Analytical Factors 
 
Analytical factors are associated with each of the different hypotheses presented above.  
There are a total of three hypotheses and thus three analytical factors in the study.  The 
analytical factors in the study include total cost of treatment, physician factors 
(specialty/primary and rural/urban) and patient investment (patient cost and Medicaid 
State per beneficiary investment in the case of dual eligible).  Each of these analytical 
factors are presented here.  Note that these analytical factors are only used in the 
explanatory models and not the base predictive models, as was previously presented.  
Also, as has already been discussed, these analytical factors are considered controllable 
risk factors (this is in contrast to the previously discussed variables, which are treated as 
non-controllable risk factors).  The premise is that a health plan has the capability to vary 
these factors for a desired outcome in the treatment of a patient.  It is the intent of this 
dissertation to find the levels of these analytical factors that yield the best outcomes in 
patients’ progression of Diabetes complications. 
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3.4.1.4.1 Total Cost of Treatment 
 
Note: The discussion in this section is also applicable to patient cost sharing, which will 
be discussed below as part of the third analytical factor. 
 
Total cost of treatment includes all costs incurred by Medicare in treating the patient.  
These costs are incurred in the base year (2010).  The idea behind total cost of treatment 
is that it is a proxy for the quality of care given to a patient.  The combination of all costs 
incurred in treating the patient during the year present a picture of the level of care that a 
patient received during the year.  These costs consist of all components of care provided.  
These components are obtained from five different claim utilization sources: Carrier, IP, 
OP, SNF and HHA.   
 
The following presents the calculation used to obtain total cost of care for each of these 
five sources17.  The final amount for total cost of treatment is then obtained as the sum of 
the total cost of treatment of each of those five components. 
 
i. Carrier 
TCCarrier18 =  
Sum (Claim payment amount) 
 
ii. IP 
                                                 
17
 All of these calculations are obtained from RESDAC, from workshop presentation ‘Intro to Economic 
Research’ (www.resdac.org) 
18
 TC stands for Total Cost 
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TCIP =  
Sum (Claim Payment Amount + (Claim Pass Thru Per Diem Amount * Claim 
Utilization Day Count)) 
 
iii. OP 
TCOP = 
Sum (Claim payment amount) 
 
iv. SNF (same as IP) 
TCSNF =  
Sum (Claim Payment Amount + (Claim Pass Thru Per Diem Amount * Claim 
Utilization Day Count)) 
 
v. HHA 
TCHHA = 
Sum (Claim payment amount) 
 
Total cost of treatment is then calculated as the sum of each of the above components, as 
shown in the following formula: 
 
Total cost of treatment = TCCarrier + TCIP + TCOP + TCSNF + TCHHA 
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One of the first adjustments applied to total cost of treatment is to examine and remove 
beneficiaries with any negative costs from the data.  This process was applied to all five 
components of cost, in addition to total cost (the sum of the five components, as 
presented above).  The following table shows the total negative costs for each cost 
component in the study19.  Note that only components OP (107) and IP (6) actually had 
negative costs, while the remaining components did not.  The table also shows the 
percent of the total that is negative, which is <=0.1% in each case.  Since the percentage 
is so low, the negative costs were removed from the study sample.  A total of 107 
beneficiaries are removed, bringing the sample size of beneficiaries from 152,601 to 
152,488 beneficiaries (this was presented earlier in the data collection section and is 
given here in more details). 
 
 
  Total Negative Percent 
Total 6 0.00393% 
Carrier - 0.00000% 
OP 107 0.07012% 
IP 6 0.00393% 
SNF - 0.00000% 
HHA - 0.00000% 
Table 13: Total occurrences of negative costs by cost component, in 2010 
 
After removing any beneficiaries with negative costs, the next consideration to make is 
with regards to outlying observations in the data.  In health insurance claims, it is not 
unusual to have some extreme individuals with unusually high costs [63].  These extreme 
                                                 
19
 The results shown in table 9 are for both non-dual and dual beneficiaries 
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cases are generally better to be left out of the study rather than to keep them in and bias 
the outcome.  One common approach to handle these outlying observations is with the 
Winsor technique, or winsorization [64].  Winsorization is a technique that censors 
extreme cases based on a designated percentile level.  This technique can be applied to 
both low as well as high extreme value by designating a range of percentiles (i.e., 1 to 99 
percentile).  However, in this study, there is no need to censor low cost values, as the 
minimum cost (after removing negative costs) is at zero.  It would not be appropriate to 
censor those zero cost values to some specified percentile level (for instance, 1 
percentile), since it would be desired to study beneficiaries who have zero costs.  
However, winsorization is applied to the high cost values.  In this study, a percentile level 
of 99 is designated as the value to censor extreme high cost values.  Thus any value 
greater than 99 percentile is set at the 99 percentile.  Winsorization is applied to each cost 
component in addition to total cost. 
 
After removing negative costs and applying the winsorization technique, the following 
tables give the summary of the cost results, by each cost component and total cost.  The 
first table (table 14) shows the summary for non-dual beneficiaries while the second table 
(table 15) shows the summary for dual beneficiaries, both for 2010.  In both tables, 
summary measures include the sum, mean, median, min and max20.   
 
 
 
                                                 
20
 Note that the sum of the cost components does not equal total cost, which is due to winsorization being 
applied to each of the cost components in addition to total cost. 
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  N  Sum   Mean   Median   Min   Max  
Total 126,942 $853,182,072.00 $6,721.04 $2,220.98 $0.00 $69,410.09 
Carrier 126,590 $305,728,412.00 $2,415.11 $1,491.73 $0.00 $17,009.21 
OP 95,962 $139,172,365.00 $1,450.29 $545.98 $0.00 $17,266.62 
IP 21,892 $299,001,403.00 $13,658.02 $9,076.75 $0.00 $80,658.69 
SNF 4,491 $59,294,697.26 $13,203.01 $10,196.46 $0.00 $52,313.05 
HHA 9,872 $54,911,844.43 $5,562.38 $3,569.01 $0.00 $32,178.97 
 Table 14: Summary measures for total cost, for non-dual beneficiaries in 2010 
 
  N  Sum   Mean   Median   Min   Max  
Total 25,546 $248,423,519.00 $9,724.56 $3,138.52 $0.00 $92,939.74 
Carrier 25,393 $65,978,398.28 $2,598.29 $1,610.23 $0.00 $16,888.99 
OP 20,132 $36,362,234.62 $1,806.19 $752.74 $0.00 $20,319.32 
IP 5,797 $84,237,071.57 $14,531.15 $8,945.29 $0.00 $94,881.76 
SNF 2,024 $30,830,609.56 $15,232.51 $11,948.36 $0.00 $58,194.43 
HHA 4,060 $31,291,360.01 $7,707.23 $4,976.32 $0.00 $54,030.22 
 Table 15: Summary measures for total cost, for dual beneficiaries in 2010 
 
After obtaining the winsorized total costs (including each cost component), a final 
transformation was to create discrete buckets for the winsorized total cost variable.  This 
new variable is a discrete variable, in contrast to the original total cost variable.  Total 
cost was divided into five equal groups (or quintiles) and the new variable is called 
cost_all.  Cost_all consists of five distinct levels, each containing 25,388 values (or 20 
percent of the entire set).  Cost levels for cost_all variable are assigned in descending 
order (i.e., the highest cost level is assigned a value of ‘0’ and the lowest cost level a 
value of ‘4’). 
 
3.4.1.4.2 Physician Factors 
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Physician factors consist of analytical factors related to the physician (MD).  There are 
two components that will be considered related to the MD factors, each according to the 
hypotheses presented earlier.  The first part will consider whether primary vs. specialty 
type physician has an impact on the development of complications in Diabetes patients.  
In the second part, the impact of urban vs. rural type physician will be evaluated on the 
development of complications in Diabetes patients.  The following will provide a 
discussion for each of those components in more detail.  
 
One unique aspect of the MD factors (both primary vs. specialty and urban vs. rural) is 
that they are both applicable only to patients who have had a physician visit during the 
year.  Thus, the data source for this part will be limited to beneficiaries who have had 
claims for a physician visit in 2010.  This is in contrast to all the other variables in the 
model that use all of the data available for beneficiaries without any such restriction21.  
Thus, all models using the MD factors (both primary vs. specialty and urban vs. rural) 
will be limited to only beneficiaries who have record of carrier claim utilization.  
However, in this study it appears that the majority of patients do actually have a 
physician visit during the year (and hence have utilization in the carrier claim file).  In 
this study, out of 152,488 total beneficiaries (as was given earlier), only 505 do not have 
any carrier claim utilization.  As was shown in tables 10 and 11 above, non-dual 
beneficiaries have a total of 126,590 beneficiaries (out of 126,942) and dual beneficiaries 
have a total of 25,393 beneficiaries (out of 25,546) with utilization in the carrier claim 
file in 2010.   
                                                 
21
 Even though LOS and cost components are also restricted in their data sources, these variables are 
updated to include zero for non-utilizers.  With MD factors, this is not possible and non-utilizers must be 
eliminated from the study data set. 
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3.4.1.4.2.1 Primary vs Specialty 
 
To determine whether a primary vs. specialty type physician has an impact on a patient’s 
development of Diabetes complications, it is first necessary to determine the type of 
physician attributed to a given patient (whether primary or specialty).  This is not a 
straightforward problem, due to the fact that a patient typically has multiple physician 
visits during the course of the year with a range of specialty types. There is considerable 
literature on the problem of provider attribution to patients [65, 66].  The approach taken 
in this dissertation follows closely the process outlined in a related CMS project, the 
Generating Medicare Physician Quality Performance Results (GEM) Project22,23.  There 
are two components to this process: first classifying physicians as primary or specialty 
and second, attributing a patient to a given physician specialty.  The following describes 
these two components. 
 
First, all of a patient’s visits during the base year (2010) are obtained from the carrier 
claim utilization file.  The classification of the physician specialty for each of these visits 
is also obtained from the carrier claim utilization file.  The carrier claim utilization file 
contains a specialty code associated with the performing physician for each visit on 
record.  These physician specialty codes obtained from the carrier claim utilization file 
are then linked to a crosswalk available from CMS, the CMS Specialty Codes/Healthcare 
                                                 
22
 http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-
Instruments/GEM/downloads/GEMMethodologies.pdf 
23
 The GEM project created quality measures for physician group practices in 2006-2007 based on 
Healthcare Effectiveness Data and Information Set (HEDIS) quality measures  
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Provider Taxonomy Crosswalk24.  This crosswalk provides a specialty description 
associated with each of the physician specialty codes.   
 
Not all physician specialties are suitable for consideration, as many represent entities 
different from a physician provider (this includes physicians, physician assistants and 
nurse practitioners).  For instance, many specialties represent labs, pharmacy or other 
non-physician type of entities.  These specialties are excluded from consideration, as the 
main objective here is to classify a patient according to that patient’s record of visits to a 
physician provider.  Following the approach in the GEM project, a set of qualifying 
physicians is obtained that restricts the total visits considered in this study.  The list of 
eligible physician providers that are considered in this analysis can be obtained from the 
GEM project, in Appendix B. 
 
One impact of limiting the physician specialties in this manner is that the data will also be 
restricted (beyond simply the restriction of beneficiaries having a physician visit in 
2010).  The impact will be illustrated below (in table 17) where the frequency of a 
physician specialty by beneficiary is presented.  
 
After obtaining and limiting physician specialties for patient visits from the 2010 carrier 
claim utilization file, these specialties are classified as either primary or specialty.  Table 
16 below shows the physician specialties that are grouped as primary.  All remaining 
specialties are subsequently grouped as specialty.  One important consideration in the 
                                                 
24
 Available from CMS at http://www.cms.gov/Medicare/Provider-Enrollment-and-
Certification/MedicareProviderSupEnroll/downloads/taxonomy.pdf 
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specialty grouping below is with regards to physician assistants and nurse practitioners.  
In many cases, these health providers’ work varies as primary or specialty, depending on 
the physician specialty type they are associated with [67].  In the GEM project, these 
specialties are classified based on the physician practice they are associated with (the 
practice where the majority of the services by the physician are performed).  However 
grouping physicians by practice is not part of this dissertation25. Instead, physician 
assistant and nurse practitioners are simply considered as primary specialties here. 
 
Primary Specialty 
General practice 
Family practice 
Internal medicine 
Geriatric medicine 
Preventive medicine 
Nurse practitioner 
Physician assistant 
Table 16: Physician primary specialty types 
 
After each physician visit is classified as either primary or specialty, the next step is to 
attribute each patients to a physician.  Instead of attributing a patient to a specific 
physician; however, the approach taken here is to attribute a patient to a physician 
specialty (primary or specialty).  Total visits for each patient are obtained in 2010 by 
primary and by specialty physician types.  These totals for primary and specialty 
physician types are then compared and the maximum is attributed as the physician 
                                                 
25
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specialty type for that patient26.  Thus, a patient’s physician will be determined according 
to the specialty type (primary or specialty) most frequently visited for that patient.  The 
following table shows the frequency results for physician specialty type for beneficiaries 
in the study, captured by a variable called ‘Prmry’ ( ‘1’ means primary and ‘0’ means 
specialty).  These results are shown for non-dual and dual beneficiaries in the year 2010. 
 
  Non-Duals   Duals 
Prmry Count Percent   Count Percent 
0 69,328 55.00%   12,025 47.82% 
1 56,726 45.00%   13,121 52.18% 
Table 17: Frequency distribution of Prmry variable, for non-dual and dual beneficiaries 
 
The results in table 17 show that the total data set is reduced from only beneficiaries who 
have a physician visit in 2010.  As was mentioned previously, limiting the physician 
specialties to only physician providers would further restrict the data set.  For non-dual 
beneficiaries, the total is reduced from 126,590 to 126,054 beneficiaries and for dual 
beneficiaries the total is reduced from 25,393 to 25,146 beneficiaries.   
 
Finally, one last restriction was considered in attributing patients to physician specialty types.  In 
the Prmry variable above, all physician visits are compared for their specialties being either 
primary or specialty.  However, in the GEM project, only a select set of primary care visits are 
considered for this comparison.  The visits are limited to only those that are office visits or 
consultations.  Thus, provider specialty attribution is limited to only primary care services 
provided by physicians.  This approach is also followed in this dissertation.  However, the 
                                                 
26
 In the case of a tie, a primary care visit is assigned as the maximum for that patient 
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definitions of office visits and consultations are obtained based on Current Procedure 
Terminology (CPT) codes criteria as defined by the Health Care Cost Institute (HCCI)27. 
 
A new variable (called ‘Prmry_p’) is obtained where physician visits are restricted to office visits 
and consultations.  Table 18 shows the frequency results for the variable Prmry_p, for non-dual 
and dual beneficiaries in 2010.  Notice how the percentages change in table 18 in comparison to 
table 17 (there is an increase in percentage of primary physician type).  The analysis portion will 
be based on Prmry_p variable, as it is the one most likely to capture the specialty type for a given 
patient. 
 
  Non-Duals   Duals 
Prmry_p Count Percent   Count Percent 
0 43,872 34.80%   7,249 28.83% 
1 82,182 65.20%   17,897 71.17% 
Table 18: Frequency distribution of Prmry_p variable, for non-dual and dual 
beneficiaries  
 
3.4.1.4.2.2 Urban vs Rural 
 
In addition to considering physician specialty type for beneficiaries, a second objective 
with regards to physician factors is to consider the impact that urban vs. rural physician 
type has on development of Diabetes complications in patients.  As was done above with 
physician specialty type, it is first important to assign each patient to either a rural or 
urban physician type.  However, as before, this is not a straightforward problem due to 
patients having multiple physician visit types during the year.   
                                                 
27
 See Appendix 4.4 in the HCCI methodology document available at: 
http://www.healthcostinstitute.org/files/HCCI%202013%20Methodology%20v3.3.pdf 
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However, unlike with physician specialty, there is no code to identify urban vs. rural 
physicians for a beneficiary in the carrier claim utilization file.  As a result, each patient’s 
urban vs. rural physician designation will be approximated using the patient’s location 
(instead of the physician’s).  This should yield a fairly close approximation as it’s pretty 
reasonable to assume that a patient is likely to visit a physician close to where that patient 
resides in most cases.  Information about a beneficiary’s location is available in the 
beneficiary file.   
 
To determine the patient’s urban vs. rural location type, there are two steps involved.  
First, the state and county for a beneficiary are identified using the beneficiary file.  Then 
the state and county are linked to a CMS crosswalk table ‘County to CBSA Crosswalk’28 
to obtain the beneficiary’s urban vs. rural classification.  A patient’s physician is then 
assigned an urban vs. rural classification based on the results of the classification 
obtained for the beneficiary.  Hence, each beneficiary is assigned an urban vs. rural 
physician type based on that beneficiary’s urban vs. rural location.   
 
Based on this approach, a new variable called ‘Urb’ was created to capture whether a 
patient is assigned an urban vs. rural physician type.  The table below shows the 
frequency results for the ‘Urb’ variable, for non-dual and dual beneficiaries in 2010.   
 
                                                 
28
 For this study, the FY 2012 ‘County to CBSA Crosswalk’ file was obtained from CMS website 
(http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY-2012-IPPS-
Final-Rule-Home-Page-Items/CMS1250507.html) 
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  Non-Duals   Duals 
Urb Count Percent   Count Percent 
Rural 31,525 24.95%   6,514 25.68% 
Urban 94,835 75.05%   18,852 74.32% 
Table 19: Frequency distribution of Urb variable, for non-dual and dual beneficiaries  
 
As was mentioned above, the distribution displayed in the table above applies only for 
beneficiaries actually having a visit to a physician during the year (i.e., having a record in 
the carrier claim utilization file).  But another restriction occurs with rural vs. urban, 
which further reduces the total number of cases available (from a total of 177,945 as 
shown above).   When linking the beneficiary file to the ‘County to CBSA Crosswalk’ 
table, there were a total of 326 beneficiaries whose state/county combination did not 
result with a match.  Thus, those 326 cases were not found in the ‘County to CBSA 
Crosswalk’ and they were not classified as either rural or urban.  These 326 cases would 
be left out of this part of the analysis.  The model for urban vs. rural physician factors 
will thus only consist of 177,619 cases. 
 
3.4.1.4.3 Patient Cost Sharing 
 
3.4.1.4.3.1 Non-Dual Beneficiaries 
 
For non-dual Medicare beneficiaries, patient cost sharing (or patient total cost) refers to 
the total amount of cost paid by the patient during the base year.  Patient total cost is 
similar to total cost of treatment discussed above.  However, a major distinction is that 
patient total cost refers to the total amount paid by the patient, instead of by Medicare as 
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was the case for total cost of treatment previously.  Medicare does not cover all expenses, 
and patients typically have to pay additional out of pocket expenses to cover their care.  
These patient out of pocket expenses typically include a combination of a deductible, 
coinsurance and/or copayment.   
 
As was done with total cost of treatment above, patient total cost is obtained by first 
calculating each component of cost based on each of the claim utilization sources 
(Carrier, IP, OP, SNF and HHA).  Then, as was also done previously, the patient total 
cost is obtained by summing each of those components of patient costs.  The following 
shows those steps, first the calculation of each cost component, then the sum to obtain the 
final patient total cost. 
 
i. Carrier 
PTCCarrier29 =  
Sum (Line Coinsurance Amount30 + Carrier Claim Cash Deductible Applied 
Amount) 
 
ii. IP 
PTCIP =  
Sum (Beneficiary Inpatient Deductible Amount + Beneficiary Part A Coinsurance 
Liability Amount + Beneficiary Blood Deductible Liability Amount) 
 
                                                 
29
 PTC stands for Patient Total Cost 
30
 Payment obtained at the line Item from carrier claim utilization  
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iii. OP 
PTCOP =  
Sum (Beneficiary Part B Deductible Amount + Beneficiary Part B Coinsurance 
Liability Amount + Beneficiary Blood Deductible Liability Amount) 
 
iv. SNF (same as IP) 
PTCSNF =  
Sum (Beneficiary Inpatient Deductible Amount + Beneficiary Part A Coinsurance 
Liability Amount + Beneficiary Blood Deductible Liability Amount) 
 
v. HHA-Populated less than .05%, and is not calculated (set to zero for all 
home health beneficiaries)31.  
PTCHH = 0 
 
Patient total cost is then calculated as the sum of each of the above components, and is 
shown in the following formula (in a similar way as total cost of treatment was obtained 
above): 
 
Patient total cost = PTCCarrier + PTCIP + PTCOP + PTCSNF + PTCHH 
 
After calculating patient total cost, additional adjustments are made similar to what was 
done above with total cost of treatment.  First, any beneficiaries with negative patient cost 
components or patient total cost are identified in the data set so that they can be removed 
                                                 
31
 From http://www.resdac.org/ 
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from the data (as was done with total cost of treatment).  However, in this case there were 
no negative cost values for any of the patient cost components or patient total cost for any 
of the beneficiaries.  Thus, no adjustment was necessary in this case. 
 
In addition to the consideration of negative costs among beneficiaries, outlying patient 
cost values are censored with the winsorization technique as was done with total cost of 
treatment.  The specifications for censoring applied for patient costs are the same as those 
used with total costs of treatment-censor only high outlying values at 99 percentile, while 
leaving the low outlying values uncensored (these values are all zero, due to no negative 
patient costs among beneficiaries).  After applying winsorization to patient costs, the 
following table shows the summary results for patient costs by components and for total 
patient cost, for non-dual beneficiaries in year 201032.   
 
  N  Sum   Mean   Median   Min   Max  
Total 126,942 $164,118,690.00 $1,292.86 $642.99 $0.00 $9,944.13 
Carrier 126,590 $85,470,663.13 $675.18 $451.52 $0.00 $4,281.33 
OP 95,962 $39,946,990.28 $416.28 $172.60 $0.00 $3,934.21 
IP 21,892 $27,236,845.88 $1,244.15 $1,100.00 $0.00 $3,300.00 
SNF 4,491 $9,969,184.00 $2,219.81 $275.00 $0.00 $11,000.00 
HHA 9,872 $0.00 $0.00 $0.00 $0.00 $0.00 
Table 20: Summary measures for patient cost, for non-dual beneficiaries  
 
Similar to what was done with total cost above, a discretized variable for patient total cost 
was also created.  The new variable is called cost_all_p, and contains five discrete 
buckets of patient total cost, as was done with total cost.  Each cost bucket for cost_all_p 
                                                 
32
 Only a summary for non-dual beneficiaries is given here-for dual beneficiaries the results will use 
Medicaid State investment (covered in the next section). 
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contains 5,109 cases (or 20% of the whole).  The levels for cost_all_p are also assigned in 
descending order, as was done with cost_all previously. 
 
3.4.1.4.3.2 Dual Beneficiaries 
 
Patient total costs for dual eligible patients are obtained differently than for non-dual 
Medicare beneficiaries.  Dual eligible beneficiaries are generally not responsible for cost 
sharing requirement as are non-dual beneficiaries.  Due to their dual enrollment eligibility 
(in both Medicare and Medicaid), the out of pocket expenses (or premiums) for dual 
eligible beneficiaries are paid for by Medicaid [68].  These expenses that Medicaid pays 
are funded in part by the state (along with a match by the federal government)33.   
 
To obtain a sense of the patient investment for dual eligible beneficiaries in this 
dissertation, data regarding each state’s Medicaid per beneficiary investment was 
obtained.  This data is available from the CMS Medicaid Statistical Information System 
(MSIS) State Summary Datamart.  The datamart used is for the year 2010, corresponding 
with the base year of this study.  Two components from the 2010 datamart are used to 
obtain total Medicaid investment per beneficiary by state.  First, total Medicaid paid 
amount is obtained, which shows the total invested by a state in Medicaid.  In addition, 
the unique beneficiary count is also obtained.  This count will be used to derive total 
Medicaid investment by beneficiary in each state.  Appendix C shows those results for 
each state, including total Medicaid paid amount, unique beneficiary count and Medicaid 
                                                 
33
 More detail on the Federal Medical Assistance Percentage (FMAP) is available at 
http://kff.org/medicaid/state-indicator/federal-matching-rate-and-multiplier/ 
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invested by beneficiary.  This latter value will be used in the analysis to evaluate the 
Medicaid investment per beneficiary corresponding with each dual eligible beneficiary in 
the study.  It is of interest in this dissertation to evaluate the impact that the amount 
invested in Medicaid per beneficiary has on development of complications Diabetes for 
dual eligible patients. 
 
After obtaining total Medicaid investment per beneficiary by state, those values are 
assigned to each beneficiary based on that beneficiary’s designated state (this value is 
obtained from the beneficiary file).  There is no need to apply winsorization in this case 
as was done above, as the values obtained for each individual beneficiary are an average 
for that beneficiary’s state of residence.  Thus, extreme values are already smoothed out 
in this data, eliminating the need for winsorization.  The summary results for Medicaid 
investment by beneficiary in year 2010 is given in table 21 below.  The results given 
below are for all beneficiaries, including all states.  For a summary listing by state, 
Appendix C provides the amount invested in Medicaid by beneficiary by state. 
 
  N  Sum   Mean   Median   Min   Max  
Total 25,517 $131,286,625.00 $5,145.07 $4,744.25 $2,870.79 $9,520.27 
Table 21: State Medicaid Investment by unique beneficiary, in year 2010 
 
Note that there are some missing beneficiaries in the results above (29 out of a total 
25,546 dual eligible beneficiaries, given earlier).  The reason is that these beneficiaries 
are from state and county regions that were not found on the county list (the ‘County to 
CBSA Crosswalk’ table, which was discussed above for provider factors).  There were 2 
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cases out of those 29 that actually did have a state and county in the ‘County to CBSA 
Crosswalk’ table.  However, for those 2 cases, they were both from Puerto Rico-which is 
not included in the list of Medicaid investment per beneficiary (see Appendix C for a 
complete list by State).  As a result, the data set for patient total cost for dual eligible 
beneficiaries will only consist of a total of 25,417 total cases (instead of the full 25,546 
cases for dual beneficiaries).   
 
Finally, a discretized variable was created for the amount spent by beneficiary in each 
state (as was done for both total cost and patient total cost above).  The new variable is 
called mcaid_all and also consists of five equal buckets.  Each bucket of mcaid_all 
consists of values.  Again, as was done previously, the levels of mcaid_all were assigned 
in descending order. 
 
3.4.2 Outcome Variables 
 
There will be three outcomes in this study, all relating to Diabetes complications: 
retinopathy, nephropathy and neuropathy.  These are the three main long-term 
microvascular complications that patients with Diabetes typically develop [7].  This study 
will seek to evaluate the impact that factors presented up to this point have on 
development of those complications in Diabetes patients.  In particular, the first part of 
the study will focus on the impact that health risk factors (socio-demographic and health 
comorbidities) have on development of those three complications.  The latter part of the 
study will focus on answering the three hypotheses presented above, related to the impact 
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of the analytical factors on development of Diabetes complications in patients: total cost 
of treatment, MD effect (primary vs. specialty and urban vs. rural) and patient cost 
sharing (or Medicaid State investment by beneficiary for dual eligible beneficiaries). 
 
Beneficiaries in this study are selected as those diagnosed with Diabetes but having no 
indication of any long-term Diabetes complications in the first year (2010).  In the 
follow-up year (2011), development of three Diabetes complications is evaluated for each 
of those beneficiaries.  The following describes the process used to identify beneficiaries 
that develop complications in 2011.  The data used for this process involves all five claim 
utilization source files for 2011 (Carrier, IP, OP, SNF and HHA).   
 
As was performed for 2010, in each of the claim utilization file sources, the primary 
diagnosis and five additional diagnosis codes were scanned for any occurrence of any of 
the three Diabetes complications.  A diabetes complication is defined based on a set of 
criteria for each of those three complications (as defined in Appendix A).  In this case; 
however, only these three complications are evaluated for occurrence for a beneficiary in 
2011.  The additional ICD-9 code range 250.7x-250.9x, which were presented earlier for 
2010, will not be considered as an outcome in 2011 (they are only used to remove 
beneficiaries with a history of any long-term Diabetes complications).  As was done in 
2010, beneficiaries are defined to have a Diabetes complication with at least one 
occurrence in claim utilization source files IP, SNF and HHA, or at least two occurrence 
for claim utilization sources Carrier and OP.  
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Based on this process, the following table presents the results of the frequency for the 
Diabetes complications in this study-retinopathy, nephropathy and neuropathy.  The 
results are shown for both non-dual and dual beneficiaries in year 2011.   
 
    Non-Duals   Duals 
Complication Count Percent Count Percent 
Retinopathy no 123,615 97.38%   24,677 96.60% 
  yes 3,327 2.62%   869 3.40% 
Nephropathy no 119,330 94.00%   23,704 92.79% 
  yes 7,612 6.00%   1,842 7.21% 
Neuropathy no  120,458 94.89%   23,698 92.77% 
  yes 6,484 5.11%   1,848 7.23% 
Table 22: Frequency distribution of Diabetes complication (retinopathy, nephropathy and 
neuropathy), for non-dual and dual beneficiaries  
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Chapter 4 Model 
 
There will be two different types of models that are explored in this dissertation.  First, 
predictive models of Diabetes complications are considered.  These predictive models 
explore the impact that various risk factors have on the development of Diabetes 
complications in Medicare and dual eligible beneficiaries.  The risk factors included in 
the predictive models include all independent variables presented in Chapter 3 
previously, with the exception of not including any of the analytical factors.  Thus, the 
risk factors that have an impact on development of Diabetes complications for 
beneficiaries are explored in these predictive models.   
 
In addition to the predictive models, explanatory models are then considered.  The 
purpose of explanatory models is to consider the impact of the analytical factors on the 
development of Diabetes complications in beneficiaries.  However, in addition to the 
analytical factors, these explanatory models will include all the independent variables 
considered in the predictive models (i.e., all independent variables presented in Chapter 3 
are included in the explanatory models).  By including the other independent variables in 
the model allows risk adjustment of the impact that analytical factors have on the 
development of Diabetes complication rates in beneficiaries.  Thus, explanatory models 
are concerned with evaluation of the risk adjusted impact that analytical factors have on 
Diabetes complication development in beneficiaries.  It is hoped that the findings from 
those models would lead to conclusion regarding the best approaches of care for 
beneficiaries.  
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In both the predictive models and the explanatory models, logistic regression will be used 
as the modeling approach.  The main reason for this modeling approach is due to having 
a binary outcome in the study.  In both models, the outcome is whether a beneficiary 
develops a certain Diabetes complication in year 2 (i.e., retinopathy in year 2).  The 
covariates in the logistic regression model will include both discrete and continuous 
variables.  All the modeling in this dissertation will be performed using SAS statistical 
software, version 9.3 (SAS Institute Inc., Cary, NC). 
 
4.1 Predictive Model 
 
The first part of the dissertation will explore predictive models of Diabetes complication 
rates.  These predictive models will include all the independent variables, as presented 
previously, with the exception of the analytical factors.  The following illustrates the 
mathematical notation of the predictive models. 
 
In equation form, these components can be represented as: 
Logit (P(Yi=1)) = ∑i Xi αi + ∑j Comorbj βj + ∑k Utilk γk  
 
Where, 
1. Logit (P(Yi=1) = ln (P(Yi=1) / (1 - P(Yi=1))) 
2. Yi is Diabetes complication outcome (0=no, 1=yes), where 
i=1, retinopathy; i=2, nephropathy; i=3 neuropathy 
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3. Xi are socio-demographic factors (age, sex and race) 
4. Comorbj are comorbidity factors 
5. Utilk  are health utilization factors (LOS, SNF stay, outpatient and inpatient 
admissions and total office visits) 
 
Each complication (i.e., retinopathy, nephropathy and neuropathy) will be modeled 
separately.  Thus, there will be three predictive models for each complication.  This 
process is repeated for both non-dual and dual beneficiaries.  The total models that will 
be fit will thus be six.   
 
Stepwise logistic regression will be used to model each of the six predictive models.  
Stepwise regression is a variable selection process where variables are considered in a 
model based on significance criteria.  However, as each variable is added to the model, 
variables that become non-significant are removed from the model.  This process 
continues until a model with only significant variables remain (based on the set criteria).  
Stepwise logistic regression will thus allow the predictive models to contain only the 
significant risk factors (all other non-significant factors are not included in the final 
results).  The criteria used in the stepwise regression process in this study is as follows 
(based on SAS terminology):  slentry=.25 and slstay=.05.  In the case of slentry, this 
refers to the significance probability required for a variable to enter a model for 
consideration.  A fairly relaxed criteria (.25) is used to allow for consideration of as large 
a number of variables.  On the other hand, slstay refers to the significance probability 
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needed for a variable to remain in the model.  A more stringent criteria is used (.05) to 
ensure that only significant risk factors are included in the final predictive model. 
 
4.2 Explanatory Model 
 
As discussed above, explanatory models will add the analytical factors to the variables 
already included in the predictive models.  However, the purpose of the two types of 
models is quite different.  In the predictive models, the risk factors are evaluated for their 
significance in development of Diabetes complications in beneficiaries.  However, 
explanatory models will use the risk factors to allow for risk adjustment of the impact 
that analytical factors have on development of Diabetes complication development in 
beneficiaries. 
 
The modeling approach for explanatory models will not use stepwise selection, as was 
the case with the predictive models.  The reason is that there is no need to only consider 
significant risk factors in risk adjustment.  All risk factors are left in the model, along 
with the analytical factors.  The modeling approach will simply use logistic regression to 
evaluate the impact that the risk adjusted analytical factors have on the development of 
Diabetes complications in beneficiaries.  However, only the impact of the analytical 
factors will be of interest in this case, as the remaining risk factors are used solely for risk 
adjustment of the analytical factors.  The results will simply include the risk adjusted 
impact of the analytical factors on the development of Diabetes complications in 
beneficiaries. 
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The following will illustrate the mathematical notation of the explanatory models.  Note 
that for each hypothesis (i.e., corresponding to each analytical factor), there will be six 
different explanatory models-three based on each outcome, and this is repeated for both 
non-dual and dual beneficiaries (as was the case with the predictive models).  Hence, 
there will be a total of 18 total explanatory models, after consider the three different 
hypotheses. 
 
4.2.1 Hypothesis I 
 
The variables in the explanatory models for hypothesis I include all the variables 
presented above in the predictive model.  In addition, treatment cost levels are also added 
to the list of covariates.  The following shows the notation for the treatment cost levels. 
 
∑k Treatk βk 
 
Where Treatk refers to the cost levels for total treatment cost.  There are a total of 5 cost 
levels, ranging from the lowest cost (level ‘4’) to the highest cost (level ‘0’).
 
 
4.2.2 Hypothesis II 
 
The variables in the explanatory models for hypothesis II include all the variables in the 
predictive model.  In addition, two physician factors are added to the model: specialist vs. 
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generalist and urban vs. rural factors.  Also, the interaction between those two physician 
factors is also added.  The notation for the physician factors in the model is as follows: 
 
∑x Phys1x α1x  +  ∑y Phys2y α2y  +  ∑x ∑y Phys1x Phys2y α3xy   
 
Where Phys1x Phys2y refer to the specialist vs. generalist and urban vs. rural physician 
factors, respectively (along with their interaction).  Both of the physician factors consist 
of two levels. 
 
4.2.3 Hypothesis III 
 
4.2.3.1 Non-Dual Beneficiaries 
 
The variables in the explanatory models for hypothesis II include all the variables in the 
predictive model.  In addition, total patient cost sharing levels are also added to the list of 
covariates.  The following shows the notation for the total patient cost sharing levels. 
 
∑n Patientn δn 
 
Where Patientn refers to the levels for total patient cost sharing.  There are a total of 5 
levels, ranging from the lowest cost (level ‘4’) to the highest cost (level ‘0’)
 
 
4.2.3.1 Dual Beneficiaries 
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For dual beneficiaries, instead of adding total patient cost sharing, state per beneficiary 
investment is added to the variables in the predictive model.  This is due to dual 
beneficiaries receiving cost sharing payment from the Medicaid program, as was 
discussed.  The following shows the notation for the state per beneficiary investment in 
Medicaid: 
 
∑m Capitam ρm 
 
Where Capitam refers to the cost levels for state per beneficiary investment.  There are a 
total of 5 levels, ranging from the lowest cost (level ‘4’) to the highest cost (level ‘0’)
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Chapter 5 Results and Discussion 
 
5.1 Predictive Model Results 
 
For the predictive models, results shown will include the outcomes of the stepwise 
logistic regression models.  The outcomes will show the significant factors for each 
model.  Those are the factors that are considered predictive of the Diabetes complication 
in each model.  In the tables shown, only the odds ratios are presented for each significant 
factor, along with confidence limits for those odds ratios.  In addition, in Appendix E, the 
full results from the model output, including parameter estimates and significance levels 
are shown.  Finally, a graphical output of the odds ratios are also included in Appendix E.  
Those graphs plot the odds ratio in descending order, to highlight those factor determined 
to be the most predictive of the Diabetes complication for each model.  
 
In each of the predictive models, only positive significant comorbidity risk factors were 
allowed to remain in the model.  Thus, if a beneficiary had a negative significant 
comorbidity (i.e., having the condition improved the complication outcome rate), then 
that comorbidity factor was removed from the model, and the model was re-fit.  The 
justification for this process is that there is acceptable clinical interpretation for this result 
and it is removed from consideration in the model34. 
 
5.1.1 Non-Dual Beneficiaries 
                                                 
34
 For all model results presented below, the variables are shown in abbreviated format.  For a more 
detailed description of the variables, refer to Appendix D, which contains a glossary of the model variables. 
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5.1.1.1 Retinopathy 
 
The following table shows the odds ratios for the significant factors for the predictive 
model of retinopathy complication among non-dual beneficiaries.  For this model, two 
comorbidity factors were removed from consideration (due to having negative significant 
results): copd and rheum_a.  The factors were removed and the model was re-fit in each 
case.  The final results are shown in Table 23.  
 
  
Odds 
Ratio 
Lower 
95% CL 
Upper 
95% CL 
race_1   Other vs White 1.111 0.937 1.317 
race_1   Black vs White 1.522 1.366 1.696 
ov_1 1.008 1.004 1.013 
snf_stay 1 vs 0 0.792 0.645 0.973 
HPTN_C   1 vs 0 1.131 1.01 1.267 
Lymp     1 vs 0 1.347 1.02 1.78 
Table 23: Odds ratios (with 95% CLs) for retinopathy complication, for non-dual 
beneficiaries 
 
 
5.1.1.2 Nephropathy 
 
The following table shows the results for the nephropathy complication, among non-dual 
beneficiaries.  For this model, there were no negative significant factors, and none were 
removed from the model for re-fitting.  However, one variable was removed initially 
from consideration, the rf variable (or renal failure).  The rf variable is very highly 
correlated with nephropathy and it was of interest to evaluate the other predictive factors 
that had an impact on development of nephropathy complication. 
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Odds 
Ratio 
Lower 
95% CL 
Upper 
95% CL 
sex           M vs F 1.319 1.258 1.384 
race_1        Other vs White 1.052 0.933 1.187 
race_1        Black vs White 1.271 1.172 1.379 
age_grp       80_over vs 64_to_69 1.837 1.719 1.963 
age_grp       75_to_79 vs 64_to_69 1.458 1.359 1.564 
age_grp       70_to_74 vs 64_to_69 1.202 1.123 1.287 
op_tot_stay_1 1.013 1.009 1.016 
ov_1 1.003 1 1.007 
snf_stay      1 vs 0 0.852 0.759 0.956 
CHF           1 vs 0 1.63 1.534 1.733 
PCD           1 vs 0 1.192 1.065 1.335 
PVD           1 vs 0 1.134 1.069 1.204 
HPTN_NC       1 vs 0 1.479 1.356 1.614 
HPTN_C        1 vs 0 1.561 1.458 1.671 
COPD          1 vs 0 1.097 1.035 1.164 
Obesity       1 vs 0 1.193 1.096 1.3 
Fluid         1 vs 0 1.323 1.235 1.418 
DA            1 vs 0 1.167 1.083 1.257 
Table 24: Odds ratios (with 95% CLs) for nephropathy complication, for non-dual 
beneficiaries 
 
5.1.1.3 Neuropathy 
 
The following table shows the results for the predictive factors for the neuropathy 
complication predictive model, among non-dual beneficiaries.  Three comorbidity were 
removed and the model re-fit, due to having negative significant results.  The factors 
removed included: coag, tumor and lymp. 
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Odds 
Ratio 
Lower 
95% CL 
Upper 
95% CL 
sex           M vs F 1.076 1.022 1.132 
race_1        Other vs White 0.815 0.706 0.941 
race_1        Black vs White 1.181 1.081 1.291 
age_grp       80_over vs 64_to_6 1.146 1.067 1.23 
age_grp       75_to_7 vs 64_to_6 1.076 1 1.158 
age_grp       70_to_7 vs 64_to_6 1.026 0.958 1.098 
op_tot_stay_1 1.006 1.002 1.01 
ov_1 1.023 1.02 1.026 
snf_stay      1 vs 0 1.227 1.09 1.38 
CHF           1 vs 0 1.104 1.029 1.185 
PVD           1 vs 0 1.359 1.277 1.446 
OthND         1 vs 0 1.214 1.097 1.344 
COPD          1 vs 0 1.065 1.001 1.133 
RF            1 vs 0 1.19 1.067 1.328 
Rheum_A       1 vs 0 1.119 1.012 1.237 
Obesity       1 vs 0 1.3 1.192 1.418 
Alcohol       1 vs 0 1.439 1.097 1.888 
Drug          1 vs 0 1.664 1.25 2.217 
Dep           1 vs 0 1.192 1.098 1.295 
Table 25: Odds ratios (with 95% CLs) for neuropathy complication, for non-dual 
beneficiaries 
 
5.1.2 Dual Beneficiaries 
 
5.1.2.1 Retinopathy 
 
The following table shows the odds ratios for the significant factors in the predictive 
model for retinopathy complication, among dual beneficiaries.  The following 
comorbidity factors were removed and the model re-fit, due to having negative 
significance: copd and wl.  
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Odds 
Ratio 
Lower 
95% CL 
Upper 
95% CL 
race_1  Other vs White 1.302 1.108 1.531 
race_1  Black vs White 1.234 1.035 1.472 
HPTN_NC 1 vs 0 1.351 1.039 1.757 
RF      1 vs 0 1.381 1.064 1.792 
Table 26: Odds ratios (with 95% CLs) for retinopathy complication, for dual 
beneficiaries 
 
5.1.2.2 Nephropathy 
 
The following table shows the odds ratios for the significant factors in the predictive 
model for nephropathy complication, among dual beneficiaries.  In addition to removing 
the rf comorbidity factor (as was done with non-dual beneficiaries), the psycho 
comorbidity factor was also removed due to having negative significance.   
 
  
Odds 
Ratio 
Lower 
95% CL 
Upper 
95% CL 
sex           M vs F 1.217 1.096 1.353 
race_1        Other vs White 0.866 0.764 0.982 
race_1        Black vs White 1.083 0.956 1.226 
age_grp       80_over vs 64_to_6 1.463 1.284 1.667 
age_grp       75_to_7 vs 64_to_6 1.216 1.055 1.401 
age_grp       70_to_7 vs 64_to_6 0.964 0.838 1.109 
op_tot_stay_1 1.007 1 1.013 
snf_stay      1 vs 0 0.804 0.674 0.959 
CHF           1 vs 0 1.49 1.333 1.667 
PVD           1 vs 0 1.121 1.005 1.25 
HPTN_NC       1 vs 0 1.364 1.129 1.647 
HPTN_C        1 vs 0 1.575 1.388 1.787 
Obesity       1 vs 0 1.241 1.062 1.452 
Fluid         1 vs 0 1.429 1.263 1.616 
Table 27: Odds ratios (with 95% CLs) for nephropathy complication, for dual 
beneficiaries 
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5.1.2.3 Neuropathy 
 
The following table shows the odds ratios results for the significant factors in the 
predictive model for neuropathy complication.  Only the psycho comorbidity factor was 
removed and the model re-fit, due to being negative significant in the model. 
 
  
Odds 
Ratio 
Lower 
95% CL 
Upper 
95% CL 
age_grp 80_over vs 64_to_6 0.88 0.769 1.006 
age_grp 75_to_7 vs 64_to_6 1.015 0.884 1.165 
age_grp 70_to_7 vs 64_to_6 1.069 0.941 1.214 
ov_1 1.018 1.012 1.023 
CHF     1 vs 0 1.261 1.127 1.411 
PVD     1 vs 0 1.338 1.201 1.49 
RF      1 vs 0 1.274 1.058 1.534 
Rheum_A 1 vs 0 1.213 1.02 1.443 
Obesity 1 vs 0 1.331 1.147 1.543 
Drug    1 vs 0 1.665 1.147 2.418 
Dep     1 vs 0 1.213 1.075 1.37 
Table 28: Odds ratios (with 95% CLs) for neuropathy complication, for dual 
beneficiaries 
 
5.1.3 Individual Risk Profiles 
 
In addition to the odds ratios for the predictive factors in each model for the Diabetes 
complications, individual risk profiles were also created.  Based on the significant risk 
factors generated in each model, the complication rate for a range of risk profiles based 
on the risk factors is obtained.  The complication rate for the two most extreme risk 
profiles (best and worst) are presented in the figures below (Figures 2 shows the results 
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for non-dual beneficiaries and Figure 3 for dual beneficiaries)35.  It is interesting to note 
the wider range for the complication rates in the case of nephropathy and neuropathy, 
compared to retinopathy.  This is due to retinopathy complication having resulted in 
fewer risk factors than the other complications.  In general, retinopathy has been the least 
predictive among all the complications.  Both nephropathy and neuropathy were 
comparable in their prediction results.  Nonetheless, in all three cases, it is interesting to 
note that a risk profile provides a useful result to evaluate beneficiaries’ potential risk of 
developing a complication in the following year, where no such complication has been so 
far detected.  Care management approaches can be implemented for various risk profiles 
among beneficiaries to allow for improved outcomes with delay of the complication 
development.  This is the purpose of the explanatory models, and their results will be 
presented next.  
 
Figure 2: Complication rate by risk profile, for non-dual beneficiaries 
                                                 
35
 For continuous significant factors (i.e., los, total office visits), best and worst were defined as 90th and 
10th percentiles, respectively 
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Figure 3: Complication rate by risk profile, for dual beneficiaries 
 
5.2 Explanatory Model Results 
 
The results for the explanatory models will include estimate results for only the analytical 
factors (corresponding with each of the hypotheses).  Appendix F contains a more 
detailed listing of the estimates for all the variables in the model.  These remaining 
variables are the risk adjustment variables for each of the analytical factors, as was 
discussed prior.  However, the only variable of interest in evaluation of each hypothesis is 
the effect that the analytical factor has on the complication outcome, risk adjusted for all 
the other variables that depict the various risk levels of the beneficiaries.   
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In all the estimate results presented, the estimate of the analytical factor is shown along 
with the standard error (in parenthesis) as well as the p-value.  In all analysis, a p-value of 
less than 0.05 was considered to be statistically significant.  Estimates found statistically 
significant are accompanied with an asterisks (*) in the results below. 
 
In all the models presented, comorbidity risk factors are based on Elixhauser factors (as 
was presented).  However, two other comorbidity risk adjustment factors are considered, 
in order to consider the impact that these may have on the results beyond those based on 
Elixhauser.  The first alternative risk adjustment factor used is the Medicare Hierarchical 
Condition Category (HCC) risk score [69].  This risk score is calculated based on ICD-9 
diagnosis variables, socio-demographics factors as well as other related factors (such as 
enrollment in Medicaid).  HCC is derived as a single risk score, which is used in place of 
the 29 Elixhauser variables in risk adjustment model.  The risk score is transformed into a 
discrete variable by creating five groups (or quintiles)36. 
 
The other approach used as an alternative to Elixhauser risk adjustment is calculated 
based on the total number of comorbidities that a beneficiary has.  These comorbidities 
are actually based on the Elixhauser factors, where a beneficiary’s total comorbidities are 
summed up based on their total number of Elixhauser conditions.  A tiered variable is 
created based on the beneficiary having 0-2 conditions (first tier), 3-4 conditions (second 
tier) and >=5 conditions (third tier).  The variable for the total number of comorbidities 
for a beneficiary is called ‘Comorb’, and this notation will be used in the tables below. 
                                                 
36
 The risk score used in the models is the community risk score (instead of the institutional risk score or 
any of the other derived risk scores) 
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The results below are presented first based on the Elixhauser risk adjustment. These 
results are presented for each hypothesis, for both non-dual and dual beneficiaries.  In 
addition to the results based on Elixhauser risk adjustment, results based on HCC and 
Comorb risk adjustments are also presented.  However, unlike with Elixhauser risk 
adjustment, HCC and Comorb risk adjustment results are not presented in every case.  
HCC and Comorb risk adjustment results are only presented when they demonstrate a 
difference of some significance from results obtained based on Elixhauser risk 
adjustment.  If the results based on HCC and Comorb risk adjustment are comparable to 
the results based on Elixhauser risk adjustment, then only Elixhauser risk adjustment are 
shown.  Conclusions for those cases will be derived simply from the results shown based 
on Elixhauser risk adjustment.   
 
5.2.1 Hypothesis I 
 
5.2.1.1 Non-Dual Beneficiaries 
 
The following table shows the estimate results for the total cost of treatment analytical 
factor (cost_all).  The results are shown for non-dual beneficiaries.  In these results, 
cost_all estimates are shown relative to level ‘4’ in each case (which is the lowest cost 
level).  Based on the results, only retinopathy and neuropathy show statistical 
significance.  For both of these complications, it appears that higher cost of treatment is 
associated with increase in complication rates.  This result is not in agreement with what 
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was expected (it was believed that an increase in treatment investment would lead to 
lowered complication rates in beneficiaries).  Further exploration was performed for all 
of the complications using both HCC and Comorb risk adjustment methods, as was 
previously discussed. 
 
    Retinopathy   Nephropathy   Neuropathy 
Parameter 
Estimate 
(SE) p-value 
Estimate 
(SE) p-value 
Estimate 
(SE) p-value 
cost_all 0 .317 (.079)* <.0001   .004 (.054) 0.9355   .534 (.057)* <.0001 
cost_all 1 .307 (.064)* <.0001 .056 (.045) 0.2176 .459 (.049)* <.0001 
cost_all 2 .291 (.060)* <.0001 -.001 (.044) 0.9899 .332 (.048)* <.0001 
cost_all 3 .139 (.060)* 0.021 .076 (.042)* 0.072 .164 (.048)* 0.0007 
cost_all 4 0 .   0 .   0 . 
Table 29: Parameter estimate results for hypothesis I (cost_all), for non-dual 
beneficiaries 
 
The results in table 30 show total cost of treatment based on both HCC and Comorb risk 
adjustment.  The results yield interesting conclusions, in comparison to the above results.  
First, for retinopathy, it appears that although the estimates are positively significant, 
there is a decreasing trend from level ‘2’ to level ‘0’.  This is observed with both HCC 
and Comorb risk adjustment.  This indicates that as treatment investment increases from 
level ‘2’ and beyond, there is a lower rate of complication for retinopathy.  For 
nephropathy, although the results were not significant in the table above they appear 
significant in this case.   In fact, the estimates show negative significance in all cases 
(with the exception of level ‘3’).  These negative estimates are decreasing as investment 
increases, meaning that rate of complication for nephropathy continues to improve 
relative to level ‘4’ with an increase in treatment investment.  Finally for neuropathy, in 
general the results appear consistent with the previous table with one small exception.  
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For HCC risk adjustment, there is a slight dip in going from level ‘1’ to level ‘0’.  This 
means that at very high treatment investments, the higher investment shows improvement 
in neuropathy complication rate (only based on HCC risk adjustment). 
 
    HCC   Comorb 
Parameter 
 
Estimate 
(SE) p-value 
 
Estimate 
(SE) p-value 
retinopathy             
cost_all 0 .214 (.081)* 0.008 .184 (.080)* 0.022 
cost_all 1 .228 (.065)* 0.001 .194 (.065)* 0.003 
cost_all 2 .232 (.061)* 0.0001 .209 (061)* 0.0007 
cost_all 3 .104 (.061) 0.087 .092 (.061) 0.129 
cost_all 4 0 . 0 . 
nephropathy           
cost_all 0 -.289 (.053)* <.0001 -.174 (.053)* 0.001 
cost_all 1 -.164 (.045)* 0.0003 -.132 (.045)* 0.004 
cost_all 2 -.148 (.044)* 0.0007 -.139 (.044)* 0.001 
cost_all 3 -.008 (.042) 0.8498 .0003 (.042) 0.9942 
cost_all 4 0 . 0 . 
neuropathy             
cost_all 0 .141 (.058)* 0.015 .387 (.058)* <.0001 
cost_all 1 .172 (.049)* 0.001 .337 (.049)* <.0001 
cost_all 2 .118 (.049)* 0.015 .233 (.048)* <.0001 
cost_all 3 .032 (.049) 0.509 .102 (.049)* 0.037 
cost_all 4 0 .   0 . 
Table 30: Parameter estimate results for hypothesis I (cost_all) for non-dual 
beneficiaries, using HCC and Comorb risk adjustment 
 
5.2.1.2 Dual Beneficiaries 
 
The following table shows the estimate results for the total cost of treatment analytical 
factor (cost_all) for dual beneficiaries.  In these results, cost_all estimates are shown 
relative to level ‘4’ in each case (which is the lowest cost level).  The results are 
somewhat comparable to those for non-dual beneficiaries above.  Only retinopathy and 
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neuropathy complications show statistically significant results; nephropathy does not 
show any statistical significance.  In both retinopathy and neuropathy, it appears that 
there is a positive trend, where higher treatment investment leads to higher complication 
rate (again, this is not what was hypothesized).  However, for retinopathy, there is a dip 
in going from level ‘2’ to level ‘1’, meaning that increasing investment at those levels 
does lead to improved outcome.  This would have to be corroborated with the other risk 
adjusters, shown below. 
 
    Retinopathy   Nephropathy   Neuropathy 
Parameter 
Estimate 
(SE) p-value 
Estimate 
(SE) p-value 
Estimate 
(SE) p-value 
cost_all 0 .632 (.158)* <.0001   .019 (.115) 0.8621   .962 (.112)* <.0001 
cost_all 1 .354 (.129)* 0.0065 .018 (.094) 0.8475 .739 (.096)* <.0001 
cost_all 2 .429 (.119)* 0.0003 .033 (.089) 0.7073 .579 (.093)* <.0001 
cost_all 3 .154 (.119) 0.1942 .075 (.086) 0.3807 .357 (.095)* 0.0002 
cost_all 4 0 .   0 .   0 . 
Table 31: Parameter estimate results for hypothesis I (cost_all), for dual beneficiaries 
 
In Table 32, the results for the estimates of total cost of treatment are shown using HCC 
and Comorb risk adjustment.  These results were not as impactful as they were for non-
dual beneficiaries.  Retinopathy has two significant values (at level ‘2’ and level ‘0’) and 
both support a positive increasing trend.  Likewise, for neuropathy, the results support a 
positive trend, similar to the results based on Elixhauser risk adjustment.  For 
nephropathy, using HCC risk adjustment shows significant results, at level ‘1’ and level 
‘0’.  Both of these results are negatively significant, meaning that they both are 
improvements from level ‘4’ (the lowest level) and level ‘0’ is a higher improvement than 
level ‘1’.  These conclusions are more in line with the expected hypothesis result.  
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However, these are not replicated with Comorb risk adjustment and they do not show 
statistical significance for other levels (beyond levels ‘0’ and ‘1’).  They appear to have 
some validity but further investigation may be warranted to make a conclusion regarding 
nephropathy complication rate. 
 
    HCC   Comorb 
Parameter 
 
Estimate 
(SE) p-value   
Estimate 
(SE) p-value 
retinopathy           
cost_all 0 .444 (.161)* 0.006 .485 (.159)* 0.002 
cost_all 1 .2 (.132) 0.131 .217 (.133) 0.103 
cost_all 2 .324 (.119)* 0.007 .324 (.121)* 0.008 
cost_all 3 .097 (.119) 0.418 .089 (.120) 0.459 
cost_all 4 0 . 0 . 
nephropathy           
cost_all 0 -.280 (.113)* 0.013 -.131 (.111) 0.238 
cost_all 1 -.204 (.093)* 0.029 -.154 (.094) 0.1 
cost_all 2 -.133 (.089) 0.133 -.144 (.089) 0.109 
cost_all 3 -.006 (.085) 0.942 -.036 (.086) 0.673 
cost_all 4 0 . 0 . 
neuropathy             
cost_all 0 .740 (.115)* <.0001 .843 (.114)* <.0001 
cost_all 1 .544 (.098)* <.0001 .600 (.099)* <.0001 
cost_all 2 .439 (.095)* <.0001 .459 (.096)* <.0001 
cost_all 3 .269 (.095)* 0.005 .273 (.096)* 0.004 
cost_all 4 0 .   0 . 
Table 32: Parameter estimate results for hypothesis I (cost_all) for dual beneficiaries, 
using HCC and Comorb risk adjustment 
 
5.2.2 Hypothesis II 
 
5.2.2.1 Non-Dual Beneficiaries 
 
 85 
 
The following table shows the estimate results for the physician analytical factor, both 
generalist vs. specialist (prmry_p) and urban vs. rural (urb).  The results are shown for 
non-dual beneficiaries.  In these results, prmry_p estimates are shown relative to level ‘1’ 
(primary) and urb estimates are shown relative to ‘urban’ level.  The results based on 
Elixhauser risk adjustment were comparable to those based on HCC and Comorb risk 
adjustment, and those results were not shown.  However, there was one distinction that 
appeared with relation to nephropathy complication, which will be discussed further.   
 
Based on the results below, retinopathy and neuropathy both appear to have higher 
complication rates among specialist vs. primary care physician.  For both of these 
complications, the results are not significant with regards to urban vs. rural physician.  
For nephropathy complication on the other hand, the reverse is true-primary vs. specialist 
does not have significant results; however, urban vs. rural providers show statistical 
significance and it appears that rural to have lower complication rates than urban 
providers.  However, primary vs. specialist did appear significant for nephropathy when 
using both HCC and Comorb risk adjustment. Based on those risk adjustments, specialist 
appeared to have a lower complication rate than generalist for nephropathy (which is the 
trend obtained using Elixhauser but which was not statistically significant).  Thus, there 
is evidence that for nephropathy, complicate rates improve both with visiting a specialist 
as well as a rural provider.  
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    Retinopathy   Nephropathy   Neuropathy 
Parameter   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value 
prmry_p 0 .088 (.044)* 0.0452   -.010 (.030) 0.7315   .119 (.031)* 0.0001 
prmry_p 1 0 . 
 
0 . 
 
0 . 
urb rural -.031 (.053) 0.5613 
 
-.118 (.037)* 0.0013 
 
-.045 (.039) 0.2434 
urb urban 0 .   0 .   0 . 
Table 33: Parameter estimate results for hypothesis II (prmry_p and urb), for non-dual 
beneficiaries 
 
5.2.2.2 Dual Beneficiaries 
 
Table 34 shows the estimate results for the physician analytical factor, both generalist vs. 
specialist (prmry_p) and urban vs. rural (urb), among dual beneficiaries.  The results are 
similar in format to the results shown in Table 33 above. 
 
For dual beneficiaries, only retinopathy showed any statistical significance for specialist 
vs. primary care physician, with specialist having higher complication rate than primary 
care physician (similar to the result obtained for non-dual beneficiaries).  For urban vs. 
rural physician type, only neuropathy shows significant results, and in this case rural 
appear to have better complication rate results than urban physicians.  This is comparable 
to the previous result obtained for nephropathy for non-dual beneficiaries.  Nephropathy 
does not show any statistically significant results, for neither specialist vs. generalist or 
urban vs. rural physician type. 
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    Retinopathy   Nephropathy   Neuropathy 
Parameter   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value 
prmry_p 0 .177 (.087)* 0.0415   -.014 (.065) 0.8328   .027 (.062) 0.6665 
prmry_p 1 0 . 
 
0 . 
 
0 . 
urb rural -.161 (.105) 0.1247 
 
.002 (.072) 0.9754 
 
-.173 (.073)* 0.0182 
urb urban 0 .   0 .   0 . 
Table 34: Parameter estimate results for hypothesis II (prmry_p and urb), for dual 
beneficiaries 
 
5.2.3 Hypothesis III 
 
5.2.3.1 Non-Dual Beneficiaries 
 
The following table shows the estimate results for the patient total cost sharing analytical 
factor (cost_all_p).  The results are shown for non-dual beneficiaries.  In these results, 
cost_all_p estimates are shown relative to level ‘4’ in each case (which is the lowest cost 
level).  The results using Elixhauser risk adjustment are pretty straightforward (and 
comparable to those obtained for total cost of treatment in hypothesis I): both retinopathy 
and neuropathy show positive significant trend, showing that increase in total patient cost 
sharing leads to higher complication rates (or put another way, reduced patient cost 
sharing leads to better outcomes with lower complication rates).  Nephropathy does not 
show any statistical significance using Elixhauser risk adjustment. 
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    Retinopathy   Nephropathy   Neuropathy 
Parameter   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value 
cost_all_p 0 .345 (.079)* <.0001   -.079 (.054) 0.1478   .410 (.057)* <.0001 
cost_all_p 1 .269 (.063)* <.0001 -.0003 (.044) 0.9952 .400 (.048)* <.0001 
cost_all_p 2 .260 (.060)* <.0001 -.026 (.043) 0.5517 .265 (.047)* <.0001 
cost_all_p 3 .103 (.059) 0.0869 .025 (.042) 0.554 .154 (.048)* 0.0013 
cost_all_p 4 0 .   0 .   0 . 
Table 35: Parameter estimate results for hypothesis III (cost_all_p), for non-dual 
beneficiaries 
 
 
The results in table 36 are based on using HCC and Comorb risk adjustments.  For 
retinopathy, there is positive statistical significance at levels ‘2’ up to level ‘0’.  
However, there appears to be a dip going from level ‘2’ to level ‘1’, appearing for both 
HCC and Comorb risk adjustments.  This means that at level ‘2’ and higher, complication 
rates for retinopathy are higher than at level ‘4’, although there is an improvement in 
complication rate from going from level ‘2’ to level ‘1’.  Nephropathy shows significant 
results with HCC and Comorb risk adjustment, in contrast to the results based on 
Elixhauser risk adjustment.  There is decreasing trend from going from level ‘2’ and 
upward, where each increasing level shows improvement in nephropathy complication 
rate.  Finally for neuropathy, HCC risk adjustment shows a positive increasing trend 
(similar to that obtained based on Elixhauser risk adjustment), with the exception at level 
‘0’ where there appears to be a dip-or an improvement in outcome-in comparison to level 
‘1’. 
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    HCC   Comorb 
Parameter 
 
Estimate 
(SE) p-value   
Estimate 
(SE) p-value 
retinopathy           
cost_all 0 .252 (.080)* 0.002 
 
.217 (.079)* 0.007 
cost_all 1 .201 (.064)* 0.002 
 
.166 (.064)*  0.01 
cost_all 2 .207 (.061)* 0.001 
 
.183 (.061)* 0.003 
cost_all 3 .079 (.060) 0.188 
 
.061 (.060) 0.312 
cost_all 4 0 . 
 
0 . 
nephropathy           
cost_all 0 -.349 (.053)* <.0001 
 
-.272 (.053)* <.0001 
cost_all 1 -.213 (.044)* <.0001 
 
-.183 (.044)* <.0001 
cost_all 2 -.181 (.043)* <.0001 
 
-.173 (.043)* <.0001 
cost_all 3 -.057 (.042) 0.169 
 
-.05 (.042) 0.229 
cost_all 4 0 . 
 
0 . 
neuropathy             
cost_all 0 .062 (.058) 0.283 
 
.270 (.058)* <.0001 
cost_all 1 .132 (.049)* 0.007 
 
.286 (.049)* <.0001 
cost_all 2 .065 (.048) 0.174 
 
.173 (.048)* 0.0003 
cost_all 3 .034 (.048) 0.476 
 
.099 (.048)* 0.037 
cost_all 4 0 .   0 . 
Table 36: Parameter estimate results for hypothesis III (cost_all_p) for non-dual 
beneficiaries, using HCC and Comorb risk adjustment  
 
5.2.3.2 Dual Beneficiaries 
 
Table 37 shows the estimate results for the state per beneficiary Medicaid investment 
analytical factor (mcaid_all).  The results are for dual beneficiaries.  In these results, 
mcaid_all estimates are shown relative to level ‘4’ in each case (which is the lowest cost 
per beneficiary level).  Based on the results shown, retinopathy appears to have negative 
significant results for all levels, with the exception of level ‘0’.  This means that higher 
state Medicaid investment per beneficiary leads to improved outcome in complication 
rate for retinopathy, up to level ‘1’.  There is not enough evidence to make a conclusion 
regarding level ‘0’.  For nephropathy, levels ‘3’ and ‘0’ are both negatively significant, 
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which means that state Medicaid investment per beneficiary at those levels leads to 
improved outcomes in comparison to state Medicaid investment per beneficiary at level 
‘4’ (the lowest level).  Finally, neuropathy does not show any significant results and no 
conclusions can be made regarding its relation to state Medicaid investment per 
beneficiary levels. 
 
    Retinopathy   Nephropathy   Neuropathy 
Parameter   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value   
Estimate 
(SE) p-value 
mcaid_all 0 -.005 (.101) 0.963   -.252 (.081)* 0.0018   -.038 (.079) 0.6331 
mcaid_all 1 -.414 (.117)* 0.0004 
 
-.029 (.081) 0.7179 
 
-.091 (.084) 0.2747 
mcaid_all 2 -.380 (.110)* 0.0006 
 
-.038 (.078) 0.6267 
 
.150 (.077) 0.0512 
mcaid_all 3 -.314 (.113)* 0.0054 
 
-.234 (.085)* 0.0057 
 
.128 (.080) 0.1104 
mcaid_all 4 0 .   0 .   0 . 
Table 37: Parameter estimate results for hypothesis II (mcaid_all), for dual beneficiaries 
 
 
5.3 Model Performance  
 
The last part of this analysis will present the measures of performance for the models in 
the study.  The model performance measure considered is the area under the receiver 
operating curve (ROC), also known as the AUC (for area under the curve) or c-statistic.  
This measure captures the ability of the model to classify outcomes correctly [70].  The 
values for the c-statistic range from 0.5 to 1, with increasing levels signifying a better 
performing model.   
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Table 38 shows the c-statistic results for both the predictive and explanatory models in 
the study.   
 
        Explanatory 
Model 
 
Predictive 
 
Hyp I Hyp II Hyp III 
Non-dual  retinopathy 0.541   0.563 0.555 0.561 
nephropathy 0.639 0.694 0.694 0.694 
neuropathy 0.604 0.609 0.606 0.607 
Dual retinopathy 0.543 0.591 0.585 0.592 
nephropathy 0.619 0.682 0.681 0.684 
  neuropathy 0.600   0.622 0.612 0.611 
Table 38: C-statistic performance results for predictive and explanatory models in study 
 
The results in Table 38 show relatively moderate model predictive capability.  In general, 
both nephropathy and neuropathy demonstrate better model performances than does 
retinopathy (this is the case for both non-dual and dual beneficiaries).  Nephropathy 
typically has a slightly better performance than does neuropathy.  Also, for both 
retinopathy and neuropathy, dual beneficiaries appear to have better model performances 
than non-dual beneficiaries.  This is the opposite; however, with nephropathy, where 
model performance for non-dual beneficiaries is better than for dual beneficiaries.  
Finally, for all complications, explanatory models have superior performance than 
predictive models37.  A demonstration for one of the models (nephropathy for dual 
beneficiaries for Hypothesis II) is shown in Figure 4 below.  The figure illustrates the 
distribution of the predicted outcomes (y_pred) stratified based on actual outcome (y=0 
or 1, if a beneficiary has a nephropathy complication).  As expected, the figure shows a 
                                                 
37
 This is expected, as the explanatory models add analytical factors to the predictive models, which would 
improve performance. 
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higher frequency of higher predicted outcomes for the case when y=1 (showing an added 
peak for those higher predicted outcomes)38.  However, the model’s discriminating ability 
is not very strong (where c-statistic is .681, as was shown in Table 38).  A model with 
higher c-statistic would have a greater discrimination capability than what Figure 4 
illustrates, and likely a higher second peak for the case where y=1.   
 
 
Figure 4: Distribution of predicted outcome for nephropathy (y_pred) stratified by actual 
outcome (y=0 or 1), for dual beneficiaries (Hypothesis II) 
 
An attempt was made to improve the c-statistic outcome for the models based on an 
innovative approach.  This approach (which will be called ‘spline logistic regression’) 
                                                 
38
 The original peak is demonstrably higher for y=0 than for y=1, showing lower predicted outcome for y=0 
having higher frequency than for y=1. 
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was based on splitting the data based on residuals obtained from fitting of the original 
models.  Cases with high residuals (poor fit) were separated from cases with low residual 
(good fit).  Then a model was fit for those two cases separately.  However, instead of 
dividing the cases based on their actual residuals, predicted residuals were obtained first.  
Those predicted residuals were obtained by fitting the original model, but with an 
outcome indicator showing each case as having high or low residual.  This creates a 
propensity score for each case, or the predicted value for each case of either having a 
high or low residual.  The propensity scores are then split by a chosen percentile39 value 
to obtain both data set of predicted low residual (or poor prediction probability) and 
another data set of predicted high residual (or good prediction probability).  Separate 
models were fit in each case and finally those two sets are combined into a final data set.  
Performance measures (c-statistic) are obtained for this final data set based on predicted 
outcomes obtained from the two model fits.  This approach is essentially spline logistic 
regression (or also segmented logistic regression), where the segmentation is based on 
propensity scores for good and poor predictability.  The results of this spline logistic 
regression approach do not show a significant improvement in c-statistic compared to the 
original predictive models (in table 38).  In general, improvements were in the range of 
0.29%-3.42% (based on all the model results).  Figure 5 below shows the results for the 
spline logistic regression approach based on the case presented in Figure 4 (nephropathy 
for dual beneficiaries for Hypothesis II).  The c-statistic for this model improved from 
.681 (in the original model) to .692 (in the spline logistic regression model)-or a 1.62% 
improvement.  Figure 5 illustrates the improvements, and it appears, for instance, that the 
additional peak for y=1 is higher compared to that in Figure 4.  However, the results are 
                                                 
39
 80th percentile for good prediction results was chosen in this study 
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still moderate and this is due to modest improvements based on the c-statistic.  Further 
improvements would be interesting to explore, both with regards to this spline regression 
approach as well as other approaches beyond spline logistic regression40.  Other 
approaches-including other variants of this approach-should be explored to seek to 
improve performance results for the models in this study. 
 
 
 
 
Figure 5: Distribution of predicted outcome for nephropathy (y_pred_spline) stratified 
by actual outcome (y=0 or 1), for dual beneficiaries (Hypothesis II) 
 
 
 
 
                                                 
40
 For instance, further breakdown of poor prediction into poor prediction for positive results (y=1) and 
negative results (y=0) could be explored.  This would yield a propensity score model with three outcomes, 
which would require multinomial logistic regression. 
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Chapter 6 Conclusion 
 
This dissertation set out to explore factors that influence development of Diabetes 
complications for Medicare and dual eligible beneficiaries.  Three Diabetes 
complications were of interest in this study: retinopathy, nephropathy and neuropathy.  
These three complications are the most common and significant microvascular types of 
complications among Diabetes patients, both from a financial and health standpoint.  
Results from both predictive and explanatory models were obtained, to gain a better 
understanding of those factors that influence the development of Diabetes complications.  
Predictive models were used to study significant factors in development of Diabetes 
complications among Medicare and dual eligible beneficiaries.  Explanatory models were 
used to explore the three main hypotheses in this dissertation.  Each of the hypotheses set 
out to study the impact that various analytical factors have on development of Diabetes 
complications in Medicare and dual eligible beneficiaries.  These factors included: 
treatment investment, physician factors and patient cost sharing (or state Medicaid per 
beneficiary investment for dual eligible beneficiaries).   
 
The results of the predictive models showed the factors that are predictive for each of the 
Diabetes complications in the study.  Odds ratio results for the predictive factors were 
shown (including a graphical presentation of those odds ratios in the appendix).  In 
general, retinopathy complication resulted in fewer predictive factors than for either 
nephropathy or neuropathy complications.  This pattern was consistent for the results for 
both non-dual and dual beneficiaries.  
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The results of the explanatory models set out to answer the three hypothesis that were 
defined initially in the study.  The first hypothesis stated that higher treatment investment 
would lead to lower rate of complications among Medicare and dual eligible 
beneficiaries.  The results were significant for both retinopathy and neuropathy, but in 
both cases contrary to the stated hypothesis (i.e., both showed an increasing relation 
between treatment investment and complication rate among Diabetes beneficiaries, both 
for non-dual and dual beneficiaries).  Results based on HCC and Comorb risk adjustment 
showed negative significant results for treatment investment for nephropathy (for 
treatment investments level ‘2’ and higher among non-dual beneficiaries and level ‘1’ 
and higher among dual beneficiaries41).  These result show support for the initial 
hypothesis regarding the impact of treatment investment on nephropathy complication 
rates among non-dual and dual beneficiaries.  
 
Hypothesis II explored the impact of physician factors on complication rates among 
beneficiaries.  For non-dual beneficiaries, retinopathy and neuropathy both showed 
higher complication rates among specialist compared to primary care physician (no 
significant result was found regarding urban vs. rural factor).  For nephropathy, rural 
physicians were shown to have lower complication rates than urban providers.  Although 
no significant results were found regarding primary vs. specialist physician for 
nephropathy, HCC and Comorb risk adjustment showed lower complication among 
specialist compared to primary care physicians.  For dual beneficiaries, there were two 
significant outcomes.  Retinopathy showed higher complication rates among specialist 
                                                 
41
 Based only on HCC risk adjustment (not Comorb risk adjustment) 
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(similar to the result obtained for non-dual beneficiaries).  Also, neuropathy was shown 
to have a lower complication rate among rural compared to urban providers (similar to 
results obtained for nephropathy complication rate among non-dual beneficiaries).   
 
Hypothesis III explored the impact that patient cost sharing had on development of 
complication rates in beneficiaries.  For non-dual beneficiaries, significant results were 
obtained for retinopathy and neuropathy, both showing a positive relation between patient 
cost sharing and rate of complications development.  Risk adjustment based on HCC and 
Comorb showed negative significant results for nephropathy, for levels ‘2’ and upward.  
Also, dips were found for both retinopathy (from levels ‘2’ to ‘1’) and neuropathy (from 
levels ‘1’ to ‘0’). 
 
For dual beneficiaries, patient cost sharing was based on state Medicaid investment per 
beneficiary.  For retinopathy, there is evidence of a negative relation between state 
Medicaid investment per beneficiary and complication development.  This negative trend 
is observed for all levels, with the exception of the highest cost level (at level ‘0’).  
Nephropathy showed some negative significant results at some of the investment cost 
levels, mainly from levels ‘3’ and ‘0’, both showing improvement from the lowest cost 
level ‘4’, with level ‘0’ (highest cost) having the greater outcome improvement.  No 
significant results were obtained for neuropathy complication rate.   
 
In conclusion, the results appear to support some of the hypothesis defined initially in the 
study, although there are some departures for complication types and among non-dual 
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compared to dual beneficiaries.  With regards to treatment investment, nephropathy 
appears to be the only complication that shows significant decrease with higher treatment 
investment levels for beneficiaries (consistent with the initial hypothesis).  For physician 
factors, the conclusions vary.  Only nephropathy is consistent with the initial hypothesis 
that specialist providers have better complication rate outcomes than primary care 
providers.  For urban vs. rural factors, none of the complications showed improvements 
among urban compared to rural physicians, as was stated in the initial hypothesis.  The 
reverse was found for both nephropathy (among non-dual beneficiaries) and neuropathy 
(among dual beneficiaries).  For patient cost sharing, higher patient cost sharing was 
found to be associated with higher complication rates among non-dual beneficiaries, for 
retinopathy and neuropathy (which is contrary to the initial hypothesis).  Some evidence 
of a negative relation was found for nephropathy (using HCC risk adjustment), which is 
the only complication that supported the initial hypothesis to some extent.  For dual 
beneficiaries, retinopathy (and to an extent nephropathy) showed a significant negative 
relation with state Medicaid investment per beneficiary.  These result support the stated 
hypothesis that higher state investment leads to lower complication rates among dual 
eligible beneficiaries.   
 
In addition to the results presented, this study showed the value of the kind of risk 
adjustment used in a model.  HCC and Comorb risk adjustments were used to 
complement results based on Elixhauser risk adjustment.  In general, these were found to 
have an impact for cost based results (i.e., total treatment investment and patient cost 
sharing).  This could be due to the nature of HCC risk adjustment, which is based on risk 
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score to predict health cost for Medicare beneficiaries.  It is not clear how Comorb would 
show similar impact as HCC, as it is obtained based on the total number of Elixhauser 
comorbidities in a beneficiary.  However, both measures are obtained as a single measure 
of risk (compared to a list of variables with Elixhauser risk adjustment).  This could be 
one reason for the similarity in the results between the HCC and Comorb risk adjustment 
results.   
 
Finally, model performance results show that the best performing models are for 
nephropathy and neuropathy complications, in comparison to retinopathy complication.  
In general, retinopathy complication did not have very strong results (which is also 
evident in the total number of factors obtained in the predictive models).  However, for 
all models, the c-statistics show that improvements could be further made to improve the 
results obtained in this study.  It would be interesting to consider further improvement in 
the models for future studies, perhaps with more innovative machine learning approaches 
that have been shown to have high performing results.  However, the results in this 
dissertation shed some light to the factors that influence development of Diabetes 
complications among Medicare and dual eligible beneficiaries.  The results should be 
helpful in implementing preventive types of care management programs for this 
population, in order to reduce the risk of Diabetes complications among beneficiaries and 
improve health outcomes.   
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Appendix A: ICD-9 codes for Diabetes complications: retinopathy, nephropathy and 
neuropathy 
 
 
Complication ICD-9 codes 
Retinopathy 250.5x, 362.0x, 379.2342 
Nephropathy 250.4x, 585.xx, 581.81, 583.81 
Neuropathy 250.6x, 357.2x, 337.1x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
42
 Does not include diagnosis for cataract or glaucoma 
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Appendix B: Elixhauser Comorbidities Frequencies, for non-dual and dual beneficiaries 
in 2010 
 
    Non-Duals   Duals 
Comorbidity   Count Percent   Count Percent 
Congestive Heart Failure no 110,120 86.75%   20,238 79.22% 
  yes 16,822 13.25%   5,308 20.78% 
Cardiac Arrhythmia no 97,673 76.94% 
 
19,644 76.90% 
  yes 29,269 23.06%   5,902 23.10% 
Valvular Disease no  109,328 86.12% 
 
22,028 86.23% 
  yes 17,614 13.88%   3,518 13.77% 
Pulmonary Circulation 
Disorders no 123,073 96.95% 
 
24,683 96.62% 
  yes 3,869 3.05%   863 3.38% 
Peripheral Vascular Disorders no 106,310 83.75% 
 
19,554 76.54% 
  yes 20,632 16.25%   5,992 23.46% 
Hypertension Uncomplicated no  14,880 11.72% 
 
2,417 9.46% 
  yes 112,062 88.28%   23,129 90.54% 
Hypertension complicated no 115,303 90.83% 
 
22,342 87.46% 
  yes 11,639 9.17%   3,204 12.54% 
Paralysis no 125,816 99.11% 
 
25,009 97.90% 
  yes 1,126 0.89%   537 2.10% 
Other Neurological Disorders no  120,637 95.03% 
 
23,229 90.93% 
  yes 6,305 4.97%   2,317 9.07% 
Chronic Pulmonary Disease no 101,940 80.30% 
 
18,259 71.47% 
  yes 25,002 19.70%   7,287 28.53% 
Hypothyroidism no 97,258 76.62% 
 
19,175 75.06% 
  yes 29,684 23.38%   6,371 24.94% 
Renal Failure no  121,503 95.72% 
 
24,146 94.52% 
  yes 5,439 4.28%   1,400 5.48% 
Liver Disease no 121,368 95.61% 
 
23,918 93.63% 
  yes 5,574 4.39%   1,628 6.37% 
Peptic Ulcer Disease excluding  no 125,509 98.87% 
 
25,032 97.99% 
bleeding yes 1,433 1.13%   514 2.01% 
AIDS/HIV no  126,879 99.95% 
 
25,496 99.80% 
  yes 63 0.05%   50 0.20% 
Lymphoma no 125,487 98.85% 
 
25,349 99.23% 
  yes 1,455 1.15%   197 0.77% 
Metastatic Cancer no 125,480 98.85% 
 
25,272 98.93% 
  yes 1,462 1.15%   274 1.07% 
Solid Tumor without  no  109,982 86.64% 
 
23,084 90.36% 
Metastasis yes 16,960 13.36%   2,462 9.64% 
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    Non-Duals   Duals 
Comorbidity   Count Percent   Count Percent 
Rheumatoid Arthritis/collagen no 120,035 94.56% 23,898 93.55% 
  yes 6,907 5.44%   1,648 6.45% 
Coagulopathy no 122,227 96.29% 24,545 96.08% 
  yes 4,715 3.71%   1,001 3.92% 
Obesity no  117,586 92.63% 23,244 90.99% 
  yes 9,356 7.37%   2,302 9.01% 
Weight Loss no 122,505 96.50% 24,113 94.39% 
  yes 4,437 3.50%   1,433 5.61% 
Fluid and Electrolyte Disorders no 114,003 89.81% 21,594 84.53% 
  yes 12,939 10.19%   3,952 15.47% 
Blood Loss Anemia no  124,942 98.42% 25,014 97.92% 
  yes 2,000 1.58%   532 2.08% 
Deficiency Anemia no 115,581 91.05% 22,453 87.89% 
  yes 11,361 8.95%   3,093 12.11% 
Alcohol Abuse no 126,247 99.45% 25,306 99.06% 
  yes 695 0.55%   240 0.94% 
Drug Abuse no  126,455 99.62% 25,310 99.08% 
  yes 487 0.38%   236 0.92% 
Psychoses no 124,640 98.19% 23,789 93.12% 
  yes 2,302 1.81%   1,757 6.88% 
Depression no  115,988 91.37% 21,431 83.89% 
  yes 10,954 8.63%   4,115 16.11% 
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Appendix C: Medicaid Investment Amount per Beneficiary, in year 2010 by State  
 
 
  
Unq Ben 
Count 
Tot Medicaid Pd 
Amt 
Amout per 
Beneficiary 
AK 126,754 $1,206,732,274.00 $9,520.27 
AL 930,899 $4,041,509,130.00 $4,341.51 
AR 772,901 $3,799,386,124.00 $4,915.75 
AZ 1,804,818 $9,510,649,340.00 $5,269.59 
CA 11,212,114 $34,685,815,704.00 $3,093.60 
CO 681,802 $3,300,099,360.00 $4,840.26 
CT 663,812 $5,389,954,788.00 $8,119.70 
DC 210,607 $1,806,400,158.00 $8,577.11 
DE 210,383 $1,342,173,263.00 $6,379.67 
FL 3,656,334 $16,130,780,320.00 $4,411.74 
GA 1,874,994 $6,969,095,736.00 $3,716.86 
HI 288,368 $1,353,091,047.00 $4,692.24 
IA 507,553 $3,004,793,099.00 $5,920.16 
ID 430,309 $1,235,325,034.00 $2,870.79 
IL 2,758,238 $11,645,717,976.00 $4,222.16 
IN 1,176,699 $5,752,820,473.00 $4,888.95 
KS 363,755 $2,295,014,237.00 $6,309.23 
KY 958,732 $5,303,527,296.00 $5,531.81 
LA 1,236,843 $5,490,825,433.00 $4,439.39 
MA 1,637,405 $11,068,961,061.00 $6,760.06 
MD 940,144 $6,837,754,161.00 $7,273.09 
ME 329,837 $1,468,070,789.00 $4,450.90 
MI 2,219,384 $11,379,559,860.00 $5,127.35 
MN 850,556 $7,135,881,709.00 $8,389.67 
MO 1,141,253 $6,196,284,095.00 $5,429.37 
MS 801,420 $3,363,712,897.00 $4,197.19 
MT 126,481 $761,806,453.00 $6,023.09 
NC 1,876,395 $9,590,980,459.00 $5,111.39 
ND 82,527 $681,780,268.00 $8,261.30 
NE 269,370 $1,586,454,999.00 $5,889.50 
NH 148,247 $1,008,839,707.00 $6,805.13 
NJ 1,229,171 $8,558,223,953.00 $6,962.60 
NM 557,415 $2,770,858,831.00 $4,970.91 
NV 333,504 $1,300,361,348.00 $3,899.09 
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Unq Ben 
Count 
Tot Medicaid Pd 
Amt 
Amout per 
Beneficiary 
NY 5,011,087 $42,723,696,604.00 $8,525.83 
OH 2,319,252 $14,450,436,551.00 $6,230.65 
OK 852,603 $3,712,748,920.00 $4,354.60 
OR 644,068 $3,186,918,628.00 $4,948.11 
PA 2,325,603 $15,893,983,198.00 $6,834.35 
RI 213,691 $1,574,200,574.00 $7,366.71 
SC 953,317 $5,090,193,772.00 $5,339.46 
SD 141,863 $777,302,644.00 $5,479.25 
TN 1,532,198 $9,060,698,768.00 $5,913.53 
TX 4,744,509 $20,718,003,336.00 $4,366.73 
UT 369,224 $1,995,359,322.00 $5,404.20 
VA 969,496 $5,860,885,947.00 $6,045.29 
VT 180,940 $999,752,703.00 $5,525.33 
WA 1,330,417 $6,311,836,604.00 $4,744.25 
WI 1,230,001 $5,403,498,655.00 $4,393.08 
WV 397,094 $2,689,936,243.00 $6,774.05 
WY 75,818 $571,684,006.00 $7,540.21 
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Appendix D: Glossary of Model Variables 
 
Variable Description Values 
Socio-Economic Variables 
 sex Sex M, F 
age_grp Age Group 64 to 69, 70 to 74, 75 to 79, 
80 and over 
race_1 Race White, Black, Other 
Health Utilization Variables 
 ip_tot_stay_1 Inpatient Total Admissions Amount >=0 
op_tot_stay_1 Outpatient Total Admissions Amount >=0 
ov_1 Total Office Visits Amount >=0 
los_1 Total Length of stay Amount >=0 
snf_stay SNF Admission yes or no 
Comorbidity Factors 
 CHF Congestive Heart Failure yes or no 
Arrhy Cardiac Arrhythmia yes or no 
VD Valvular Disease yes or no 
PCD Pulmonary Circulation Disorders yes or no 
PVD Peripheral Vascular Disorders yes or no 
HPTN_NC Hypertension Uncomplicated yes or no 
HPTN_C Hypertension complicated yes or no 
Para Paralysis yes or no 
OthND Other Neurological Disorders yes or no 
COPD Chronic Pulmonary Disease yes or no 
Hptothy Hypothyroidism yes or no 
RF Renal Failure yes or no 
LD Liver Disease yes or no 
PUD_NB Peptic Ulcer Disease excluding bleeding yes or no 
HIV AIDS/HIV yes or no 
Lymp Lymphoma yes or no 
METS Metastatic Cancer yes or no 
Tumor Solid Tumor without Metastasis yes or no 
Rheum_A Rheumatoid Arthritis/collagen yes or no 
Coag Coagulopathy yes or no 
Obesity Obesity yes or no 
WL Weight Loss yes or no 
Fluid Fluid and Electrolyte Disorders yes or no 
BLA Blood Loss Anemia yes or no 
DA Deficiency Anemia yes or no 
Alcohol Alcohol Abuse yes or no 
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Drug Drug Abuse yes or no 
Psycho Psychoses yes or no 
Dep Depression yes or no 
Analytical Factors 
 cost_all Cost Levels, Total Cost of Treatment '0' (highest) to '4' (lowest) 
cost_all_p Cost Levels, Total Patient Cost Sharing '0' (highest) to '4' (lowest) 
mcaid_all Cost Levels, State per Beneficiary Investment '0' (highest) to '4' (lowest) 
prmry_p Primary vs. Specialist (Primary Care Services) '1' (primary) or '0' (specialist) 
urb Urban vs. Rural urban or rural 
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Appendix E: Base Model Results 
 
 
A. Non-Dual Beneficiaries-Retinopathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.7457 0.0294 16201.22 <.0001 
race_1 Other 1 0.105 0.087 1.4558 0.2276 
race_1 Black 1 0.4201 0.0553 57.6385 <.0001 
ov_1 1 0.00842 0.00237 12.5649 0.0004 
snf_stay 1 1 -0.2332 0.1049 4.9415 0.0262 
HPTN_C 1 1 0.1232 0.0579 4.529 0.0333 
Lymp 1 1 0.298 0.1421 4.4003 0.0359 
 
 
 
 
 
 
 
 113 
 
B. Non-Dual Beneficiaries- Nephropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept 1 -3.8961 0.0515 5717.83 <.0001 
sex M 1 0.2772 0.0242 131.0616 <.0001 
race_1 Other 1 0.0507 0.0614 0.6811 0.4092 
race_1 Black 1 0.24 0.0414 33.6761 <.0001 
age_grp 80_over 1 0.6083 0.0339 322.6536 <.0001 
age_grp 75_to_7 1 0.3771 0.0359 110.4345 <.0001 
age_grp 70_to_7 1 0.184 0.0347 28.1257 <.0001 
op_tot_stay_1 1 0.0126 0.00183 47.6859 <.0001 
ov_1 1 0.00337 0.00166 4.1337 0.042 
snf_stay 1 1 -0.1603 0.0587 7.4704 0.0063 
CHF 1 1 0.4888 0.0311 247.7805 <.0001 
PCD 1 1 0.1758 0.0577 9.2898 0.0023 
PVD 1 1 0.1261 0.0302 17.4745 <.0001 
HPTN_NC 1 1 0.3916 0.0443 77.9467 <.0001 
HPTN_C 1 1 0.4452 0.0347 164.8844 <.0001 
COPD 1 1 0.0929 0.03 9.5502 0.002 
Obesity 1 1 0.1767 0.0436 16.403 <.0001 
Fluid 1 1 0.28 0.0353 62.8034 <.0001 
DA 1 1 0.1541 0.0379 16.5391 <.0001 
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C. Non-Dual Beneficiaries- Neuropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept 1 -3.4332 0.0334 10594.43 <.0001 
sex M 1 0.073 0.0261 7.8132 0.0052 
race_1 Other 1 -0.2043 0.0733 7.7656 0.0053 
race_1 Black 1 0.1667 0.0451 13.6521 0.0002 
age_grp 80_over 1 0.1359 0.0363 14.0465 0.0002 
age_grp 75_to_7 1 0.0732 0.0375 3.8239 0.0505 
age_grp 70_to_7 1 0.0254 0.0349 0.5321 0.4657 
op_tot_stay_1 1 0.00576 0.00203 8.0122 0.0046 
ov_1 1 0.0227 0.00162 195.7852 <.0001 
snf_stay 1 1 0.2042 0.06 11.5798 0.0007 
CHF 1 1 0.0991 0.0362 7.51 0.0061 
PVD 1 1 0.3068 0.0317 93.696 <.0001 
OthND 1 1 0.1942 0.0518 14.0663 0.0002 
COPD 1 1 0.0627 0.0317 3.9136 0.0479 
RF 1 1 0.1742 0.0559 9.7171 0.0018 
Rheum_A 1 1 0.1127 0.0512 4.8343 0.0279 
Obesity 1 1 0.2623 0.0442 35.18 <.0001 
Alcohol 1 1 0.3638 0.1385 6.8959 0.0086 
Drug 1 1 0.5094 0.1462 12.1394 0.0005 
Dep 1 1 0.176 0.0421 17.4914 <.0001 
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D. Dual Beneficiaries- Retinopathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.7482 0.1324 801.5499 <.0001 
race_1 Other 1 0.2643 0.0824 10.2822 0.0013 
race_1 Black 1 0.2106 0.0899 5.4868 0.0192 
HPTN_NC 1 1 0.3007 0.134 5.0355 0.0248 
RF 1 1 0.3226 0.1331 5.8779 0.0153 
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E. Dual Beneficiaries- Nephropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.333 0.1077 958.3138 <.0001 
sex M 1 0.1967 0.0538 13.3906 0.0003 
race_1 Other 1 -0.1436 0.064 5.0349 0.0248 
race_1 Black 1 0.0795 0.0634 1.5737 0.2097 
age_grp 80_over 1 0.3806 0.0666 32.7075 <.0001 
age_grp 75_to_7 1 0.1956 0.0724 7.3053 0.0069 
age_grp 70_to_7 1 -0.0371 0.0715 0.2694 0.6037 
op_tot_stay_1 1 0.00674 0.00325 4.3106 0.0379 
snf_stay 1 1 -0.2181 0.0901 5.865 0.0154 
CHF 1 1 0.3991 0.057 49.0149 <.0001 
PVD 1 1 0.114 0.0558 4.1707 0.0411 
HPTN_NC 1 1 0.3102 0.0963 10.3764 0.0013 
HPTN_C 1 1 0.4541 0.0643 49.8123 <.0001 
Obesity 1 1 0.2162 0.0798 7.3404 0.0067 
Fluid 1 1 0.3569 0.0629 32.2196 <.0001 
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F. Dual Beneficiaries- Neuropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -2.9273 0.0543 2908.764 <.0001 
age_grp 80_over 1 -0.1283 0.0684 3.519 0.0607 
age_grp 75_to_7 1 0.0148 0.0705 0.0438 0.8343 
age_grp 70_to_7 1 0.0664 0.0652 1.0392 0.308 
ov_1 1 0.0173 0.00271 40.9632 <.0001 
CHF 1 1 0.2318 0.0574 16.3135 <.0001 
PVD 1 1 0.2913 0.055 28.0431 <.0001 
RF 1 1 0.2422 0.0948 6.5265 0.0106 
Rheum_A 1 1 0.1933 0.0885 4.7731 0.0289 
Obesity 1 1 0.2857 0.0756 14.269 0.0002 
Drug 1 1 0.5098 0.1903 7.1791 0.0074 
Dep 1 1 0.1935 0.0619 9.761 0.0018 
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Appendix F: Explanatory Model Results 
 
 
I. Hypothesis 1 
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A. Non-Dual Beneficiaries-Retinopathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.8873 0.0742 2746.562 <.0001 
cost_all 3 1 1.39E-01 
6.01E-
02 5.3298 0.021 
cost_all 2 1 0.2908 0.0603 23.2304 <.0001 
cost_all 1 1 0.3065 0.064 22.9067 <.0001 
cost_all 0 1 0.3168 0.0793 15.9744 <.0001 
sex M 1 -0.0562 0.0369 2.3182 0.1279 
race_1 Other 1 0.1099 0.0872 1.5857 0.2079 
race_1 Black 1 0.4035 0.0561 51.6578 <.0001 
age_grp 80_over 1 -0.0921 0.0519 3.146 0.0761 
age_grp 75_to_7 1 0.00652 0.0512 0.0162 0.8988 
age_grp 70_to_7 1 0.0697 0.046 2.2908 0.1301 
ip_tot_stay_1 1 -0.00787 0.0496 0.0251 0.8741 
op_tot_stay_1 1 0.000218 0.00335 0.0042 0.9482 
ov_1 1 0.00503 0.00298 2.8457 0.0916 
snf_stay 1 1 -0.2971 0.117 6.4439 0.0111 
los_1 1 0.00254 0.00528 0.2325 0.6297 
CHF 1 1 0.1093 0.0557 3.8419 0.05 
Arrhy 1 1 -0.0123 0.0469 0.0682 0.794 
VD 1 1 -0.1228 0.0553 4.9232 0.0265 
PCD 1 1 -0.00363 0.1083 0.0011 0.9733 
PVD 1 1 0.0663 0.0481 1.9022 0.1678 
HPTN_NC 1 1 0.0426 0.0575 0.5479 0.4592 
HPTN_C 1 1 0.0944 0.0595 2.5142 0.1128 
Para 1 1 -0.0199 0.1909 0.0109 0.917 
OthND 1 1 -0.0391 0.0851 0.2106 0.6463 
COPD 1 1 -0.1455 0.0482 9.0988 0.0026 
Hptothy 1 1 -0.0296 0.043 0.4721 0.492 
RF 1 1 0.1074 0.0829 1.6814 0.1947 
LD 1 1 -0.0401 0.0866 0.2145 0.6433 
PUD_NB 1 1 -0.0878 0.1671 0.276 0.5994 
HIV 1 1 0.8234 0.5177 2.5295 0.1117 
Lymp 1 1 0.2908 0.1429 4.1383 0.0419 
METS 1 1 -0.1517 0.1785 0.7217 0.3956 
Tumor 1 1 -0.1075 0.0552 3.7954 0.0514 
Rheum_A 1 1 -0.2432 0.0847 8.2498 0.0041 
Coag 1 1 -0.1686 0.1001 2.8353 0.0922 
Obesity 1 1 -0.0247 0.0675 0.1342 0.7142 
WL 1 1 0.075 0.0934 0.6449 0.422 
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Fluid 1 1 0.0699 0.0607 1.325 0.2497 
BLA 1 1 0.1952 0.1293 2.2814 0.1309 
DA 1 1 0.0357 0.0618 0.3339 0.5634 
Alcohol 1 1 0.1315 0.225 0.3414 0.559 
Drug 1 1 -0.2891 0.3218 0.8069 0.3691 
Psycho 1 1 -0.2218 0.1505 2.1724 0.1405 
Dep 1 1 -0.019 0.0649 0.0854 0.7701 
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B. Non-Dual Beneficiaries- Nephropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.9255 0.0576 4643.804 <.0001 
cost_all 3 1 7.62E-02 
4.24E-
02 3.2364 0.072 
cost_all 2 1 -0.00055 0.0437 0.0002 0.9899 
cost_all 1 1 0.0556 0.0451 1.52 0.2176 
cost_all 0 1 0.00436 0.0539 0.0065 0.9355 
sex M 1 0.2371 0.0257 85.117 <.0001 
race_1 Other 1 0.0633 0.0629 1.0117 0.3145 
race_1 Black 1 0.2236 0.0427 27.3631 <.0001 
age_grp 80_over 1 0.5436 0.0351 239.9502 <.0001 
age_grp 75_to_7 1 0.3347 0.0368 82.5151 <.0001 
age_grp 70_to_7 1 0.1679 0.0354 22.4946 <.0001 
ip_tot_stay_1 1 -0.0471 0.0304 2.3964 0.1216 
op_tot_stay_1 1 0.00767 0.00201 14.5057 0.0001 
ov_1 1 0.00265 0.00195 1.8454 0.1743 
snf_stay 1 1 -0.1695 0.0677 6.2749 0.0122 
los_1 1 0.00104 0.00315 0.1091 0.7412 
CHF 1 1 0.404 0.0339 142.308 <.0001 
Arrhy 1 1 0.0429 0.0309 1.9268 0.1651 
VD 1 1 0.00731 0.0349 0.044 0.8339 
PCD 1 1 0.1531 0.0614 6.2197 0.0126 
PVD 1 1 0.1171 0.0314 13.8595 0.0002 
HPTN_NC 1 1 0.3344 0.0451 54.9281 <.0001 
HPTN_C 1 1 0.1834 0.037 24.6033 <.0001 
Para 1 1 -0.1451 0.1282 1.281 0.2577 
OthND 1 1 -0.0621 0.0552 1.2633 0.261 
COPD 1 1 0.1029 0.0311 10.9294 0.0009 
Hptothy 1 1 -0.0284 0.0298 0.9115 0.3397 
RF 1 1 2.0007 0.0337 3529.091 <.0001 
LD 1 1 -0.0875 0.0604 2.097 0.1476 
PUD_NB 1 1 -0.0145 0.1066 0.0184 0.892 
HIV 1 1 -0.2656 0.6101 0.1895 0.6633 
Lymp 1 1 0.1418 0.1033 1.884 0.1699 
METS 1 1 0.1055 0.1064 0.9823 0.3216 
Tumor 1 1 0.0395 0.036 1.2063 0.2721 
Rheum_A 1 1 -0.0297 0.0534 0.3096 0.5779 
Coag 1 1 -0.036 0.0596 0.3648 0.5459 
Obesity 1 1 0.1633 0.0451 13.1256 0.0003 
WL 1 1 0.0447 0.0609 0.5396 0.4626 
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Fluid 1 1 0.1581 0.0386 16.8076 <.0001 
BLA 1 1 0.0891 0.0875 1.0368 0.3086 
DA 1 1 0.1302 0.0399 10.6327 0.0011 
Alcohol 1 1 0.2024 0.1462 1.9161 0.1663 
Drug 1 1 -0.00186 0.1869 0.0001 0.992 
Psycho 1 1 0.0101 0.0856 0.0139 0.9061 
Dep 1 1 0.0615 0.0436 1.9954 0.1578 
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C. Non-Dual Beneficiaries- Neuropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.5852 0.0566 4006.947 <.0001 
cost_all 3 1 1.64E-01 
4.84E-
02 11.3918 0.0007 
cost_all 2 1 0.3321 0.0476 48.7446 <.0001 
cost_all 1 1 0.4593 0.0485 89.643 <.0001 
cost_all 0 1 0.5335 0.0567 88.5906 <.0001 
sex M 1 0.0916 0.0269 11.5485 0.0007 
race_1 Other 1 -0.1996 0.0734 7.3875 0.0066 
race_1 Black 1 0.177 0.0455 15.1436 <.0001 
age_grp 80_over 1 0.1354 0.0367 13.5999 0.0002 
age_grp 75_to_7 1 0.0732 0.0376 3.7816 0.0518 
age_grp 70_to_7 1 0.0254 0.035 0.528 0.4675 
ip_tot_stay_1 1 -0.0595 0.0305 3.809 0.051 
op_tot_stay_1 1 0.0025 0.00217 1.3216 0.2503 
ov_1 1 0.0184 0.00186 97.3392 <.0001 
snf_stay 1 1 0.1183 0.0659 3.2279 0.0724 
los_1 1 0.00646 0.00295 4.7999 0.0285 
CHF 1 1 0.0827 0.0382 4.7031 0.0301 
Arrhy 1 1 -0.0317 0.0327 0.938 0.3328 
VD 1 1 -0.0728 0.0375 3.7661 0.0523 
PCD 1 1 -0.0402 0.0698 0.3319 0.5646 
PVD 1 1 0.266 0.032 69.1537 <.0001 
HPTN_NC 1 1 -0.0401 0.0419 0.9146 0.3389 
HPTN_C 1 1 0.0321 0.0423 0.5767 0.4476 
Para 1 1 -0.0156 0.1196 0.0171 0.8961 
OthND 1 1 0.1434 0.0531 7.3026 0.0069 
COPD 1 1 0.0435 0.0324 1.8027 0.1794 
Hptothy 1 1 -0.0142 0.0308 0.2133 0.6442 
RF 1 1 0.1704 0.0565 9.097 0.0026 
LD 1 1 0.0362 0.0585 0.3837 0.5356 
PUD_NB 1 1 -0.0268 0.1106 0.0587 0.8085 
HIV 1 1 0.193 0.5188 0.1383 0.71 
Lymp 1 1 -0.2617 0.1223 4.5771 0.0324 
METS 1 1 -0.0174 0.1149 0.0229 0.8797 
Tumor 1 1 -0.1688 0.0395 18.2632 <.0001 
Rheum_A 1 1 0.0841 0.0513 2.6885 0.1011 
Coag 1 1 -0.1318 0.0648 4.1311 0.0421 
Obesity 1 1 0.2342 0.0444 27.8205 <.0001 
WL 1 1 -0.0818 0.066 1.5338 0.2155 
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Fluid 1 1 -0.013 0.0422 0.0942 0.7589 
BLA 1 1 -0.00436 0.095 0.0021 0.9634 
DA 1 1 -0.0118 0.0435 0.0737 0.786 
Alcohol 1 1 0.3128 0.1396 5.0217 0.025 
Drug 1 1 0.4587 0.1464 9.8147 0.0017 
Psycho 1 1 0.1019 0.0842 1.4627 0.2265 
Dep 1 1 0.1398 0.0425 10.8379 0.001 
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D. Dual Beneficiaries-Retinopathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.7948 0.1633 539.9824 <.0001 
cost_all 3 1 1.54E-01 
1.19E-
01 1.6853 0.1942 
cost_all 2 1 0.4295 0.1185 13.1448 0.0003 
cost_all 1 1 0.3535 0.1299 7.4062 0.0065 
cost_all 0 1 0.6318 0.158 15.9847 <.0001 
sex M 1 -0.03 0.0801 0.1399 0.7084 
race_1 Other 1 0.2455 0.0855 8.2484 0.0041 
race_1 Black 1 0.2041 0.092 4.9261 0.0265 
age_grp 80_over 1 -0.1298 0.0986 1.7325 0.1881 
age_grp 75_to_7 1 -0.0955 0.1031 0.8577 0.3544 
age_grp 70_to_7 1 0.0537 0.0924 0.3377 0.5612 
ip_tot_stay_1 1 -0.0735 0.0936 0.6159 0.4326 
op_tot_stay_1 1 -0.00067 0.00538 0.0154 0.9011 
ov_1 1 -0.00337 0.00533 0.4003 0.5269 
snf_stay 1 1 -0.0221 0.1583 0.0195 0.8889 
los_1 1 -0.00994 0.0112 0.7865 0.3752 
CHF 1 1 0.0542 0.0954 0.323 0.5698 
Arrhy 1 1 -0.1251 0.0937 1.7828 0.1818 
VD 1 1 0.0727 0.1049 0.4796 0.4886 
PCD 1 1 0.2075 0.1972 1.1069 0.2928 
PVD 1 1 0.0488 0.0846 0.3322 0.5643 
HPTN_NC 1 1 0.2555 0.1358 3.5413 0.0599 
HPTN_C 1 1 0.0677 0.1055 0.4116 0.5212 
Para 1 1 0.3317 0.2169 2.3395 0.1261 
OthND 1 1 0.085 0.1263 0.4534 0.5007 
COPD 1 1 -0.3248 0.0873 13.8546 0.0002 
Hptothy 1 1 0.024 0.0821 0.0856 0.7698 
RF 1 1 0.3485 0.1369 6.4789 0.0109 
LD 1 1 0.034 0.1428 0.0566 0.8119 
PUD_NB 1 1 -0.2004 0.2672 0.5626 0.4532 
HIV 1 1 0.1005 0.7268 0.0191 0.8901 
Lymp 1 1 -0.3511 0.458 0.5876 0.4433 
METS 1 1 0.3519 0.3295 1.1412 0.2854 
Tumor 1 1 -0.2817 0.1367 4.2449 0.0394 
Rheum_A 1 1 -0.1021 0.1474 0.4794 0.4887 
Coag 1 1 -0.1027 0.1902 0.2915 0.5892 
Obesity 1 1 0.0482 0.1201 0.1608 0.6884 
WL 1 1 -0.505 0.1916 6.9503 0.0084 
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Fluid 1 1 -0.1287 0.11 1.3686 0.2421 
BLA 1 1 -0.3175 0.2871 1.2232 0.2687 
DA 1 1 0.0732 0.1071 0.4674 0.4942 
Alcohol 1 1 0.2427 0.3319 0.5346 0.4647 
Drug 1 1 0.2145 0.3296 0.4235 0.5152 
Psycho 1 1 -0.2294 0.1576 2.1166 0.1457 
Dep 1 1 0.0657 0.0985 0.4448 0.5048 
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E. Dual Beneficiaries-Nephropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.3549 0.1197 784.9242 <.0001 
cost_all 3 1 7.53E-02 
8.59E-
02 0.7684 0.3807 
cost_all 2 1 0.0334 0.089 0.141 0.7073 
cost_all 1 1 0.018 0.0935 0.037 0.8475 
cost_all 0 1 0.0199 0.1145 0.0302 0.8621 
sex M 1 0.139 0.0565 6.0494 0.0139 
race_1 Other 1 -0.1346 0.0664 4.1098 0.0426 
race_1 Black 1 0.0794 0.0664 1.4308 0.2316 
age_grp 80_over 1 0.3046 0.0694 19.2466 <.0001 
age_grp 75_to_7 1 0.1566 0.0745 4.4163 0.0356 
age_grp 70_to_7 1 -0.0724 0.0732 0.9773 0.3229 
ip_tot_stay_1 1 -0.032 0.0519 0.3808 0.5372 
op_tot_stay_1 1 0.00262 0.00359 0.5331 0.4653 
ov_1 1 0.00132 0.00361 0.1331 0.7152 
snf_stay 1 1 -0.2128 0.1076 3.9117 0.048 
los_1 1 -0.00341 0.00513 0.4412 0.5066 
CHF 1 1 0.3059 0.0633 23.3547 <.0001 
Arrhy 1 1 0.0883 0.063 1.9643 0.1611 
VD 1 1 -0.00116 0.0735 0.0003 0.9874 
PCD 1 1 0.1124 0.1269 0.7849 0.3757 
PVD 1 1 0.097 0.0591 2.6965 0.1006 
HPTN_NC 1 1 0.2385 0.0988 5.8281 0.0158 
HPTN_C 1 1 0.2008 0.0696 8.3224 0.0039 
Para 1 1 -0.1335 0.1823 0.5364 0.4639 
OthND 1 1 0.0201 0.0888 0.051 0.8214 
COPD 1 1 0.0606 0.0584 1.0772 0.2993 
Hptothy 1 1 0.0213 0.0587 0.1313 0.7171 
RF 1 1 1.9015 0.0671 803.4205 <.0001 
LD 1 1 0.184 0.0989 3.4652 0.0627 
PUD_NB 1 1 -0.1566 0.1814 0.7451 0.388 
HIV 1 1 -1.3788 1.0244 1.8115 0.1783 
Lymp 1 1 -0.0251 0.2702 0.0086 0.9261 
METS 1 1 0.061 0.2326 0.0689 0.793 
Tumor 1 1 -0.00793 0.0872 0.0083 0.9276 
Rheum_A 1 1 -0.2397 0.1074 4.9785 0.0257 
Coag 1 1 -0.0678 0.1226 0.3062 0.58 
Obesity 1 1 0.1816 0.0833 4.7539 0.0292 
WL 1 1 -0.0697 0.1097 0.4041 0.525 
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Fluid 1 1 0.2368 0.07 11.4272 0.0007 
BLA 1 1 0.1085 0.1587 0.4677 0.494 
DA 1 1 0.0456 0.0748 0.3722 0.5418 
Alcohol 1 1 -0.0497 0.2599 0.0366 0.8482 
Drug 1 1 0.3153 0.2335 1.8229 0.177 
Psycho 1 1 -0.3069 0.1103 7.7391 0.0054 
Dep 1 1 -0.0543 0.072 0.5694 0.4505 
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F. Dual Beneficiaries-Neuropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.1278 0.1144 748.0233 <.0001 
cost_all 3 1 3.57E-01 
9.46E-
02 14.2529 0.0002 
cost_all 2 1 0.5794 0.0934 38.4477 <.0001 
cost_all 1 1 0.739 0.0962 59.0534 <.0001 
cost_all 0 1 0.9622 0.1124 73.226 <.0001 
sex M 1 -0.0177 0.0562 0.0992 0.7528 
race_1 Other 1 -0.078 0.0627 1.5437 0.2141 
race_1 Black 1 -0.1216 0.0686 3.1448 0.0762 
age_grp 80_over 1 -0.1513 0.0704 4.6184 0.0316 
age_grp 75_to_7 1 0.00523 0.0714 0.0054 0.9417 
age_grp 70_to_7 1 0.0612 0.0656 0.8708 0.3507 
ip_tot_stay_1 1 -0.0286 0.0526 0.2961 0.5863 
op_tot_stay_1 1 -0.0035 0.00356 0.9645 0.3261 
ov_1 1 0.00861 0.0032 7.2107 0.0072 
snf_stay 1 1 -0.1715 0.1032 2.7638 0.0964 
los_1 1 -0.00745 0.00604 1.5218 0.2173 
CHF 1 1 0.1716 0.0627 7.492 0.0062 
Arrhy 1 1 -0.1265 0.0625 4.1014 0.0428 
VD 1 1 -0.0677 0.0717 0.8914 0.3451 
PCD 1 1 0.00395 0.1283 0.0009 0.9755 
PVD 1 1 0.2315 0.0561 17.0378 <.0001 
HPTN_NC 1 1 -0.0705 0.088 0.6419 0.423 
HPTN_C 1 1 0.0579 0.071 0.6652 0.4147 
Para 1 1 -0.0642 0.1666 0.1484 0.7 
OthND 1 1 0.00421 0.086 0.0024 0.961 
COPD 1 1 0.0274 0.0556 0.2431 0.622 
Hptothy 1 1 -0.0504 0.0571 0.7797 0.3772 
RF 1 1 0.2285 0.0964 5.6192 0.0178 
LD 1 1 -0.1323 0.099 1.7854 0.1815 
PUD_NB 1 1 -0.0482 0.1639 0.0864 0.7688 
HIV 1 1 0.3087 0.4783 0.4166 0.5187 
Lymp 1 1 0.1191 0.2459 0.2347 0.6281 
METS 1 1 -0.11 0.236 0.2174 0.6411 
Tumor 1 1 -0.1515 0.0868 3.0476 0.0809 
Rheum_A 1 1 0.1472 0.0888 2.7476 0.0974 
Coag 1 1 0.1472 0.1123 1.7171 0.1901 
Obesity 1 1 0.2484 0.0765 10.5491 0.0012 
WL 1 1 -0.0883 0.1075 0.675 0.4113 
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Fluid 1 1 0.1061 0.0693 2.3398 0.1261 
BLA 1 1 -0.2681 0.1762 2.315 0.1281 
DA 1 1 0.0215 0.0728 0.0874 0.7675 
Alcohol 1 1 -0.1146 0.252 0.2068 0.6493 
Drug 1 1 0.484 0.1915 6.3885 0.0115 
Psycho 1 1 -0.3555 0.1084 10.7588 0.001 
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II. Hypothesis 2 
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A. Non-Dual Beneficiaries-Retinopathy 
 
Parameter     DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept     1 -3.7893 0.0694 2979.882 <.0001 
prmry_p 0 1 8.83E-02 
4.41E-
02 4.0109 0.0452 
urb rural 1 -0.0305 0.0525 0.3374 0.5613 
prmry_p*urb 0 rural 1 0.1228 0.0858 2.0463 0.1526 
sex M 1 -0.0678 0.0371 3.3308 0.068 
race_1 Other 1 0.0931 0.0888 1.0988 0.2945 
race_1 Black 1 0.3977 0.0569 48.8418 <.0001 
age_grp 80_over 1 -0.0751 0.0522 2.0727 0.15 
age_grp 75_to_7 1 0.0172 0.0515 0.1121 0.7378 
age_grp 70_to_7 1 0.0731 0.0463 2.4917 0.1145 
ip_tot_stay_1 1 0.015 0.0457 0.1083 0.7421 
op_tot_stay_1 1 0.00199 0.00332 0.3615 0.5477 
ov_1 1 0.00889 0.00283 9.8505 0.0017 
snf_stay 1 1 -0.2753 0.1166 5.5698 0.0183 
los_1 1 0.00122 0.0054 0.0506 0.8219 
CHF 1 1 0.1126 0.056 4.0336 0.0446 
Arrhy 1 1 0.00446 0.0471 0.009 0.9245 
VD 1 1 -0.1133 0.0556 4.1541 0.0415 
PCD 1 1 -0.018 0.1089 0.0272 0.869 
PVD 1 1 0.0878 0.0481 3.3333 0.0679 
HPTN_NC 1 1 0.0573 0.0578 0.9806 0.3221 
HPTN_C 1 1 0.1019 0.0597 2.9116 0.0879 
Para 1 1 -0.00466 0.191 0.0006 0.9805 
OthND 1 1 -0.022 0.0853 0.0666 0.7964 
COPD 1 1 -0.1321 0.0484 7.4435 0.0064 
Hptothy 1 1 -0.0217 0.0431 0.2539 0.6143 
RF 1 1 0.1067 0.0832 1.6444 0.1997 
LD 1 1 -0.0192 0.0867 0.049 0.8247 
PUD_NB 1 1 -0.0736 0.1672 0.1939 0.6597 
HIV 1 1 0.8647 0.518 2.7873 0.095 
Lymp 1 1 0.273 0.1443 3.5801 0.0585 
METS 1 1 -0.1715 0.1785 0.9231 0.3367 
Tumor 1 1 -0.0994 0.0554 3.2206 0.0727 
Rheum_A 1 1 -0.2457 0.0851 8.3466 0.0039 
Coag 1 1 -0.1732 0.1003 2.9807 0.0843 
Obesity 1 1 -0.0144 0.0678 0.0452 0.8316 
WL 1 1 0.0879 0.0936 0.8822 0.3476 
Fluid 1 1 0.0892 0.0609 2.1428 0.1432 
 136 
 
BLA 1 1 0.2026 0.1294 2.4526 0.1173 
DA 1 1 0.0487 0.062 0.6177 0.4319 
Alcohol 1 1 0.1069 0.2303 0.2157 0.6424 
Drug 1 1 -0.2906 0.3219 0.8153 0.3665 
Psycho 1 1 -0.1959 0.1507 1.6899 0.1936 
Dep 1   1 0.000794 0.0651 0.0001 0.9903 
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B. Non-Dual Beneficiaries-Nephropathy 
 
Parameter     DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept     1 -3.8604 0.0546 4999.326 <.0001 
prmry_p 0 1 
-1.04E-
02 
3.03E-
02 0.1178 0.7315 
urb rural 1 -0.1182 0.0367 10.3623 0.0013 
prmry_p*urb 0 rural 1 0.037 0.0612 0.3661 0.5451 
sex M 1 0.2365 0.0258 83.9462 <.0001 
race_1 Other 1 0.0609 0.0634 0.922 0.3369 
race_1 Black 1 0.2033 0.0432 22.1081 <.0001 
age_grp 80_over 1 0.5409 0.0352 236.1332 <.0001 
age_grp 75_to_7 1 0.3326 0.037 80.932 <.0001 
age_grp 70_to_7 1 0.1695 0.0355 22.791 <.0001 
ip_tot_stay_1 1 -0.0543 0.0281 3.7429 0.053 
op_tot_stay_1 1 0.00914 0.00201 20.6556 <.0001 
ov_1 1 0.00163 0.00191 0.7337 0.3917 
snf_stay 1 1 -0.187 0.067 7.7833 0.0053 
los_1 1 0.00104 0.00313 0.1097 0.7404 
CHF 1 1 0.4076 0.0338 145.0286 <.0001 
Arrhy 1 1 0.0432 0.0309 1.9555 0.162 
VD 1 1 0.00195 0.0349 0.0031 0.9555 
PCD 1 1 0.1486 0.0615 5.8336 0.0157 
PVD 1 1 0.1161 0.0313 13.7374 0.0002 
HPTN_NC 1 1 0.3378 0.0454 55.2995 <.0001 
HPTN_C 1 1 0.1807 0.037 23.8043 <.0001 
Para 1 1 -0.1511 0.1282 1.3889 0.2386 
OthND 1 1 -0.0613 0.0552 1.2336 0.2667 
COPD 1 1 0.1064 0.0311 11.6645 0.0006 
Hptothy 1 1 -0.0302 0.0298 1.0259 0.3111 
RF 1 1 2.0025 0.0338 3510.897 <.0001 
LD 1 1 -0.0958 0.0605 2.5075 0.1133 
PUD_NB 1 1 -0.0146 0.1066 0.0188 0.8909 
HIV 1 1 -0.2695 0.6114 0.1944 0.6593 
Lymp 1 1 0.1467 0.1034 2.0132 0.1559 
METS 1 1 0.0987 0.1063 0.8613 0.3534 
Tumor 1 1 0.0376 0.0361 1.0837 0.2979 
Rheum_A 1 1 -0.0337 0.0535 0.3959 0.5292 
Coag 1 1 -0.0421 0.0597 0.4986 0.4801 
Obesity 1 1 0.1635 0.0451 13.1455 0.0003 
WL 1 1 0.0474 0.0609 0.6066 0.4361 
Fluid 1 1 0.161 0.0386 17.4315 <.0001 
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BLA 1 1 0.0881 0.0875 1.0138 0.314 
DA 1 1 0.1285 0.04 10.3386 0.0013 
Alcohol 1 1 0.1981 0.1463 1.834 0.1757 
Drug 1 1 -0.00036 0.1868 0 0.9985 
Psycho 1 1 0.0146 0.0856 0.0292 0.8643 
Dep 1   1 0.06 0.0436 1.891 0.1691 
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C. Non-Dual Beneficiaries-Neuropathy 
 
Parameter     DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept     1 -3.4417 0.0511 4531.255 <.0001 
prmry_p 0 1 1.19E-01 
3.13E-
02 14.5139 0.0001 
urb rural 1 -0.0454 0.0389 1.3605 0.2434 
prmry_p*urb 0 rural 1 0.00346 0.0632 0.003 0.9563 
sex M 1 0.0785 0.027 8.4278 0.0037 
race_1 Other 1 -0.2026 0.0738 7.5255 0.0061 
race_1 Black 1 0.1703 0.0459 13.7986 0.0002 
age_grp 80_over 1 0.1536 0.0368 17.4126 <.0001 
age_grp 75_to_7 1 0.0841 0.0378 4.9673 0.0258 
age_grp 70_to_7 1 0.0314 0.035 0.8049 0.3696 
ip_tot_stay_1 1 -0.00058 0.0283 0.0004 0.9836 
op_tot_stay_1 1 0.00675 0.00213 10.0217 0.0015 
ov_1 1 0.0229 0.0018 161.4299 <.0001 
snf_stay 1 1 0.1608 0.0661 5.9258 0.0149 
los_1 1 0.00387 0.00305 1.612 0.2042 
CHF 1 1 0.1034 0.0384 7.2552 0.0071 
Arrhy 1 1 -0.013 0.0329 0.1548 0.694 
VD 1 1 -0.0573 0.0377 2.3084 0.1287 
PCD 1 1 -0.0547 0.0703 0.6064 0.4361 
PVD 1 1 0.3006 0.032 88.3443 <.0001 
HPTN_NC 1 1 -0.00506 0.0422 0.0144 0.9044 
HPTN_C 1 1 0.0421 0.0425 0.9832 0.3214 
Para 1 1 0.0107 0.12 0.008 0.9289 
OthND 1 1 0.1611 0.0535 9.0838 0.0026 
COPD 1 1 0.0654 0.0325 4.0442 0.0443 
Hptothy 1 1 -0.00663 0.0309 0.0461 0.83 
RF 1 1 0.1684 0.0567 8.8297 0.003 
LD 1 1 0.0577 0.0587 0.9658 0.3257 
PUD_NB 1 1 -0.00058 0.111 0 0.9958 
HIV 1 1 0.2064 0.5192 0.1581 0.6909 
Lymp 1 1 -0.2481 0.1226 4.093 0.0431 
METS 1 1 -0.0261 0.1152 0.0514 0.8207 
Tumor 1 1 -0.1512 0.0397 14.5225 0.0001 
Rheum_A 1 1 0.0977 0.0514 3.6092 0.0575 
Coag 1 1 -0.1357 0.0651 4.3426 0.0372 
Obesity 1 1 0.2522 0.0445 32.1295 <.0001 
WL 1 1 -0.0678 0.0663 1.0469 0.3062 
Fluid 1 1 0.00793 0.0426 0.0347 0.8521 
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BLA 1 1 -0.00177 0.0957 0.0003 0.9852 
DA 1 1 0.00299 0.0437 0.0047 0.9455 
Alcohol 1 1 0.3479 0.1399 6.1882 0.0129 
Drug 1 1 0.4702 0.147 10.2356 0.0014 
Psycho 1 1 0.1262 0.0848 2.2139 0.1368 
Dep 1   1 0.1659 0.0427 15.1224 0.0001 
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D. Dual Beneficiaries-Retinopathy 
 
Parameter     DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept     1 -3.651 0.1585 530.934 <.0001 
prmry_p 0 1 1.77E-01 
8.67E-
02 4.1553 0.0415 
urb rural 1 -0.1611 0.1049 2.3568 0.1247 
prmry_p*urb 0 rural 1 -0.2681 0.1898 1.9951 0.1578 
sex M 1 -0.0194 0.0804 0.058 0.8097 
race_1 Other 1 0.2008 0.0877 5.2488 0.022 
race_1 Black 1 0.1886 0.0928 4.1269 0.0422 
age_grp 80_over 1 -0.1118 0.0994 1.2653 0.2606 
age_grp 75_to_7 1 -0.0848 0.1041 0.6641 0.4151 
age_grp 70_to_7 1 0.0758 0.093 0.6658 0.4145 
ip_tot_stay_1 1 0.0151 0.0865 0.0305 0.8615 
op_tot_stay_1 1 0.00543 0.0053 1.0485 0.3059 
ov_1 1 0.000983 0.00509 0.0372 0.847 
snf_stay 1 1 0.097 0.1554 0.3901 0.5323 
los_1 1 -0.0119 0.0112 1.1327 0.2872 
CHF 1 1 0.0967 0.0958 1.02 0.3125 
Arrhy 1 1 -0.1282 0.0947 1.8333 0.1757 
VD 1 1 0.0907 0.1054 0.7405 0.3895 
PCD 1 1 0.1899 0.1976 0.9236 0.3365 
PVD 1 1 0.0774 0.0847 0.8341 0.3611 
HPTN_NC 1 1 0.2896 0.1375 4.4332 0.0352 
HPTN_C 1 1 0.0804 0.1057 0.5789 0.4467 
Para 1 1 0.3756 0.2177 2.9756 0.0845 
OthND 1 1 0.1233 0.1268 0.9447 0.3311 
COPD 1 1 -0.2877 0.0878 10.7356 0.0011 
Hptothy 1 1 0.0284 0.0826 0.1183 0.7309 
RF 1 1 0.3488 0.1372 6.4629 0.011 
LD 1 1 0.0387 0.1431 0.0733 0.7866 
PUD_NB 1 1 -0.1862 0.2673 0.4851 0.4861 
HIV 1 1 0.1176 0.7288 0.026 0.8718 
Lymp 1 1 -0.3449 0.4578 0.5677 0.4512 
METS 1 1 0.38 0.3295 1.3297 0.2489 
Tumor 1 1 -0.2766 0.1371 4.0678 0.0437 
Rheum_A 1 1 -0.0905 0.1488 0.37 0.543 
Coag 1 1 -0.113 0.1908 0.351 0.5536 
Obesity 1 1 0.0363 0.1215 0.0892 0.7652 
WL 1 1 -0.4884 0.1919 6.4764 0.0109 
Fluid 1 1 -0.0925 0.1107 0.6981 0.4034 
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BLA 1 1 -0.3186 0.2876 1.2277 0.2679 
DA 1 1 0.0776 0.1077 0.5194 0.4711 
Alcohol 1 1 0.2731 0.3326 0.6741 0.4116 
Drug 1 1 0.2452 0.33 0.5523 0.4574 
Psycho 1 1 -0.2432 0.1608 2.2856 0.1306 
Dep 1   1 0.1031 0.0989 1.0874 0.297 
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E. Dual Beneficiaries-Nephropathy 
 
Parameter     DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept     1 -3.3081 0.1165 806.8484 <.0001 
prmry_p 0 1 
-1.38E-
02 
6.54E-
02 0.0446 0.8328 
urb rural 1 0.00221 0.0716 0.0009 0.9754 
prmry_p*urb 0 rural 1 -0.00224 0.125 0.0003 0.9857 
sex M 1 0.1352 0.0569 5.6466 0.0175 
race_1 Other 1 -0.1261 0.068 3.4378 0.0637 
race_1 Black 1 0.0857 0.0669 1.6419 0.2001 
age_grp 80_over 1 0.3 0.0697 18.5417 <.0001 
age_grp 75_to_7 1 0.1522 0.0748 4.1356 0.042 
age_grp 70_to_7 1 -0.0865 0.0737 1.3777 0.2405 
ip_tot_stay_1 1 -0.0391 0.0483 0.6544 0.4185 
op_tot_stay_1 1 0.0036 0.00363 0.9874 0.3204 
ov_1 1 0.00105 0.00351 0.0901 0.764 
snf_stay 1 1 -0.2238 0.1043 4.6028 0.0319 
los_1 1 -0.00305 0.00505 0.3645 0.546 
CHF 1 1 0.3088 0.0631 23.9749 <.0001 
Arrhy 1 1 0.0913 0.063 2.1015 0.1472 
VD 1 1 -0.00369 0.0735 0.0025 0.9599 
PCD 1 1 0.1129 0.1269 0.7923 0.3734 
PVD 1 1 0.0934 0.0589 2.5138 0.1129 
HPTN_NC 1 1 0.233 0.0998 5.4518 0.0195 
HPTN_C 1 1 0.1893 0.0698 7.3593 0.0067 
Para 1 1 -0.1594 0.1844 0.7467 0.3875 
OthND 1 1 0.0154 0.0889 0.03 0.8624 
COPD 1 1 0.0624 0.0584 1.1435 0.2849 
Hptothy 1 1 0.0298 0.0588 0.2571 0.6121 
RF 1 1 1.8984 0.0673 794.5444 <.0001 
LD 1 1 0.1853 0.0989 3.5098 0.061 
PUD_NB 1 1 -0.1582 0.1813 0.7614 0.3829 
HIV 1 1 -1.3338 1.0264 1.6889 0.1937 
Lymp 1 1 -0.025 0.2702 0.0086 0.9263 
METS 1 1 0.0596 0.2323 0.0659 0.7974 
Tumor 1 1 -0.0151 0.0876 0.0297 0.8632 
Rheum_A 1 1 -0.2471 0.1078 5.2589 0.0218 
Coag 1 1 -0.0677 0.1226 0.3046 0.581 
Obesity 1 1 0.1768 0.0835 4.4826 0.0342 
WL 1 1 -0.0709 0.1097 0.4172 0.5183 
Fluid 1 1 0.2401 0.0698 11.8281 0.0006 
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BLA 1 1 0.1091 0.1587 0.4723 0.4919 
DA 1 1 0.0478 0.0748 0.4088 0.5226 
Alcohol 1 1 -0.0368 0.2605 0.02 0.8876 
Drug 1 1 0.3134 0.2335 1.801 0.1796 
Psycho 1 1 -0.3006 0.1105 7.4073 0.0065 
Dep 1   1 -0.0606 0.0721 0.7062 0.4007 
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F. Dual Beneficiaries-Neuropathy 
 
Parameter     DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept     1 -2.8439 0.1045 740.9165 <.0001 
prmry_p 0 1 2.68E-02 
6.21E-
02 0.1858 0.6665 
urb rural 1 -0.1734 0.0734 5.5779 0.0182 
prmry_p*urb 0 rural 1 0.0536 0.1254 0.183 0.6688 
sex M 1 -0.0397 0.0566 0.4906 0.4837 
race_1 Other 1 -0.1071 0.0642 2.7844 0.0952 
race_1 Black 1 -0.1382 0.0692 3.9823 0.046 
age_grp 80_over 1 -0.107 0.0708 2.2838 0.1307 
age_grp 75_to_7 1 0.0305 0.072 0.1799 0.6715 
age_grp 70_to_7 1 0.0904 0.0659 1.881 0.1702 
ip_tot_stay_1 1 0.0702 0.0494 2.0252 0.1547 
op_tot_stay_1 1 0.0033 0.00354 0.8704 0.3508 
ov_1 1 0.0153 0.00308 24.8887 <.0001 
snf_stay 1 1 -0.0451 0.1025 0.1936 0.6599 
los_1 1 -0.0103 0.00621 2.7654 0.0963 
CHF 1 1 0.2259 0.0632 12.7771 0.0004 
Arrhy 1 1 -0.1049 0.0634 2.7367 0.0981 
VD 1 1 -0.0413 0.0724 0.3252 0.5685 
PCD 1 1 -0.0445 0.1298 0.1175 0.7317 
PVD 1 1 0.2907 0.0563 26.6752 <.0001 
HPTN_NC 1 1 0.00166 0.0891 0.0003 0.9851 
HPTN_C 1 1 0.0907 0.0713 1.6173 0.2035 
Para 1 1 -0.00549 0.1678 0.0011 0.9739 
OthND 1 1 0.0533 0.0869 0.3757 0.5399 
COPD 1 1 0.0826 0.056 2.1779 0.14 
Hptothy 1 1 -0.0413 0.0574 0.5169 0.4721 
RF 1 1 0.2241 0.0969 5.3508 0.0207 
LD 1 1 -0.1078 0.0995 1.1749 0.2784 
PUD_NB 1 1 -0.014 0.1643 0.0072 0.9322 
HIV 1 1 0.3914 0.4803 0.6639 0.4152 
Lymp 1 1 0.1697 0.246 0.4758 0.4903 
METS 1 1 -0.0625 0.2371 0.0696 0.792 
Tumor 1 1 -0.1256 0.0876 2.0566 0.1516 
Rheum_A 1 1 0.1976 0.0891 4.9157 0.0266 
Coag 1 1 0.1645 0.113 2.1199 0.1454 
Obesity 1 1 0.279 0.0767 13.2495 0.0003 
WL 1 1 -0.0606 0.108 0.3151 0.5746 
Fluid 1 1 0.156 0.0701 4.9469 0.0261 
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BLA 1 1 -0.2691 0.1772 2.3052 0.1289 
DA 1 1 0.0437 0.0732 0.3563 0.5506 
Alcohol 1 1 -0.0437 0.253 0.0299 0.8628 
Drug 1 1 0.5257 0.1922 7.4838 0.0062 
Psycho 1 1 -0.3269 0.1097 8.8748 0.0029 
Dep 1   1 0.1923 0.0653 8.6618 0.0032 
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I. Hypothesis 3 
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A. Non-Dual Beneficiaries-Retinopathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.8646 0.0741 2723.547 <.0001 
Cost_all_p 3 1 1.03E-01 
5.99E-
02 2.9314 0.0869 
Cost_all_p 2 1 0.2603 0.0601 18.7818 <.0001 
Cost_all_p 1 1 0.2699 0.0634 18.1254 <.0001 
Cost_all_p 0 1 0.3453 0.0791 19.0744 <.0001 
sex M 1 -0.0595 0.0369 2.5926 0.1074 
race_1 Other 1 0.1084 0.0872 1.5453 0.2138 
race_1 Black 1 0.4052 0.0562 52.0719 <.0001 
age_grp 80_over 1 -0.0844 0.0519 2.6398 0.1042 
age_grp 75_to_7 1 0.011 0.0512 0.0462 0.8298 
age_grp 70_to_7 1 0.072 0.046 2.4461 0.1178 
ip_tot_stay_1 1 -0.0294 0.0492 0.3584 0.5494 
op_tot_stay_1 1 -0.00034 0.0034 0.0101 0.9199 
ov_1 1 0.00472 0.003 2.4822 0.1151 
snf_stay 1 1 -0.3093 0.1167 7.029 0.008 
los_1 1 0.00292 0.00524 0.3101 0.5776 
CHF 1 1 0.1131 0.0557 4.1236 0.0423 
Arrhy 1 1 -0.0107 0.0469 0.0522 0.8193 
VD 1 1 -0.1242 0.0554 5.0322 0.0249 
PCD 1 1 -0.0038 0.1082 0.0012 0.972 
PVD 1 1 0.0653 0.0481 1.8443 0.1744 
HPTN_NC 1 1 0.0416 0.0575 0.5231 0.4695 
HPTN_C 1 1 0.0947 0.0595 2.5294 0.1117 
Para 1 1 -0.0188 0.1908 0.0097 0.9215 
OthND 1 1 -0.0393 0.0851 0.2131 0.6443 
COPD 1 1 -0.1441 0.0483 8.9196 0.0028 
Hptothy 1 1 -0.0257 0.043 0.356 0.5508 
RF 1 1 0.1103 0.0829 1.7698 0.1834 
LD 1 1 -0.0398 0.0866 0.2106 0.6463 
PUD_NB 1 1 -0.0908 0.1671 0.2953 0.5868 
HIV 1 1 0.8473 0.5177 2.6779 0.1017 
Lymp 1 1 0.2891 0.1429 4.0904 0.0431 
METS 1 1 -0.1599 0.1784 0.8027 0.3703 
Tumor 1 1 -0.1089 0.0552 3.8865 0.0487 
Rheum_A 1 1 -0.2429 0.0847 8.2244 0.0041 
Coag 1 1 -0.1668 0.1002 2.7744 0.0958 
Obesity 1 1 -0.0252 0.0675 0.1395 0.7088 
WL 1 1 0.0759 0.0934 0.6606 0.4164 
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Fluid 1 1 0.0695 0.0607 1.3123 0.252 
BLA 1 1 0.1949 0.1293 2.2736 0.1316 
DA 1 1 0.0402 0.0618 0.4241 0.5149 
Alcohol 1 1 0.1338 0.225 0.3538 0.552 
Drug 1 1 -0.2849 0.3218 0.7837 0.376 
Psycho 1 1 -0.2202 0.1505 2.1419 0.1433 
Dep 1 1 -0.0182 0.0649 0.0787 0.7791 
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B. Non-Dual Beneficiaries-Nephropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.9044 0.0574 4627.81 <.0001 
Cost_all_p 3 1 2.48E-02 
4.20E-
02 0.3502 0.554 
Cost_all_p 2 1 -0.0257 0.0431 0.3544 0.5517 
Cost_all_p 1 1 -0.00027 0.0443 0 0.9952 
Cost_all_p 0 1 -0.0785 0.0543 2.0948 0.1478 
sex M 1 0.2369 0.0257 84.9435 <.0001 
race_1 Other 1 0.0605 0.0629 0.9241 0.3364 
race_1 Black 1 0.2207 0.0428 26.6355 <.0001 
age_grp 80_over 1 0.5434 0.0351 239.954 <.0001 
age_grp 75_to_7 1 0.3358 0.0368 83.1135 <.0001 
age_grp 70_to_7 1 0.1686 0.0354 22.6742 <.0001 
ip_tot_stay_1 1 -0.0358 0.0303 1.3998 0.2368 
op_tot_stay_1 1 0.00843 0.00202 17.3768 <.0001 
ov_1 1 0.00363 0.00196 3.4277 0.0641 
snf_stay 1 1 -0.1606 0.0677 5.6277 0.0177 
los_1 1 0.000622 0.00316 0.0387 0.8441 
CHF 1 1 0.4046 0.0338 143.0927 <.0001 
Arrhy 1 1 0.0449 0.0309 2.1072 0.1466 
VD 1 1 0.0108 0.0349 0.0958 0.7569 
PCD 1 1 0.1511 0.0614 6.0501 0.0139 
PVD 1 1 0.1219 0.0315 15.002 0.0001 
HPTN_NC 1 1 0.3378 0.0451 56.0204 <.0001 
HPTN_C 1 1 0.1864 0.037 25.4013 <.0001 
Para 1 1 -0.1417 0.1282 1.2216 0.269 
OthND 1 1 -0.0588 0.0553 1.1332 0.2871 
COPD 1 1 0.1049 0.0311 11.3646 0.0007 
Hptothy 1 1 -0.0271 0.0298 0.8275 0.363 
RF 1 1 2.0002 0.0337 3526.776 <.0001 
LD 1 1 -0.0852 0.0605 1.9873 0.1586 
PUD_NB 1 1 -0.011 0.1066 0.0105 0.9182 
HIV 1 1 -0.2699 0.6111 0.1951 0.6587 
Lymp 1 1 0.1446 0.1034 1.9583 0.1617 
METS 1 1 0.1061 0.1064 0.9932 0.319 
Tumor 1 1 0.0454 0.036 1.5884 0.2076 
Rheum_A 1 1 -0.0276 0.0534 0.2668 0.6055 
Coag 1 1 -0.0364 0.0596 0.3716 0.5421 
Obesity 1 1 0.166 0.0451 13.5659 0.0002 
WL 1 1 0.046 0.0609 0.5722 0.4494 
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Fluid 1 1 0.1603 0.0386 17.2568 <.0001 
BLA 1 1 0.0915 0.0875 1.0937 0.2956 
DA 1 1 0.1321 0.0399 10.9384 0.0009 
Alcohol 1 1 0.2042 0.1463 1.9468 0.1629 
Drug 1 1 9.56E-06 0.1869 0 1 
Psycho 1 1 0.0128 0.0856 0.0223 0.8812 
Dep 1 1 0.0642 0.0436 2.1674 0.141 
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C. Non-Dual Beneficiaries-Neuropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.5668 0.0564 4001.818 <.0001 
Cost_all_p 3 1 1.54E-01 
4.76E-
02 10.4062 0.0013 
Cost_all_p 2 1 0.2653 0.0472 31.589 <.0001 
Cost_all_p 1 1 0.4001 0.0478 70.1636 <.0001 
Cost_all_p 0 1 0.4103 0.0569 52.0026 <.0001 
sex M 1 0.0886 0.0269 10.82 0.001 
race_1 Other 1 -0.2012 0.0734 7.509 0.0061 
race_1 Black 1 0.1786 0.0455 15.421 <.0001 
age_grp 80_over 1 0.1467 0.0367 15.9751 <.0001 
age_grp 75_to_7 1 0.0797 0.0376 4.4856 0.0342 
age_grp 70_to_7 1 0.0289 0.0349 0.686 0.4075 
ip_tot_stay_1 1 -0.0417 0.0303 1.9013 0.1679 
op_tot_stay_1 1 0.00325 0.00218 2.2204 0.1362 
ov_1 1 0.0197 0.00187 110.5867 <.0001 
snf_stay 1 1 0.1392 0.066 4.4486 0.0349 
los_1 1 0.00583 0.00297 3.8442 0.0499 
CHF 1 1 0.0921 0.0382 5.8211 0.0158 
Arrhy 1 1 -0.0257 0.0328 0.6125 0.4338 
VD 1 1 -0.0695 0.0376 3.4233 0.0643 
PCD 1 1 -0.0422 0.0699 0.3647 0.5459 
PVD 1 1 0.2731 0.032 72.7312 <.0001 
HPTN_NC 1 1 -0.0361 0.0419 0.7409 0.3894 
HPTN_C 1 1 0.0371 0.0423 0.7681 0.3808 
Para 1 1 -0.00425 0.1197 0.0013 0.9717 
OthND 1 1 0.1492 0.0531 7.8868 0.005 
COPD 1 1 0.0476 0.0324 2.1629 0.1414 
Hptothy 1 1 -0.00893 0.0308 0.0842 0.7717 
RF 1 1 0.1706 0.0565 9.1038 0.0026 
LD 1 1 0.0409 0.0585 0.4883 0.4847 
PUD_NB 1 1 -0.024 0.1107 0.0471 0.8281 
HIV 1 1 0.2092 0.519 0.1625 0.6868 
Lymp 1 1 -0.2516 0.1224 4.2256 0.0398 
METS 1 1 -0.00946 0.1149 0.0068 0.9344 
Tumor 1 1 -0.16 0.0395 16.3879 <.0001 
Rheum_A 1 1 0.0903 0.0513 3.0987 0.0784 
Coag 1 1 -0.1283 0.0649 3.9041 0.0482 
Obesity 1 1 0.2386 0.0444 28.8833 <.0001 
WL 1 1 -0.0792 0.0661 1.4384 0.2304 
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Fluid 1 1 -0.00899 0.0423 0.0452 0.8316 
BLA 1 1 -0.00062 0.0951 0 0.9948 
DA 1 1 -0.00307 0.0435 0.005 0.9439 
Alcohol 1 1 0.32 0.1396 5.2547 0.0219 
Drug 1 1 0.4699 0.1465 10.2882 0.0013 
Psycho 1 1 0.1072 0.0843 1.6172 0.2035 
Dep 1 1 0.145 0.0425 11.6557 0.0006 
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D. Dual Beneficiaries-Retinopathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.5075 0.1695 428.0886 <.0001 
mcaid_all 3 1 
-3.14E-
01 
1.13E-
01 7.7439 0.0054 
mcaid_all 2 1 -0.38 0.1104 11.851 0.0006 
mcaid_all 1 1 -0.4138 0.1167 12.5827 0.0004 
mcaid_all 0 1 -0.0047 0.1011 0.0022 0.963 
sex F 1 0.0465 0.0801 0.3374 0.5613 
race_1 Other 1 0.1719 0.0881 3.8037 0.0511 
race_1 Black 1 0.2322 0.0922 6.3429 0.0118 
age_grp 80_over 1 -0.1183 0.0986 1.4396 0.2302 
age_grp 75_to_7 1 -0.0886 0.1032 0.7374 0.3905 
age_grp 70_to_7 1 0.0614 0.0925 0.4407 0.5068 
ip_tot_stay_1 1 0.0165 0.0864 0.0365 0.8484 
op_tot_stay_1 1 0.00562 0.0051 1.2123 0.2709 
ov_1 
 
1 0.00074 0.00502 0.0218 0.8827 
snf_stay 1 1 0.1104 0.1551 0.5063 0.4767 
los_1 
 
1 -0.0121 0.0112 1.1668 0.2801 
CHF 1 1 0.0971 0.0957 1.0293 0.3103 
Arrhy 1 1 -0.106 0.0942 1.2674 0.2603 
VD 1 1 0.0946 0.1053 0.807 0.369 
PCD 1 1 0.1885 0.1978 0.9079 0.3407 
PVD 1 1 0.0693 0.0846 0.6702 0.413 
HPTN_NC 1 1 0.3012 0.1356 4.9371 0.0263 
HPTN_C 1 1 0.0713 0.1057 0.4556 0.4997 
Para 1 1 0.3804 0.2175 3.0583 0.0803 
OthND 1 1 0.1321 0.1268 1.0845 0.2977 
COPD 1 1 -0.288 0.0875 10.834 0.001 
Hptothy 1 1 0.033 0.0822 0.1611 0.6881 
RF 1 1 0.3456 0.137 6.3578 0.0117 
LD 1 1 0.0247 0.1432 0.0298 0.863 
PUD_NB 1 1 -0.2069 0.2676 0.5979 0.4394 
HIV 1 1 0.0512 0.7284 0.0049 0.944 
Lymp 1 1 -0.2988 0.4575 0.4265 0.5137 
METS 1 1 0.3958 0.3295 1.4429 0.2297 
Tumor 1 1 -0.2624 0.1368 3.6772 0.0552 
Rheum_A 1 1 -0.0651 0.1475 0.1947 0.659 
Coag 1 1 -0.0841 0.1906 0.1945 0.6592 
Obesity 1 1 0.0499 0.1202 0.1725 0.6779 
WL 1 1 -0.4884 0.1919 6.4743 0.0109 
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Fluid 1 1 -0.0993 0.1107 0.8042 0.3698 
BLA 1 1 -0.3243 0.2874 1.2728 0.2592 
DA 1 1 0.0819 0.1072 0.5831 0.4451 
Alcohol 1 1 0.2533 0.3326 0.5801 0.4463 
Drug 1 1 0.2987 0.3302 0.8184 0.3657 
Psycho 1 1 -0.1968 0.158 1.5528 0.2127 
Dep 1 1 0.1121 0.0986 1.2946 0.2552 
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E. Dual Beneficiaries-Nephropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -3.0925 0.1251 611.127 <.0001 
mcaid_all 3 1 
-2.34E-
01 
8.46E-
02 7.6415 0.0057 
mcaid_all 2 1 -0.038 0.0781 0.2365 0.6267 
mcaid_all 1 1 -0.0293 0.0811 0.1305 0.7179 
mcaid_all 0 1 -0.2518 0.0808 9.7059 0.0018 
sex F 1 -0.1344 0.0566 5.6402 0.0176 
race_1 Other 1 -0.1495 0.0684 4.7803 0.0288 
race_1 Black 1 0.0829 0.0666 1.5479 0.2134 
age_grp 80_over 1 0.3073 0.0694 19.5875 <.0001 
age_grp 75_to_7 1 0.1622 0.0746 4.7352 0.0296 
age_grp 70_to_7 1 -0.0731 0.0733 0.994 0.3188 
ip_tot_stay_1 1 -0.0386 0.0483 0.6382 0.4244 
op_tot_stay_1 1 0.00239 0.00354 0.4553 0.4998 
ov_1 
 
1 0.00187 0.0035 0.284 0.5941 
snf_stay 1 1 -0.2168 0.104 4.3474 0.0371 
los_1 
 
1 -0.00297 0.00505 0.3467 0.556 
CHF 1 1 0.3099 0.063 24.2123 <.0001 
Arrhy 1 1 0.0883 0.0628 1.977 0.1597 
VD 1 1 -0.00819 0.0736 0.0124 0.9114 
PCD 1 1 0.1161 0.1269 0.8368 0.3603 
PVD 1 1 0.1094 0.0587 3.4705 0.0625 
HPTN_NC 1 1 0.245 0.0987 6.1622 0.0131 
HPTN_C 1 1 0.2 0.0698 8.219 0.0041 
Para 1 1 -0.1455 0.1823 0.6371 0.4248 
OthND 1 1 0.0173 0.0886 0.0382 0.845 
COPD 1 1 0.0605 0.0582 1.078 0.2992 
Hptothy 1 1 0.0217 0.0587 0.1359 0.7124 
RF 1 1 1.8962 0.0672 796.2964 <.0001 
LD 1 1 0.18 0.099 3.3055 0.0691 
PUD_NB 1 1 -0.1783 0.1816 0.964 0.3262 
HIV 1 1 -1.3715 1.027 1.7832 0.1818 
Lymp 1 1 -0.0301 0.2708 0.0123 0.9115 
METS 1 1 0.0669 0.2326 0.0826 0.7738 
Tumor 1 1 -0.00091 0.0872 0.0001 0.9917 
Rheum_A 1 1 -0.255 0.1078 5.5978 0.018 
Coag 1 1 -0.0687 0.1225 0.3141 0.5752 
Obesity 1 1 0.1765 0.0833 4.4881 0.0341 
WL 1 1 -0.0654 0.1096 0.356 0.5507 
 157 
 
Fluid 1 1 0.2352 0.0697 11.3986 0.0007 
BLA 1 1 0.1169 0.159 0.5408 0.4621 
DA 1 1 0.0499 0.0748 0.444 0.5052 
Alcohol 1 1 -0.0442 0.2604 0.0289 0.8651 
Drug 1 1 0.3006 0.2337 1.6551 0.1983 
Psycho 1 1 -0.3029 0.1103 7.5441 0.006 
Dep 1 1 -0.0578 0.0718 0.6487 0.4206 
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F. Dual Beneficiaries-Neuropathy 
 
Parameter   DF Estimate Std Err 
Wald 
Chi-Sq p-value 
Intercept   1 -2.9468 0.1157 648.891 <.0001 
mcaid_all 3 1 1.28E-01 
8.02E-
02 2.5488 0.1104 
mcaid_all 2 1 0.1502 0.077 3.8025 0.0512 
mcaid_all 1 1 -0.0914 0.0837 1.1929 0.2747 
mcaid_all 0 1 -0.0376 0.0788 0.2278 0.6331 
sex F 1 0.0394 0.0562 0.4917 0.4832 
race_1 Other 1 -0.0833 0.0644 1.6711 0.1961 
race_1 Black 1 -0.1345 0.0687 3.8356 0.0502 
age_grp 80_over 1 -0.1197 0.0704 2.8913 0.0891 
age_grp 75_to_7 1 0.0226 0.0715 0.0997 0.7521 
age_grp 70_to_7 1 0.0753 0.0655 1.3215 0.2503 
ip_tot_stay_1 1 0.0684 0.0495 1.9058 0.1674 
op_tot_stay_1 1 0.00264 0.00344 0.588 0.4432 
ov_1 
 
1 0.0167 0.00306 29.8299 <.0001 
snf_stay 1 1 -0.0451 0.1023 0.1943 0.6594 
los_1 
 
1 -0.0104 0.00623 2.7776 0.0956 
CHF 1 1 0.2221 0.0631 12.4045 0.0004 
Arrhy 1 1 -0.0945 0.0632 2.2336 0.135 
VD 1 1 -0.0407 0.0724 0.3171 0.5733 
PCD 1 1 -0.0406 0.1297 0.0978 0.7545 
PVD 1 1 0.3061 0.0562 29.6705 <.0001 
HPTN_NC 1 1 -0.013 0.0876 0.022 0.882 
HPTN_C 1 1 0.0976 0.0713 1.8739 0.171 
Para 1 1 -0.00223 0.1677 0.0002 0.9894 
OthND 1 1 0.0481 0.0868 0.3068 0.5797 
COPD 1 1 0.0724 0.0558 1.6838 0.1944 
Hptothy 1 1 -0.0366 0.0573 0.4091 0.5225 
RF 1 1 0.2277 0.0966 5.5601 0.0184 
LD 1 1 -0.0879 0.0995 0.7801 0.3771 
PUD_NB 1 1 -0.00179 0.1646 0.0001 0.9913 
HIV 1 1 0.3466 0.4786 0.5246 0.4689 
Lymp 1 1 0.1785 0.2458 0.5273 0.4677 
METS 1 1 -0.0691 0.2371 0.0851 0.7705 
Tumor 1 1 -0.1085 0.0871 1.5517 0.2129 
Rheum_A 1 1 0.1947 0.089 4.7822 0.0288 
Coag 1 1 0.17 0.1129 2.2678 0.1321 
Obesity 1 1 0.2812 0.0766 13.4802 0.0002 
WL 1 1 -0.0584 0.1079 0.2925 0.5886 
 159 
 
Fluid 1 1 0.1477 0.07 4.4536 0.0348 
BLA 1 1 -0.2642 0.1772 2.2227 0.136 
DA 1 1 0.0456 0.0732 0.3881 0.5333 
Alcohol 1 1 -0.0566 0.2526 0.0501 0.8228 
Drug 1 1 0.5004 0.1922 6.7814 0.0092 
Psycho 1 1 -0.3031 0.1087 7.7725 0.0053 
Dep 1 1 0.1999 0.065 9.4514 0.0021 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
